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Oral absorption depends on many physiological, physiochemical and formulation factors. 26 
Two important properties that govern oral absorption are in vitro permeability and solubility, 27 
which are commonly used as indicators of human intestinal absorption. Despite this, the 28 
nature and exact characteristics of the relationship between these parameters are not well 29 
understood. In this study a large dataset of human intestinal absorption was collated along 30 
with in vitro permeability, aqueous solubility, melting point, and maximum dose for the same 31 
compounds. The dataset allowed a permeability threshold to be established objectively to 32 
predict high or low intestinal absorption. Using this permeability threshold, classification 33 
decision trees incorporating a solubility-related parameter such as experimental or predicted 34 
solubility, or the melting point based absorption potential (MPbAP), along with structural 35 
molecular descriptors were developed and validated to predict oral absorption class. The 36 
decision trees were able to determine the individual roles of permeability and solubility in 37 
oral absorption process. Poorly permeable compounds with high solubility show low 38 
intestinal absorption, whereas poorly water soluble compounds with high or low permeability 39 
may have high intestinal absorption provided that they have certain molecular characteristics 40 
such as a small polar surface or specific topology.  41 
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1. INTRODUCTION 52 
The assessment of pharmacokinetic properties, especially absorption, is now well established 53 
in early drug discovery. The need to determine absorption of new chemical entities is 54 
essential for successful orally administered compounds, as well as efficacy, toxicity and other 55 
ADME (absorption, distribution, metabolism, excretion) properties [1]. The prediction of oral 56 
absorption can be carried out with experimental assays and/or the use of in silico models. 57 
These experimental and computer models can be used as an indication of intestinal 58 
absorption in humans, which is carried out later on in drug development. By testing drug 59 
compounds using these models, compounds with undesirable properties can be removed 60 
earlier, therefore improving cost effectiveness [2, 3]. 61 
Intestinal absorption depends on many physiological, physiochemical and formulation 62 
factors. Two important properties that govern oral absorption are permeability and solubility 63 
as utilised by the Biopharmaceutics Classification System (BCS) [4].  For a drug to be 64 
absorbed it must firstly dissolve in the gastrointestinal fluid in order to then permeate the 65 
intestinal membrane. The relationship between these properties is closely, usually inversely, 66 
related [5, 6]. As an increasing number of new chemical entities (NCE) have high 67 
lipophilicity and low solubility, predicting absorption of NCEs is problematic. Inadequate 68 
aqueous solubility can lead to poor, erratic, variable absorption, so it is important to consider 69 
the effects of solubility for the prediction of intestinal absorption [7] . 70 
The importance of solubility on oral absorption is highlighted in the literature, but there are 71 
few studies that incorporate both experimental solubility and permeability values within a 72 
model, in order to see the effect these two properties have on oral absorption [8, 9]. Early oral 73 
absorption models are too small to effectively represent all the different biological processes 74 
of absorption and the physiochemical properties including solubility [10, 11]. Most studies 75 
have removed compounds with solubility issues when modelling oral absorption [12, 13], 76 
which is not ideal due to the increasing number of poorly soluble drugs being developed. 77 
Zhao and co-workers demonstrated that predicting BCS Class II compounds (low solubility 78 
and high permeability) resulted in an overestimation of fraction absorbed by their model [12]. 79 
Solubility itself is a complex parameter and in turn dependent on numerous factors, therefore 80 
it is important to investigate what multiple elements such as those calculated from the 81 















Molecular descriptors that describe the process of solubilisation of the drug such as crystal 83 
lattice energy, solvent cavity formation energy and solvation energy are utilised in the 84 
prediction of solubility [14, 15]. The general solubility equation (GSE) is a simple method 85 
that predicts aqueous solubility using only two parameters, logP and melting point [16]. 86 
Other methods may employ more specific molecular descriptors to improve the prediction 87 
accuracy [17, 18]. GSE and its variants have been used for the estimation of oral absorption-88 
related parameters termed absorption potential [19, 20]. Recently a melting point based 89 
absorption potential (MPbAP) has been proposed which is derived from the GSE and 90 
includes maximum dose, to give an indication of oral absorption. In general, it was found that 91 
the lower the melting point the higher the tendency the compound had to be highly-absorbed 92 
and vice versa, and it was also found that for higher melting points absorption was limited by 93 
dose [21]. 94 
Permeability in drug discovery is routinely measured using in vitro cell based assays to give 95 
an indication of permeability of drug compounds in the intestine, blood brain barrier, nasal 96 
cavity and skin [22]. Apparent permeability (Papp) is the rate of permeation across cell 97 
monolayers and is usually measured in cm/s-1. The ideal permeability model for the small 98 
intestine mimics the physical and biochemical processes of intestinal absorption [1]. There 99 
are many different cell lines that can be used to measure permeability. Human colon 100 
adenocarcinoma (Caco-2) is a commonly used cell line [23-25], which displays biological and 101 
characteristic properties of the enterocytes of the small intestine such as the brush border and 102 
tight junctions [1, 25-27]. These cells can express a variety of transporters and metabolic 103 
enzymes, allowing other transport and metabolism mechanisms to be investigated [28]. 104 
Drawbacks of this particular cell line are inter-laboratory differences, variable transporter 105 
expression, long culture time, tighter junctions compared with in vivo situation and lack of 106 
mucus secreting goblet cells [1, 29, 30]. Some of these problems have been resolved by other 107 
cell lines such as 2/4/A1, a rat intestinal epithelial cell line, which has leakier tight junctions 108 
[31, 32]; also, the cell line HT29-MTX is a co-culture of Caco-2 cells with mucus secreting 109 
goblet cells to study the effects of mucus on absorption [33]. Another cell line that has been 110 
gaining popularity is MDCK II (Madin-Darby Canine Kidney strain II) cells, due to shorter 111 
culture time (of 3-5 days), leakier tight junctions and low expression of transporters 112 
compared with Caco-2, making it an ideal cell line for passive permeability assessment even 113 















between Caco-2 and MDCK cell lines. Despite this there is a linear relationship between the 115 
two shown using small compound sets [22, 34, 35]. 116 
The relationship between permeability and fraction absorption in humans can be determined 117 
numerically or categorically. From a classification perspective a permeability threshold 118 
indicates high or low intestinal absorption (absorption class). The permeability thresholds 119 
defined in the literature vary greatly and the majority of studies appear to set the permeability 120 
threshold subjectively from a visual inspection of the graphical fit, rather than using an 121 
objective method [13, 37-40]. For example, Artusson et al [37], using a dataset of 20 122 
compounds, defined that a compound would have complete absorption if it had a 123 
permeability > 1 x10-6 cm/s. More recent studies have indicated higher permeability 124 
thresholds than 1 x10-6 to define a high absorption compound [8, 38, 41]. In a recent 125 
investigation, Varma et al [36], used Receiver Operating Characteristic (ROC) analysis to 126 
objectively define the best permeability threshold for fraction absorbed based on a dataset of 127 
82 compounds with permeability measured in a low transporter expression MDCK II cell 128 
line. The threshold defined was > 5 x 10-6 cm/s for ≥ 80% or ≥ 90% fraction absorbed. 129 
Additionally, the FDA has recommended a set of high and low permeability standards with 130 
known fraction absorbed [42]. These standard compounds can be measured alongside NCEs 131 
which are then considered as highly or poorly permeable, depending on whether the 132 
permeability is greater or lower than the standards; this can then be related to fraction 133 
absorbed based on these FDA standards. Potential problems with this are the choice of 134 
standard. For example, the high permeability standards propranolol, verapamil and 135 
metoprolol have differences in their permeability which could result in potential incorrect 136 
prediction depending which standard is used when testing alongside NCEs.  137 
In order to see the effects of solubility and permeability on fraction absorbed, a large dataset 138 
is needed. Therefore, the first aim of this work was to expand the permeability dataset by 139 
combining data from Caco-2 and MDCK cell lines. By studying the relationship and the 140 
effect of different absorption mechanisms between the two cell lines and from the differences 141 
already known between the two cell lines, the justification of combining the datasets can be 142 
shown. Secondly, the determination of a permeability threshold to predict fraction absorbed 143 
class using an objective decision tree method is tested on an external validation set of the 144 
permeability dataset collected. Using this permeability threshold, decision trees using 145 
experimental and predicted solubility and related properties such as dose number and melting 146 















to predict fraction absorbed class. Therefore, the QSAR endpoint is the categorical variable 148 
indicating the ‘high’ or ‘low’ fraction absorbed class. Based on this work, one can obtain an 149 
increased understanding around the relationship between two popular cell based assays and 150 
how they can be used to predict absorption class using an objective permeability threshold. In 151 
addition, the effect of solubility and related properties on the prediction of fraction absorbed 152 
models is explored. 153 
2. METHODS AND MATERIALS 154 
2.1 Datasets 155 
With an extensive search in the literature, multiple datasets were collated consisting of data 156 
for human intestinal absorption, transport route, permeability, solubility, dose number, 157 
aqueous solubility and melting point. For each compound the name, property value, CAS 158 
number, references and additional comments from the authors relating to the data is included 159 
and can be found in the Supporting Information I. Whenever possible, the original 160 
literature was consulted to evaluate data quality. In some cases data from secondary sources 161 
was included when original literature could not be located. 162 
2.1.1 Human Intestinal absorption 163 
Intestinal absorption can be assessed and calculated from different types of data such as 164 
bioavailability, and urinary and faecal excretion mass balance studies. We used the same 165 
principles to calculate and evaluate the reliability of fraction absorbed value as defined by 166 
other works [12, 43]. Intestinal absorption values were initially obtained from the published 167 
datasets of Hou et al [13] and Varma et al [43]; this data was scrutinised by checking the 168 
original publications. An exhaustive search of the literature was then carried out and 169 
additional compounds were also added from the drug information obtained from the FDA 170 
Drugs@FDA database (accessed from June 2012 to May 2013) [44]. Where there was no 171 
numerical value defined in the literature, categorical values for fraction absorbed were also 172 
included for this dataset. At the end, the dataset consisted of 913 numerical and 19 173 
categorical fraction absorption values creating a final dataset of 932 compounds. 174 
2.1.2 Permeability 175 
Apparent permeability (Papp) data measured in cm/s-1 was collected for compounds with 176 















different cell lines Caco-2 and MDCK obtained from the literature. The dataset contains 386 178 
Caco-2
 
and 246 MDCK Papp values for drug and drug-like compounds. For 185 compounds 179 
the permeability was found for both cell lines, and this dataset was used to investigate the 180 
relationship between the two cell lines. Where there were multiple permeability values for a 181 
single compound these results were averaged unless they were very different, in which case 182 
comparison of MDCK and Caco-2 permeability was carried out (if available) or careful 183 
examination of the experimental conditions of the specific value was performed in order to 184 
justify inclusion. 185 
For Caco-2 permeability, the published dataset by Pham-The et al [45] was used as the 186 
starting point from which an exhaustive literature search was carried out. For MDCK 187 
permeability, permeability data from two studies by Varma and co-workers [36, 46] were 188 
used as a starting point. As there are different strains of this cell line, it was important to 189 
reference what strain (if known) was used in the study. In addition, it was decided not to just 190 
isolate data collection on one strain, but make a note which would aid in interpretation at a 191 
later stage. The main two types of MDCK strains collected were MDCK II and MDCK-192 
MDR1. A preliminary statistical paired t test of these two main strains showed no significant 193 
difference between these two strains in this dataset (p > 0.05), therefore all the data for 194 
MDCK was used together for comparison with Caco-2. 195 
2.1.3 Identification of absorption mechanisms 196 
The knowledge about absorption mechanism will help with interpretation of models and give 197 
us a better understanding of the influence of transporter systems on absorption as this is 198 
increasingly important in the prediction of drug absorption. For each compound the 199 
absorption route was assessed using literature data, review articles and transporter databases. 200 
It was recorded if compounds underwent any absorption mechanism other than passive 201 
transcellular route. This included carrier mediated systems, such as efflux and influx 202 
transporters, and paracellular absorption. A total of 201 (out of 932) were identified to be 203 
absorbed via routes other than passive transcellular. It must be noted that, firstly, if no 204 
information or evidence was found to suggest alternative absorption mechanisms, this does 205 
not necessarily mean it is not a substrate of a transporter or transported via the paracellular 206 
route; it may not have been tested and/or results have not been published in the literature. 207 
Therefore, in the future we anticipate that this number could increase further when more 208 















carrier mediated system, this does not mean that the transport system is the dominating 210 
process [47]. 211 
2.1.4 Aqueous solubility 212 
Aqueous solubility for 483 compounds in mg/mL was obtained primarily from the 213 
AQUASOL dATAbASE (6th Edition) and SRC (PHYSPROP) databases 214 
(http://esc.srcinc.com/fatepointer/search.asp) and the literature. Solubility was converted to 215 
log molar units (M) and log mg/mL units in this work. For the AQUASOL data, those values 216 
that had the highest evaluation codes as defined by the database were selected, and those 217 
compounds with more than one value were averaged.  218 
In addition to these values, predicted solubility values were also utilised and compared with 219 
experimental in the modelling section of this work. Solubility was calculated by the revised 220 
general solubility equation (GSE) using experimental melting point and calculated logP.[16] 221 
(Equation 1 below). 222 
Log Sol GSE
  0.5  0.01   25
                                                                    (1) 223 
2.1.5 Dose number 224 
Dose number is a dimensionless number used to determine high or low solubility in the 225 
Biopharmaceutical Classification System (BCS) [4]. It is calculated using the solubility and 226 
maximum strength dose (Equation 2).  227 
Do = (Mo /Vo) / S                                                                                                                      (2) 228 
Where Do is dose number, Mo is the highest dose strength, Vo is 250ml and S is the aqueous 229 
solubility (mg/ml). The maximum strength dose was obtained for the compounds in this 230 
dataset from the British National Formulary (2012)[48], FDA electronic orange book 2012 231 
(accessed December 2012-January 2013) and Martindale (2009) [49]. Where there were still 232 
missing values, an extensive literature search was carried out and the values presented are the 233 
authors’ best recommendation based on an evaluation of the literature data. Where doses 234 
were based on bodyweight, a body weight of 70kg was used to calculate the maximum dose 235 

















2.1.6 Melting point 239 
Experimental melting point (in oC) was obtained from the AQUASOL dATAbASE, SRC 240 
(Physprop), the Hazardous substances data bank (HSDB) (http://toxnet.nlm.nih.gov/cgi-241 
bin/sis/htmlgen?HSDB) and the literature. The average was taken if a melting point range 242 
was stated.  243 
2.1.7 Melting point based absorption potential 244 
The melting point based absorption potential (MPbAP) was derived from the GSE but 245 
utilising maximum dose as well as melting point [21]. As shown by Equation 3 below. 246 
 MPbAP   0.5  0.01   25
  log 4 ∗   !
                                                       (3) 247 
2.2 Calculated molecular descriptors 248 
Calculated molecular descriptors were calculated from structures using the software packages 249 
TSAR 3D v3.3 (Accelrys Inc.), MDL QSAR (Accelrys Inc.), MOE v2010.10 (Chemical 250 
Computing Group Inc.) and Advanced Chemistry Development ACD Laboratories/LogD 251 
Suite v12. Including the seven descriptors of permeability, solubility and related parameters, 252 
a total of 220 molecular descriptors were utilised for analysis. 253 
2.3 Training and validation sets 254 
Using the combined permeability data from the two cell lines yielded an initial dataset of 447 255 
compounds. Compounds with MDCK and Caco-2 permeability data that differed by more 256 
than one log unit and one compound that did not have a numerical value for HIA were 257 
removed (14 compounds in total). This resulted in a dataset of 433 compounds. The 433 258 
compounds were split into a training set and a validation set. To ensure a similar distribution 259 
of fraction absorbed in these two sets, compounds were sorted according to ascending %HIA 260 
and then logP values. From each group of six consecutive compounds, five were assigned to 261 
the training set, and one compound was allocated to the validation set randomly. The initial 262 
training set consisted of 356 compounds and the validation set consisted of 78 compounds.  263 
For models used to determine the influence of solubility and related parameters, compounds 264 
that had missing values for solubility, melting point and dose number were removed from the 265 
initial training and validation sets. The final compound numbers for decision tree analysis are 266 















<<INSERT TABLE 1 HERE>> 268 
2.4 Classification and regression trees (CARTs) 269 
STATISTICA v11 (StatSoft Ltd.) software was used for permeability threshold determination 270 
and classification of compounds using CART analysis. CARTs (called C&RT in the 271 
STATISTICA software) use decision trees to solve regression and classification problems 272 
developed by Breinman et al [50]. Hence, in this work the QSAR models are represented as 273 
decision trees (a type of graph). According to the observed %HIA values in the data set, 274 
compounds were placed into either the “high” class if %HIA was equal to or greater than a 275 
specified HIA cut-off (e.g.50%) or the “low” class if %HIA was less than this specified 276 
%HIA cutoff. In this work binary classification of (low or high HIA) was carried out using 277 
calculated molecular descriptors from the chemical structure, permeability and solubility 278 
related parameters. The QSAR models (in the form of decision trees) used in this work were 279 
validated by measuring the predictive accuracy of model predictions (prediction of “High” or 280 
“Low” oral absorption class) for the compounds in the validation set, as described earlier 281 
(section 2.3 – training and validation sets). 282 
 283 
Preliminary results indicated that permeability and not solubility was the dominant property 284 
selected statistically by CART. Therefore in order to gauge the relative importance of these 285 
two parameters, the decision trees were built in two phases. The first phase forced CART to 286 
select a suitable permeability threshold for different HIA class definitions. The second phase 287 
involved forcing CART to choose thresholds for solubility and related parameters for the 288 
second split of the decision tree. After this, CART was allowed to build the remainder of the 289 
tree automatically using structural molecular descriptors. These trees were compared with a 290 
CART tree developed using the parameters selected automatically by the tree from 291 
permeability or solubility parameters or the molecular descriptors provided. 292 
 293 
2.5 Permeability threshold determination using CART 294 
The permeability threshold is the numerical value chosen by CART that best predicts HIA 295 
class. In this work several different analyses were performed where high absorption 296 
compounds were defined as those having HIA values of above 30, 50, 70, 80 or 90%. Using 297 
the training set of 356 compounds, HIA class was used as the dependent variable and 298 















to give the permeability threshold. This threshold was tested using a validation set of 78 300 
compounds. Due to the class imbalance, where there are many more highly-absorbed than 301 
poorly-absorbed compounds, higher misclassification costs were applied to false positives to 302 
overcome this bias. Based on previous works the use of misclassification costs has shown 303 
improved model accuracy [51]. The misclassification cost values applied depended on the 304 
class distribution of the dataset. For instance, when the “high absorption” class is defined as 305 
having %HIA ≥ 30%, the cost of a false positive was considered five times the cost of a false 306 
negative due to roughly five times more highly absorbed compounds in the data set. 307 
Misclassification costs of 5, 4, 3, 2.5 and 2 were applied to false positives in the analyses 308 
where the high HIA class had been defined as those compounds having %HIA values equal 309 
or above 30, 50, 70, 80 and 90%, respectively. 310 
2.6 Permeability and solubility related model analysis for oral absorption class 311 
determination 312 
In this section, models were built using HIA class as the dependent variable where high 313 
absorption was defined as HIA ≥ 80% and molecular descriptors were utilised as the 314 
independent variables for model building. The HIA class definition of ≥ 80% was selected 315 
based on preliminary work, where when using lower HIA class definition such as 30-70% 316 
due to the lower number of poorly absorbed compounds only poor models could be achieved. 317 
Using a higher threshold of 90% resulted in poorer overall accuracy (based on preliminary 318 
analysis), and this threshold is too high to predict oral absorption class effectively with a high 319 
number of false negatives. 320 
In this work permeability was set as the first split variable and two alternative approaches 321 
were used to choose the remaining split variables. In the first one, the CART tree was 322 
allowed to grow automatically. In the second one, each of the solubility and related 323 
parameters (dose number and melting point) were manually chosen as then second split 324 
variable (note that CART still chooses the cut-off point automatically) and then the tree was 325 
allowed to grow automatically. Stopping factors were used to prevent overfitting of the 326 
CART trees and was the minimum number of compounds for splitting. This was set at 11 for 327 
the permeability only CART trees and eight for permeability and solubility trees.  328 















To determine the relationship between Caco-2 and MDCK permeability, MINITAB 330 
Statistical Software (version 16.1.1.0) and Prism (GraphPad Software, Inc) v.5.02 were used 331 
to carry out linear regression, identify outliers and perform statistical significance testing 332 
between the different absorption mechanisms. For linear regression the parameter reported to 333 
assess the fit of the two variables was the squared correlation coefficient, r2 forced through 334 
the origin. For correlation analysis the Pearson’s correlation coefficient and the Spearman’s 335 
ranking correlation coefficient (rs) were calculated. It must be emphasised here that r2 based 336 
on the regression line forced through the origin is not comparable to r2 values where the 337 
regression line is not forced through the origin [52]. The statistical significance of the 338 
correlations and regression lines and comparison of the regression lines for different 339 
absorption mechanisms (using the intercept and the slope values) was depicted by p values. P 340 
values <0.05 indicated significance.  341 
The predictive performance of the classification models built using CART in this work was 342 
measured using sensitivity (SE), specificity (SP) and SP × SE. Sensitivity is the ratio of 343 
correct classifications for the highly absorbed compound class (SE = TP/(TP + FN)), where 344 
TP is the number of true positives and FN is the number of false negatives. Specificity is the 345 
ratio of correct classifications of poorly absorbed compounds (SP = TN/(TN + FP)), where 346 
TN is the number of true negatives and FP is the number of false positives. In this work 347 
overall accuracy is defined by specificity multiplied by sensitivity (SP × SE). This measure 348 
represents the overall predictive performance of both high and low class prediction. In 349 
addition, this measure will not be overly influenced by the classification accuracy of the 350 
majority high absorption class, and it has been used in previous investigations [51, 53]. 351 
3. RESULTS AND DISCUSSIONS 352 
In this work in order to investigate the effects of permeability and solubility a large dataset of 353 
human intestinal absorption was gathered from the original literature and then for the same 354 
compounds Caco-2 and MDCK permabilities, solubility, melting point and dose were 355 
gathered from the original literature. Table 2 shows the collated data which is available in the 356 
supporting information I, where n denotes the number of compounds for each property. 357 
This data was used in order to develop models for predicting high/low oral absorption and to 358 
explore suitability of different solubility and permeability measures from different sources as 359 















<<INSERT TABLE 2 HERE>> 361 
In terms of permeability, we have gathered permeability measured in both Caco-2 and 362 
MDCK cell lines. In vitro permeability through different cell lines is commonly used as a 363 
high throughput measure of effective intestinal absorption in early drug discovery. Other cell 364 
lines such as MDCK, 2/4/A1 and HT29-MTX have also been used to assess compound 365 
permeability. There have been a few studies, which show the linear relationship between 366 
these cell lines. For example, Braun et al [22] studied the relationship between Caco-2 and 367 
MDCK cell lines and from 14 compounds achieved an r2 of 0.86. However, Adveef et al [35] 368 
achieved a r2 of 0.90 using a dataset of 79 compounds.  369 
3.1 Comparison of Caco-2 and MDCK apparent permeability as indicators of intestinal 370 
absorption 371 
For 185 compounds, the in vitro apparent permeability from both Caco-2 and MDCK cell 372 
lines was obtained from the literature. By an exhaustive literature search transport routes 373 
were identified for all these compounds. Plotting the permeability of these two cell lines on a 374 
log scale a linear relationship is shown (Figure 1) where the transport routes have also been 375 
highlighted. Out of 185 compounds in this figure, 96 compounds were found to be substrates 376 
of a transporter system and 11 compounds have been suggested to be absorbed to some extent 377 
via paracellular route.  378 
<<INSERT FIGURE 1 HERE>> 379 
It can be seen in the plot that Caco-2 and MDCK permeability of majority of compounds 380 
regardless of their absorption routes correlate well with each other. However, there are 381 
compounds that deviate significantly from this line and removal of 9 outlier compounds 382 
(compound names shown in the Figure 1) improves the correlation significantly (Table 3). 383 
Details of the outlier compounds and a description of reasons can be found in Supporting 384 
Information II. A better linear relationship between the two cell lines is also achieved when 385 
only compounds undergoing passive transcellular absorption are plotted (Table 3). It may be 386 
noted in Table 3 that the correlation between the cell lines are better after the removal of 9 387 
outliers than after the removal of all the compounds with a transporter effect. It is also 388 
noteworthy that not all the outliers were substrates of a transporter; examples are 389 















been identified. Both these drugs have poor solubilities (dissolution limiting solubility) and 391 
classed in Class II of Biopharmaceutics classification system (BCS) [54, 55]. 392 
Similar conclusions can be made from the results of previous studies where transporter 393 
mediated effects could not be identified by correlating the permeability through different cell 394 
lines. Irvine et al [34] compared the apparently permeability of 55 compounds using MDCK 395 
and Caco-2 cells. This study achieved an r2 of 0.79. Irvine identified 12 compounds that were 396 
substrates for carrier mediated systems. We crossed referenced the remaining compounds 397 
used by Irvine with our database and identified an additional 18 compounds to be substrates 398 
for carrier mediated systems. Therefore over half of this original dataset has now been found 399 
to be affected by a carrier mediated route. The 12 compounds highlighted as undergoing 400 
carrier systems in most cases were within the linear fit of Irvine’s, with only a few 401 
exceptions. The explanation by Irvine of why known P-gp substrates were not identified in 402 
comparing the two cell lines is not suitable. For the P-gp substrates highlighted in the work, it 403 
was stated the reason they could not be identified was due to saturation of the transport 404 
mechanism in the assay. Braun et al [22] used the same compounds but at lower 405 
concentrations, and they were still unable to identify known P-gp substrates. It was concluded 406 
that using the relationship between MDCK and Caco-2 could not identify P-gp substrates. 407 
From this work the correlation between MDCK and Caco-2 permeability does indicate the 408 
same result that compounds with carrier mediated mechanisms do not deviate from the 409 
correlation between Caco-2 and MDCK permeabilities. This is despite the fact that the 410 
transporters have different abundance levels in these two cell lines.  411 
<<INSERT TABLE 3 HERE>> 412 
We have complied a table that compares the cells and small intestine in terms of species 413 
origin, tightness of the cell junctions and also the transporter and enzyme expressions (Table 414 
S1 in Supporting Information III). One thing to note is the lack of information/evidence in 415 
the literature for transporter and enzyme expression especially for the specific strains of the 416 
MDCK cell line, which is less well studied. For the small intestine the expression of 417 
transporters and enzyme systems can vary from the three sections of the small intestine, as 418 
compounds are not just absorbed from one section, we tried to accommodate an overview of 419 
expression from the human small intestine [56]. It can be seen from Table S1 that the main 420 
differences between MDCK and Caco-2 cell lines in general are that MDCK does not express 421 















transporters compared to Caco-2 cell lines. However it must be noted that expression of 423 
transporters or enzymes does not necessarily correlate with their functionality for affecting 424 
the absorption of the compounds across different membrane/cell lines [57, 58], and as it was 425 
shown earlier, most substrates of different transporters do not deviate from the correlation 426 
between Caco-2 and MDCK permeabilities.  427 
The different expression levels of metabolising enzymes in the different cell lines could also 428 
potentially affect the permeability of compounds. The expression and activity of CYP3A4 429 
enzymes in Caco-2 cells are either not present or very weak [30, 59]. A recent investigation 430 
has found no evidence of CYP3A4 expression in MDCK II cells [60]. Unfortunately the lack 431 
of information regarding enzymatic activity in the cell lines makes it difficult to 432 
comprehensively compare and contrast the suitability of these in vitro tools as indicators of 433 
intestinal absorption. 434 
Cell based assays, particularly Caco-2, have a reputation for variability. The differences can 435 
arise from the experimental conditions, which in turn can affect the monolayer, those that 436 
affect the analysis of samples and also the physiochemical properties of the compound [61]. 437 
A good example is solubility, which depending on experimental conditions can cause 438 
variation particularly for compounds with low solubility such as the outlier compounds 439 
phenazopyridine and glipizide [54, 55] (Figure 1). 440 
The prime purpose of cell based assays such as Caco-2 and MDCK is to study the rate of 441 
passive permeability rather than other transport routes involving influx and efflux 442 
transporters. In this dataset, out of the 185 compounds, 96 were identified as undergoing 443 
transport routes other than passive. In some cases, more than one route was identified as 444 
being involved for the transport of the compound (Table 4). 445 
<<INSERT TABLE 4 HERE>> 446 
From Table 4, there are a higher number of compounds identified as carrier mediated efflux 447 
substrates compared to influx substrates. The majority of compounds that were identified as 448 
efflux substrates are substrates of the P-gp transporter, which is always tested due to the great 449 
influence this transporter has on reducing absorption of many compounds.  450 
We compared the permeability values obtained from Caco-2 and MDCK cell lines for all 451 















in Table 4. Two statistical methods were employed; 1) paired student t-test to compare 453 
MDCK and Caco-2 permeability values of a subgroup of compounds, and 2) comparison of 454 
the coefficients of the correlation lines of subgroups of compounds, e.g. efflux substrates and 455 
compounds with passive transcellular absorption. The results for subgroups indicated that 456 
permeabilities through MDCK and Caco-2 cell lines are correlated with similar slopes and 457 
intercepts for compounds with different absorption mechanisms (Figures S1-S7 and Table 458 
S2 in the Supporting Information III). The only significant difference between the 459 
correlation lines was the difference between compounds undergoing transcellular and 460 
paracellular absorption routes (p value 0.0023). However, despite the different tightness of 461 
the Caco-2 and MDCK cell lines, the observed difference may be due to the narrow range of 462 
permeability values of the compounds with paracellular absorption route resulting in a non-463 
significant correlation between MDCK and Caco-2 solubility of this subgroup (Figure S1 in 464 
Supporting Information III). This hypothesis is supported by the results of a paired student 465 
t test between the permeability values of the two cell lines for the 11 compounds undergoing 466 
paracellular absorption (as a main or shared transport route) showed no significant difference 467 
between Caco-2 and MDCK permeabilities (p > 0.05). In addition paired t tests for all 468 
different absorption mechanism groups and no significant differences between the two cell 469 
lines for these absorption groups were found. Therefore, we can conclude that in general 470 
there are no statistically significant differences between the two cell lines even when 471 
considering separately the compounds with different absorption mechanisms. Therefore, the 472 
data from both these cell lines can be combined into a larger permeability dataset for use in 473 
further modelling. 474 
3.2 Determining permeability threshold for an effective oral absorption 475 
In this work we use the large dataset of combined Caco-2 and MDCK permeability and a 476 
statistical method (CART) to identify statistically valid permeability threshold for high/low 477 
oral absorption. Using CART analysis, a permeability threshold value was obtained to predict 478 
the high or low intestinal absorption (HIA class) using a training set of 356 compounds. 479 
Several different analyses were performed where high absorption compounds were defined as 480 
those having HIA values of above 30, 50, 70, 80 or 90%. In order to optimise the threshold 481 
selection, various CART models using different misclassification cost ratios for false 482 
positives: false negatives (FP:FN) were generated [51, 53]. The results below show the 483 
permeability threshold selected by the CART analyses and the accuracy, specificity and 484 















<<INSERT TABLE 5 HERE>> 486 
It can be seen in Table 5 that using high ratios of (FP:FN) misclassification costs results in 487 
improved accuracy of the permeability threshold for classification of compounds into high or 488 
low absorption groups for all definitions of HIA class. For example using equal 489 
misclassification costs to find permeability threshold for dividing compounds into ≥ 30% or < 490 
30% HIA is not successful at all (Model 1 Table 5) but increasing the cost of false positives 491 
to five times that of the false negatives results in a high accuracy of classification and a 492 
robust threshold of -5.98 (in log units) (model 6). It must be noted here that different  493 
high/low definitions of HIA result in different proportions of compounds in “high” or “low” 494 
absorption classes, and hence the choice of misclassification cost ratios to reflect the ratios of 495 
highly absorbed to poorly absorbed compounds [51, 53]. Therefore by applying higher 496 
misclassification costs to reduce false positives, this has shifted the permeability threshold in 497 
order to reduce the number of false positives due to the under representation of the poorly 498 
absorbed class (Figure 2). The one exception to this is the 80% HIA class definition, where 499 
applying misclassification costs had no effect on the permeability threshold. In practice, when 500 
using the permeability threshold to classify high/low absorption compounds, the suitable 501 
threshold suggested by models 6-10 can be used for HIA class definition. The permeability 502 
thresholds determined by CART when applying higher misclassification costs from Table 5 503 
can be shown below (Figure 2) when plotting fraction absorbed against permeability for the 504 
training and validation sets. 505 
<<INSERT FIGURE 2 HERE>> 506 
As can be seen by Figure 2 there is a correlation between fraction absorbed and permeability. 507 
It is common in the literature to assume a sigmoid fit to the relationship between HIA and 508 
permeability [32, 36, 62]. However, there are too few points at the lower plateau region to 509 
justify fitting a sigmoidal fit from statistical point of view; in spite of this we found a r2 of 510 
0.435 for a sigmoid fit to the whole 433 compounds. The collection of more data in the 0-511 
50% region may resolve this problem.  512 
From Figure 2, there are compounds that are highly absorbed but have permeability values 513 
below the threshold and vice versa. The most pronounced outliers have been shown in the 514 
figure (Figure 2) using boxes A and B. Compounds with low permeability but high fraction 515 
absorbed (Region A on Figure 2) have been identified as mainly highly soluble and 516 















lamivudine [63, 64]. Due to the lower levels of these transporters, particularly PEPT1 in 518 
vitro, the cell permeability underestimates the percentage absorbed of this set of compounds. 519 
On the other hand, compounds with high permeability but low fraction absorbed tend to be 520 
those that are susceptible to gut metabolism and poorly soluble from this dataset (Region B 521 
on Figure 2). Examples of compounds in this outlier group are lovastatin and tacrolimus [65, 522 
66]. 523 
Although the liver is the main metabolising organ, gut metabolism can contribute 524 
significantly to overall metabolism and should be considered [67]. Compounds susceptible to 525 
gut metabolism, specifically CYP3A4 substrates, are highly permeable in vitro but are poorly 526 
absorbed in vivo. However there are other CYP3A4 substrates in this dataset which do not 527 
appear to undergo extensive gut metabolism so are both highly absorbed and highly 528 
permeable. Reasons for why some compounds are susceptible to gut metabolism and others 529 
are not even though they are both CYP3A4 substrates could be due to the different 530 
biotransformation rate by this enzyme, solubility/ dissolution rate, permeation rate, dose 531 
amount and substrate affinity [67-69]. A list of these compounds in regions A and B in 532 
Figure 2 can be found in the Supporting Information II. 533 
3.3 Oral absorption prediction using solubility, dose number and melting point 534 
From Figure 2, we have identified potential outliers in the relationship between oral 535 
absorption and permeability. Using the models built with permeability and solubility 536 
parameters and molecular descriptors, these misclassifications could be classified correctly 537 
due to the influence of solubility and other related parameters on oral absorption. For 538 
example, false positives are highly permeable compounds with poor oral absorption. These 539 
compounds maybe poorly soluble compounds or those undergoing gut metabolism. 540 
CART classification models to predict highly absorbed or poorly absorbed class of 541 
compounds (HIA ≥ 80 or < 80%) were built using the training sets described in the material 542 
and methods section. The permeability for ≥ 80% absorption (at -5.15 log scale according to 543 
Table 5) was used to develop the models. The 80% class definition was chosen as when 544 
using lower HIA% values to define high or low absorption led to very low number of poorly 545 
absorbed compounds, compared with highly absorbed compounds which would seriously 546 
reduce significance of models.  The HIA 90% cut-off for class definition, although used in 547 
some previous work, was not chosen in this work as (based on our preliminary analysis) that 548 















too high to predict oral absorption class effectively. Selected CART models produced for the 550 
prediction of HIA class (HIA> or ≤80%) using permeability and solubility related parameters 551 
and molecular descriptors are shown in Table 6. Note that for all models permeability was 552 
always used as the first split variable and the table gives the variables used for the second 553 
splits. After the second splits, CART picks the most significant parameter out of all the 554 
molecular descriptors and physicochemical properties available. In Table 6, in model 1 after 555 
permeability as the first split variable, CART automatically builds the rest of the tree by 556 
selecting the most significant property/molecular descriptor. For models 2-4, solubility; 557 
calculated solubility (GSE method or melting point based absorption potential (MPbAP)) 558 
were used on both (high and low permeability) sides of the tree for the second split, and after 559 
this CART automatically built the rest of the tree. Models 5-10 were built using different 560 
combinations of solubility and related parameters on either the high or low permeability side 561 
of the trees. Finally, models 11-12 were combinations of the molecular descriptors and 562 
solubility related parameters in high or low permeability sides of the trees.  563 
<<INSERT TABLE 6 HEERE>>564 
From Table 6 it is interesting to note which properties were used to build the selected 565 
models. Note that many combinations of melting point, dose and solubility related parameters 566 
were tested and Table 6 is a selection of the best models based on accuracy (SE X SP). Using 567 
melting point did not yield high prediction models (data not shown). It was thought that due 568 
to the relationship between melting point and solubility this parameter might be a useful 569 
alternative to solubility, as these two properties share similar functions such as enthalpy 570 
energies which must be overcome in order to solubilise or melt. Additionally, dose number 571 
was useful only for splitting the high permeability compounds and the combination with 572 
MPbAP yielded for a good prediction model (Model 6 in Table 6). Dose number is used to 573 
define high and low solubility for the BCS system [4, 42]. By definition, increasing the dose 574 
or a low solubility will result in a high dose number and this is expected to lead to poor oral 575 
absorption of highly permeable compounds. 576 
The majority of the selected models in Table 6 incorporate solubility and predicted solubility 577 
especially for highly permeable compounds. Unlike GSE solubility which was used on both 578 
sides of the CART trees, MPbAP only yielded good models when used for splitting on the 579 
high permeability compounds. Experimental solubility in two units, mg/ml or molar, have 580 















smaller for high molecular weight compounds, was utilised for splitting of the low 582 
permeability compounds (Models 8, 9 and 10). 583 
In terms of the role of solubility in the absorption process, one would expect poor absorption 584 
of poorly soluble compounds, due to solubility being the rate limiting factor in absorption. 585 
However, this is not the picture presented by the classification trees 1-12 (See Supporting 586 
Information III). According to the classification tree models, the low permeability and high 587 
solubility compounds always have low intestinal absorption (< 80%). This is probably due to 588 
the highly polar nature of such compounds. On the other hand, poorly water soluble 589 
compounds of low permeability may be highly absorbed from the small intestine if they have 590 
small polar surface area (models 3-7) or a small sum of absolute atomic partial charge, ABSQ 591 
(models 2, 8, 9, 10), which also indicates polarity of molecules. The absorption limiting 592 
effect of poor aqueous solubility is not seen for highly permeable compounds either. Here, 593 
highly permeable compounds with poor aqueous solubility are still highly absorbable from 594 
GI, with the exception of compounds with high polar surface area, low dipole moment 595 
(models 2, 5, 9) or small Balaban Topological index which is an indicator of molecular shape 596 
(models 3, 4, 10, 11). The reason for not observing the limiting effect of poor aqueous 597 
solubility here could be firstly the lack of enough representation of these solubility limiting 598 
compounds in the dataset and secondly the effect of formulation of oral dosage forms with 599 
measures taken for improved dissolution rate (excipients, particles size, etc) which could 600 
mask previous solubility limiting effects of such compounds.  601 
The top molecular descriptors used in models 1-12 in Table 6 are polar surface area (PSA) 602 
and Balaban topological index. Both of these descriptors are related to both absorption and 603 
solubility prediction models [70, 71]. PSA is the area of the van der Waals surface that arises 604 
from oxygen and nitrogen atoms or hydrogen atoms bound to these atoms [70]. The Balaban 605 
topological index, J, is the average-distance sum connectivity and relates to the shape of the 606 
molecule [72]. The next popular descriptors are sum of absolute charges on each atom of the 607 
molecule (ABSQ) and lowest unoccupied molecular orbital energy (LUMO) calculated by 608 
VAMP [73]. 609 
3.4 Selected CART models 610 
In order to generally compare models 1-12 from Table 6, the compound datasets used to 611 
build the resulting models should be taken into account. The degree of difficulty of the 612 















dataset is large, e.g. in the case of model 1, there are more compounds that maybe harder to 614 
classify in the dataset. The model with the highest SP x SE for the validation set is model 8, 615 
with a value of 0.697; however this is based on a training set of only 197 and a validation set 616 
of 40 compounds due to the missing experimental solubility or melting point values. On the 617 
other hand, model 12 has a slightly lower SP x SE of 0.682 for the validation set, but it was 618 
built using a training set of 257 and assessed using a validation set of 51 compounds; 619 
therefore it may be more suitable for generalization ability for new compounds, as it covers a 620 
wider chemical space compared with model 8. Moreover the only experimental parameter 621 
used in this model is melting point that is used for the calculation of MPbAP. We also 622 
selected model 7, which has used calculated solubility and MPbAP, and model 3 which has 623 
used only the calculated solubility to indicate the roles of solubility and absorption potential. 624 
The CART models are presented in Figures 3-5. Brief description of molecular descriptors 625 
has been presented in Supporting Information III (Table S3). 626 
 627 
<<INSERT FIGURE 3 HERE>> 628 
 629 
In Figure 3, Model 3, permeability is used as the first CART split variable and then 630 
calculated solubility from GSE equation on both sides of the tree was used as the second split 631 
variable. Polar surface area and Balaban index were picked automatically by the CART 632 
analysis. The model shows that highly permeable and highly soluble compounds have high 633 
intestinal absorption (node 7). Moreover, compounds with low predicted solubility (≤-4.74) 634 
can still be classed as highly absorbed if the Balaban index is > 1.57.  Compounds with a low 635 
Balaban index will be poorly absorbed and such examples include mebendazole and 636 
ketoconazole. In spite of this there are misclassifications in this node 8 in Figure 3; 637 
ziprasidone and tiagabine are misclassified as poorly absorbed when in fact they have HIA ≥ 638 
80%. Balaban topological index, J, a highly discriminant topological descriptor, gives an 639 
indication of shape including branching and cyclicity of a molecule. A high index can 640 
indicate a high number of branches, close proximity of the position of these branches, as well 641 
as increased number of double bonds on a molecule. A low index can indicate a low level of 642 
branching as well as a larger number of cyclic groups [72]. The relationship between Balaban 643 
index and solubility with reference to melting point has been shown previously in the 644 
literature [15]. In spite of this there is not much difference between the calculated GSE 645 















average melting points (222 oC compared with 193 oC in nodes 8 and 9 respectively), 647 
suggesting a possible effect of melting point on absorption.  648 
Poorly permeable compounds are highly absorbed only for compounds with predicted 649 
solubility ≤ -1.12 if the PSA is low. This is a higher solubility value than the threshold seen in 650 
splitting of node 3, and is not expected to limit the intestinal absorption. There are some 651 
misclassified compounds in this group, which are actually poorly absorbed despite having a 652 
low PSA, therefore classified as highly-absorbed according to this tree. The reasons for 653 
misclassifications is mostly due to efflux mechanisms reducing the absorption of compounds 654 
and examples include nadolol and norfloxacin which both have low PSA and classed as 655 
highly absorbed but are observed to have poor oral absorption due to transporter effects [31, 656 
74]. Unlike nadolol which is classed as highly soluble, norfloxacin is considered as a poorly 657 
soluble compound in class IV of the BCS system.  One may speculate that presence of more 658 
such compounds in this dataset, may have led to further split of this node based on solubility 659 
to class compounds with extremely low aqueous solubility as poorly soluble.   660 
<<INSERT FIGURE 4 HERE>> 661 
Model 7 was built using GSE solubility for the second split of the poorly permeable 662 
compounds (node 2) and MPbAP for the second split of highly permeable compounds in 663 
node 3. This model was chosen due to high validation SP x SE using a larger training and 664 
validation set. The descriptors used in this tree are the same as in Figure 3. Model 3, 665 
however, using the split based on MPbAP appears to split more compounds into node 6 to be 666 
classed by Balaban topological index. In this tree a lower threshold of 1.54 for Balaban 667 
Topological index increases the number of correctly classified poorly absorbed compounds 668 
when permeability is high examples of this type of compounds include the BCS class II 669 
compounds spironolactone and ketoconazole. 670 
<<INSERT FIGURE 5 HERE>> 671 
From Figure 5 classification of highly permeable compounds in node 3 is the same as Figure 672 
4. Poorly permeable compounds with a high number of hydrogen bonding donors (SHHBd 673 
>6.61) will be poorly absorbed, which is confirmed by the literature such as Lipinski’s rule of 674 
five, where compounds are likely to be poorly absorbed if two or more of the following rules 675 
are broken: more than > 5 hydrogen bond donors, > 10 hydrogen bond acceptors, logP > 5 676 















based on a higher number of hydrogen bond donor groups mainly due to being highly 678 
absorbed due to substrate specificity for influx transporters. Examples of misclassified 679 
compounds include ribavirin and folinic acid.  680 
A poorly permeable compound will still be highly absorbed if HOMO energy is greater than -681 
8.76. A comparison of the molecular structures in this node indicates that these compounds 682 
have more aromatic rings compared with compounds with lower HOMO energy (node ID 8) 683 
where the average number of aromatic rings is one. In addition it was also found that a 684 
number of low HOMO compounds had a permanent quaternary ammonium or ionisable 685 
centre such as trospium and neostigmine.  686 
Even if a poorly permeable compound has a low HOMO energy it can still be classed as 687 
highly absorbed if the compound has few methyl groups (SsCH3 ≤ 3.509) or log P > 1.239.   688 
Compounds with logP < 1.24 are classified as poorly absorbed, but there are false negatives 689 
such as orally administered cephradine and baclofen, which are both highly absorbed but are 690 
predicted as poorly absorbed by having a low logP. The reason for some of the false 691 
negatives in this node is that some of these compounds are substrates for influx carrier 692 
mediated systems. 693 
3.5 Discussion of related literature 694 
3.5.1 Subjective definition of a permeability threshold for oral absorption prediction 695 
Permeability from in vitro cell based assays has been utilised frequently in the literature. 696 
These thresholds are then used to give an indication of potential oral absorption from 697 
permeability data. A summary of a few permeability thresholds defined by other works is 698 
shown in Table 7.  699 
<<INSERT TABLE 7 HERE>> 700 
Early permeability thresholds defined by works in the literature are based on small compound 701 
datasets. Artusson et al [37] set a permeability threshold of > 1 x 10-6 cm/s for complete 702 
absorption based on 20 compounds. Based on other works in the literature this value is too 703 
low to predict complete absorption, where other works have permeability thresholds one 704 
order of magnitude higher. For example, from Table 7, Yee et al [41] has stated > 10 x 10-6 705 
cm/s permeability is related to absorption > 70%. What is apparent is the difference between 706 















compounds tested and inter and intra laboratory differences [13]. In comparison, our 708 
permeability thresholds are statistically defined by CART rather than a subjective 709 
determination; the thresholds picked by CART are similar to those in the literature, especially 710 
when high absorption was set at either as > 70%, > 80% or > 90%, indicating that high 711 
absorption is related to permeability > 7 x 10-6 cm/s. The permeability threshold determined 712 
by Hou et al [13] of 6 x 10-6 cm/s is based on data from numerous sources and is very similar 713 
to our 70 - 90% class permeability thresholds.  714 
Di et al (2011) [40] used MDCK II cells with low efflux endogenous transporter expression 715 
(MDCK-LE) to define a threshold of 3 x 10-6 cm/s to distinguish between low/medium 716 
absorbed compounds (< 80% HIA) and highly absorbed compounds. A dataset published by 717 
Varma et al (2012) [36] using the MDCK-LE cell line shows that the permeability threshold 718 
defined ROC analysis using this cell line (≥ 5.0 x 10-6 cm/s) is similar to Caco-2 thresholds in 719 
the literature, and this value is in agreement with CART permeability thresholds in this work. 720 
The threshold similarity between Caco-2 and MDCK cell lines is expected by the linear 721 
relationship between these two cell lines shown in this work.  722 
Finally more recently Pham-The et al (2013) [62] established a rank order relationship 723 
between Caco-2 permeability and oral absorption for 324 compounds. The thresholds defined 724 
were based on standard compounds from the FDA with known fraction absorbed values. For 725 
example, for a compound to be considered highly absorbed, it must have an apparent 726 
permeability greater than metoprolol, a FDA standard compound with known HIA. In this 727 
case Caco-2 permeability greater than 16 x 10-6 cm/s, which is 0.8 times the metoprolol 728 
permeability was used to take into account the lower HIA threshold of 85% used. For the low 729 
absorption threshold an average value of 0.7 x 10-6 cm/s, based on the permeability of 730 
mannitol was used. In this study this threshold was to define compounds with HIA < 30% 731 
however mannitol has a reported HIA of ~18% therefore the use of this permeability 732 
threshold may increase the number of false negatives. 733 
3.5.2 The influence of permeability and solubility on oral absorption modelling 734 
Permeability and solubility are two important factors important for oral absorption. Therefore 735 
the effect these two properties have on oral absorption and in turn how they influence oral 736 
absorption prediction is important to establish. From the literature there is a lot of focus on 737 
permeability and as shown in this work there is a rank order relationship between HIA and 738 















permeability in relation to oral absorption, but as a factor that can lead to poor (solubility 740 
limited) absorption in addition to other limiting factors such as transporter and enzyme 741 
effects. Furthermore, the relative importance of solubility could be dependent on the research 742 
organization and the mechanistic importance of solubility in regards to oral absorption may 743 
not be considered [6]. In spite of this the main reasons for poor oral absorption have been 744 
shown to be either poor permeability or poor solubility or both [76]. 745 
The results of this work indicate that permeability is the most important parameter 746 
influencing oral absorption prediction. Permeability was always picked as top molecular 747 
descriptor when building CART models. In contrast, solubility and the related parameters 748 
were never picked as the top descriptor or even in the second split, unless selected manually 749 
at this second level in order to examine if there was any influence of solubility on oral 750 
absorption prediction. 751 
It is apparent that solubility can be a rate-limiting step in oral absorption [4, 12, 77]. This is 752 
based on the principle that a drug must be dissolved in the gastrointestinal fluid in order to 753 
then permeate the membrane to be absorbed. However formulation development strategies 754 
can overcome this problem, for example by employing solubilising agents, pH control, or 755 
complexation [78]. 756 
In any case, the results obtained here do not directly indicate the poor absorption of poorly 757 
soluble compounds and the effects of poor solubility in limiting absorption. According to this 758 
study, in general compounds that are highly permeable but have low solubility can be 759 
predicted as highly or poorly absorbed depending on the other molecular properties. 760 
Moreover, poorly permeable but highly soluble compounds are classed as poorly absorbed, 761 
although there are exceptions to this i.e. the false negatives. One important consideration in 762 
analysing these results is the threshold of solubility in the models. For example, poorly 763 
permeable compounds with poor solubility may have high oral absorption (see models 3 and 764 
7 for example). However, it must be noted here that poor solubility has been defined as <-765 
1.12 in log unit, which is quite high when comparing with the threshold values suggested in 766 
the literature for BCS classes II and IV [4].  A further observation from the models could be 767 
the poor representation of very poorly soluble compounds in the dataset i.e. those having 768 
solubility-limited absorption. As a result, it may not be statistically advantageous to further 769 
split the classification tree to allocate these compounds into a separate terminal node. For 770 















out of 648 compounds[13]. Besides this the formulation techniques may improve the 772 
dissolution rate of these compounds and overcome the low solubility issues of compounds in 773 
the fraction absorbed dataset used in this work. 774 
It is difficult to directly compare other models in the literature with this work, as different 775 
data sets and methods have been used. Early oral absorption models which use a diverse 776 
dataset are too small to represent all the different biological processes of absorption and other 777 
factors such as solubility. The majority of oral absorption models in the literature do not 778 
include compounds which have solubility issues [10, 79]. Therefore, these and other models 779 
may only be useful for predicting absorption for compounds with no solubility issues. In 780 
addition, some of these studies also removed compounds with transporter effects or 781 
compounds with a permanent charge [13, 80]. This simplifies the resulting models by 782 
removing those compounds with these rate-limiting steps. However, the main issue with this 783 
is the potential impact on the generalizability of the resulting models which will fail to 784 
predict the oral absorption of these excluded compound classes despite the increased need in 785 
current drug discovery projects for prediction of absorption of the increasingly poorly-soluble 786 
compounds.  787 
In studies by Zhao and co-workers, data with solubility and dose dependency was defined 788 
and not used in the majority of the initial models. However upon inclusion of these 789 
compounds with solubility issues the resulting models had higher error [81]. It was also noted 790 
however that the more insoluble a compound the lower the resulting absorption. In a later 791 
study compounds identified with no solubility issues were used to built models and some of 792 
these resulting models were then used to predict absorption for the compounds with dose-793 
limiting and dose dependency effects. Overall prediction of absorption of these excluded 794 
compounds was in agreement with observed values or the models tended to overestimate 795 
absorption [12]. Our oral absorption models are able to predict oral absorption class even 796 
with poor solubility for majority of compounds by incorporating molecular descriptors in 797 
addition to permeability and solubility into the models. From the list of 27 compounds with 798 
solubility and related problems defined by Zhao et al (2001) [12], 14 were utilised in this 799 
work with experimental permeability and solubility values present. Using the best models 800 
chosen, 11 out of 14 compounds were predicted correctly by model 3, 12 out of 14 correct 801 















With the extended use of BCS classification in drug discovery, the influence of solubility and 803 
permeability is of great interest [82]. In work by Pham-The et al (2013), oral absorption was 804 
predicted, taking into account solubility, which is a general aim of the BCS. In this study, 805 
Pham-The, using a rank order relationship, noted that the relationship between permeability 806 
and oral absorption is less certain for poorly absorbed compounds which is a similar 807 
observation to our results. They also found various contour plots that incorporating solubility 808 
improves classification of HIA based on permeability data by about 10%; therefore showing 809 
that potentially using solubility in models is advantageous for oral absorption prediction. 810 
From the literature examples as well as this work the influence of solubility could be included 811 
to help predict oral absorption. However the main issue is the lack of experimental solubility 812 
for drug compounds to be used in oral absorption modelling. The use of experimental 813 
solubility data in the prediction of oral absorption alongside permeability yields good 814 
accuracy to predict oral absorption however the lack of experimental solubility limits the 815 
application for the prediction of new compounds. Therefore, according to our results, 816 
predicted solubility such as GSE solubility and parameters such as MPbAP can be used 817 
successfully instead of experimental solubility. These are based on simple properties of 818 
lipophilicity, melting point and dose. Despite this, melting point alone was not successful in 819 
providing an adequate alternative to experimental solubility, even though partition coefficient 820 
was also available to be used concurrently in the same model. Due to the complexity of 821 
solubility it is difficult to find one molecular descriptor to adequately describe all the 822 
solubility processes.  823 
4. CONCLUSION 824 
The two main properties influencing oral absorption are permeability and solubility. In order 825 
to establish the relationship of these two properties with oral absorption classification, firstly, 826 
a larger dataset was established from different sources. This was made possible through 827 
combining Caco-2 and MDCK permeability after comparing a linear relationship between 828 
these two cell lines, even for compounds with different absorption mechanisms.  829 
Secondly, using the combined permeability dataset, a permeability threshold for various 830 
levels of oral absorption was investigated using CART analysis. Due to the larger number of 831 
highly absorbed compounds, misclassification costs were applied and improved the threshold 832 















to some of those in the literature using mainly subjective methods to determine permeability 834 
thresholds.  835 
Finally the permeability thresholds were then used to build decision trees with the CART 836 
method, incorporating solubility and related parameters, as well as the calculated molecular 837 
descriptors to predict oral absorption class.  Melting point is not a useful parameter to predict 838 
absorption when used stand-alone. However, when melting point is utilised to calculate 839 
combined parameters such as predicted (GSE) solubility and melting point-based absorption 840 
potential, it yielded high accuracy models compared with experimental solubility. This is due 841 
to the possibility of using more data for the training of the models when calculated or more 842 
easily accessible experimental parameters are used. Therefore, models built using predicted 843 
values of solubility and melting point-based absorption gave rise to better predictive models. 844 
Molecular descriptors utilised in the models, such as those describing size, shape, 845 
polarizability and hydrogen bonding, can be related to both permeability and solubility and 846 
therefore oral absorption. These molecular descriptors were shown to be necessary for oral 847 
absorption models to correctly classify the compounds with solubility-limited absorption. The 848 
models built in this work are useful for a better mechanistic understanding of the effect of 849 
these properties and how they contribute to overall oral absorption. 850 
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Supporting information I contains the dataset of 932 compounds with HIA%, Caco-2 852 
permeability, MDCK permeability, aqueous solubility, melting point and the references. 853 
Supporting information II contains compound lists and information regarding the outliers in 854 
Figures 1 and 3 including references. Supporting Information III contains a table comparing 855 
the differences in transporter and enzyme expression between the human small intestine, 856 
Caco-2 and MDCK cell lines, the significance testing and graphs for the different absorption 857 
mechanisms when comparing Caco-2 and MDCK cell lines, all the models (CART decision 858 
trees) produced from this work, and finally a list of molecular descriptor utilised in the 12 859 
models presented in this work.  860 
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Table 1. Compound numbers used in the training and validation sets for decision tree 
analysis 






Permeability 433 356 77 
Solubility 296 242 54 
GSE solubility 315 262 53 
Dose number 292 239 53 
Melting point 315 262 53 

























Table 2. Data sets collated from the literature 
Property n 
Human intestinal absorption 932 
Caco-2 permeability 386 
MDCK permeability 246 
Aqueous solubility 482 
Dose number 465 
































Table 3. Statistical parameters for the linear relationship between MDCK and Caco-2 
permeability measured using PRISM 
Datasets r2 (with intercept) r2 (non-intercept) Rp Rs 
All compounds (185) 0.63 0.60 0.79 0.79 
Passive transcellular (83) 0.71 0.69 0.84 0.74 
OUTLIERS Removed (9 removed) 
All compounds (176) 0.73 0.72 0.86 0.84 



































Table 4. The different identified absorption mechanism of the 185 compounds  
Transport route Number of 
compounds 
Examples 
Passive transcellular (A) 83 sumatriptan, valsartan 
Passive paracellular (B) 6 lucifer yellow, mannitol 
Efflux (C) 62 vinblastine, saquinavir 
Efflux and paracellular (D) 2 famotidine, cimetidine 
Influx (E) 15 amoxicillin, tolbutamide 
Influx and paracellular (F) 2 soltalol, atenolol 
Efflux and influx (G) 14 talinolol, acebutolol 




























Table 5. The permeability thresholds selected by CART and HIA class prediction with equal and higher misclassification costs applied to false 






Set Misclassification Costs (FP:FN) 
Accuracy 










1 30% t 1:1 0.000 1.000 0.000 -6.11 0.78 
v 0.000 0.986 0.000 
2 50% t 1:1 0.626 0.905 0.692 -6.02 0.96 
v 0.470 0.939 0.500 
3 70% t 1:1 0.562 0.910 0.618 -5.91 1.23 
v 0.522 0.948 0.550 
4 80% t 1:1 0.645 0.745 0.865 -5.15 7.08 
v 0.630 0.741 0.850 
5 90% t 1:1 0.565 0.785 0.720 -5.08 8.32 
v 0.487 0.762 0.639 
6 30% t 5:1 0.672 0.874 0.769 -5.98 1.05 
v 0.800 0.914 0.875 
7 50% t 4:1 0.664 0.803 0.827 -5.64 2.29 
v 0.720 0.864 0.833 
8 70% t 3:1 0.645 0.745 0.865 -5.15 7.08 
v 0.630 0.741 0.850 
9 80% t 2.5:1 0.645 0.745 0.865 -5.15 7.08 
v 0.630 0.741 0.850 
10 90% t 2:1 0.566 0.759 0.745 -5.00 10.0 
v 0.533 0.738 0.722 














Table 6. The results of CART analysis for the best permeability and solubility related trees using permeability threshold for ≥ 80% or < 80% 
HIA as the first split 
Model   
Parameter used for second 
split 
Misclassification cost ratios 
(FP:FN) 
















1 Molecular Descriptorsa 
Molecular 
Descriptorsa 3:1 6:1 
t 356 0.72 0.754 0.955 
v 77 0.519 0.593 0.875 
2 Solubility (mg/ml) 
Solubility 
(mg/ml) 2:1 10:1 
t 241 0.723 0.823 0.879 




solubility 2:1 1:1 
t 261 0.695 0.891 0.779 
v 53 0.638 0.829 0.769 
4 MPbAP  MPbAP 1:1 1:1 t 249 0.753 0.876 0.859 
v 48 0.631 0.757 0.833 
5 Solubility (mg/ml) 
GSE 
solubility 2:1 10:1 
t 200 0.754 0.820 0.920 
v 40 0.583 0.667 0.875 
6 Dose number   MPbAP 2:1 10:1 t 196 0.758 0.791 0.958 
v 40 0.636 0.636 1.000 
7 MPbAP GSE 
solubility 2:1 1:1 
t 256 0.723 0.884 0.818 
v 51 0.667 0.800 0.833 
8 MPbAP Solubility (M)  2:1 1:1 
t 197 0.776 0.866 0.896 
v 40 0.697 0.697 1.000 
9 Solubility (mg/ml) 
Solubility 
(M)  2:1 10:1 
t 241 0.754 0.766 0.985 




(M)  2:1 1:1 
t 201 0.722 0.881 0.820 




Descriptorsa 2:1 1:1 
t 262 0.717 0.887 0.809 
v 53 0.650 0.780 0.833 
12 MPbAP Molecular Descriptorsa 2:1 1:1 
t 257 0.746 0.880 0.848 
v 51 0.688 0.750 0.917 
a
 These are the molecular descriptors statistically selected by CART out of all the molecular descriptors and solubility parameters. 













Table 7. Examples of permeability thresholds determined by the literature 
Study Cell line Papp threshold 





Artusson (1991) [37] Caco-2 >1  
















Hou (2007) [13] Caco-2 ≥ 6 .0 High 
(>80) 
69 






Varma (2012) [36] MDCKII* ≥ 5.0 ≥ 80/90 97 
Pham-The (2013) [62] Caco-2 ~ 0.7 














































Log MDCK Papp = 1.009*Log Caco-2 Papp
r2= 0.600 rp=0.792 n=185
Transport Route














































































Tree graph for 80.000000

























<= -5.150000 > -5.150000
GSE solubility
<= -1.120000 > -1.120000
ACD_PSA
<= 89.240000 > 89.240000
GSE solubility
<= -4.740000 > -4.740000
Balaban Topological index
<= 1.569850 > 1.569850















Tree graph for 80.000000

























<= -5.150000 > -5.150000
GSE solubility
<= -1.120000 > -1.120000
ACD_PSA
<= 89.240000 > 89.240000
MPbAP
<= 2.160000 > 2.160000
Balaban Topological index
<= 1.539019 > 1.539019















Tree graph for 80.000000

































<= -5.150000 > -5.150000
SHHBd
<= 6.612200 > 6.612200
VAMP HOMO
<= -8.757106 > -8.757106
SsCH3
<= 3.509010 > 3.509010
LogP
<= 1.239340 > 1.239340
MPbAP
<= 2.160000 > 2.160000
Balaban Topological index
<= 1.539019 > 1.539019















• A large dataset of solubility, permeability and oral absorption was collated 
• A permeability threshold was defined to predict oral absorption using decision tree 
• Predictive decision trees were developed and the molecular descriptors explained 
• Poorly permeable compounds with high solubility show low intestinal absorption 























1 Olsalazine 15722-48-2 Oc1ccc(N=Nc2cc(C(O)=O)c(O)cc2)cc1C(O)=O8 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
2 Lincomycin 154-21-2 S(C)C1OC(C(NC(=O)C2N(CC(C2)CCC)C)C(O)C)C(O)C(O)C1O28 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
3 Cefuroxime 55268-75-2 S1C2N(C(=O)C2NC(=O)\C(=N\OC)\c2occc2)C(C(O)=O)=C(C1)COC(=O)N44.5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
4 Penicillin_V 87-08-1 O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)COc1ccccc1)[C@H]3SC2(C)C59 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
5 Loperamide_Hydrochloride 53179-11-6 Clc1ccc(cc1)C4(O)CCN(CCC(c2ccccc2)(c3ccccc3)C(=O)N(C)C)CC476 Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.EF 
6 Mitoxantrone 65271-80-9 Oc1c2c(C(=O)c3c(C2=O)c(NCCNCCO)ccc3NCCNCCO)c(O)cc1Poor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
7 Bretylium 59-41-6 Brc1ccccc1C[N+](CC)(C)C23 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
8 Amoxicillin 26787-78-0 S1C2N(C(C(O)=O)C1(C)C)C(=O)C2NC(=O)C(N)c1ccc(O)cc192 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
9 Zolmitriptan 139264-17-8 O=C1OC[C@@H](N1)Cc2ccc3c(c2)c(cn3)CCN(C)C91.5 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
10 Acyclovir 59277-89-3 O=C1NC(=Nc2n(cnc12)COCCO)N23 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
11 Sotalol 3930-20-9 S(=O)(=O)(Nc1cc(OCC(O)CNC(C)C)ccc1)C95 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
12 Lamivudine 134678-17-4 S1CC(OC1CO)N1CCC(=NC1=O)N86 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
13 Sulpiride 15676-16-1 S(=O)(=O)(N)c1cc(C(=O)NCC2CCN(C2)CC)c(OC)cc140 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
14 Lisinopril 76547-98-3 OC(=O)C1N(CCC1)C(=O)C(NC(CCc1ccccc1)C(O)=O)CCCCN27 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
15 Oseltamivir 196618-13-0 O(C(CC)CC)C1C=C(CC(N)C1NC(=O)C)C(OCC)=O75 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
16 Gabapentin 60142-96-3 OC(=O)C1(CCCCC1)CN74 Stewart BH, Kugler AR, Thompson PR, et al,  Pharm Res, 1993, 10, 276-81.Originally was cited as 57% (Hou 2012) however fraction absorbed should not be lower than BA. Dose dependancy at higher concentrations due to saturation of uptake transporters in intestine. At concentration of 100mg fraction absorbed was 74% - main route is renal excretion and not metabolised
17 Saquinavir 127779-20-8 OC(C(NC(=O)C(NC(=O)c1nc2c(cc1)cccc2)CC(=O)N)Cc1ccccc1)CN1CC2C(CC1C(=O)NC(C)(C)C)CCCC230 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
18 Telithromycin 191114-48-4 O1C(CC)C2(OC(=O)N(C2C(C)C(=O)C(CC(OC)(C)C(OC2OC(CC(N(C)C)C2O)C)C(C)C(=O)C(C)C1=O)C)CCCCn1cc(nc1)-c1cccnc1)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1 32-1137
19 Ganciclovir 82410-32-0 O=C2/N=C(\Nc1n(cnc12)COC(CO)CO)N4 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
20 Sulfasalazine 599-79-1 S(=O)(=O)(Nc1ncccc1)c1ccc(N=Nc2cc(C(O)=O)c(O)cc2)cc113 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
21 Valsartan 137862-53-4 OC(=O)C(N(Cc1ccc(cc1)-c1ccccc1-c1[nH]nnn1)C(=O)CCCC)C(C)C55 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
22 Cimetidine 51481-61-9 S(Cc1nc[nH]c1C)CCN\C(=N\C)\NC#N100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137Variable reuslts - not d in the literature due to gastric motility - could explain the variation - Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. Takamatsu N (2002) AND The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon Rebecca L. Oberle (1986)
23 Sumatriptan 103628-46-2 S(=O)(=O)(NC)Cc1cc2c([nH]cc2CCN(C)C)cc167 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
24 Neostigmine 59-99-4 O(C(=O)N(C)C)c1cc([N+](C)(C)C)ccc12 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
25 Ranitidine 66357-35-5 S(Cc1oc(cc1)CNC)CCN\C(=N\[N+](=O)[O-])\NC57 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
26 Azithromycin 83905-01-5 O1C(CC)C(O)(C)C(O)C(N(CC(CC(O)(C)C(OC2OC(CC(N(C)C)C2O)C)C(C)C(OC2OC(C)C(O)C(OC)(C2)C)C(C)C1=O)C)C)C60 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med hem 2010, 53,, 1098-1 08.
27 Famotidine 76824-35-6 s1cc(nc1\N=C(\N)/N)CSCC/C(=N/S(=O)(=O)N)/N45 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
28 Cycloserine 68-41-7 O1NC(=O)C(N)C172 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
29 Tetracycline 60-54-8 C[C@]1(c2cccc(c2C(=O)C3=C([C@]4([C@@H](C[C@@H]31)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
30 Chlorothiazide 58-94-6 Clc1cc2N=CNS(=O)(=O)c2cc1S(=O)(=O)N60 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
31 Lucifer_Yellow Numerous for different saltsS(O)(=O)(=O)c1cc2c3c(cc(S(O)(=O)=O)cc3c1N)C(=O)N(NNC(=O)NN)C2=O0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
32 Rosuvastatin 287714-41-4 O=S(=O)(N(c1nc(c(c(n1)C(C)C)/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c2ccc(F)cc2)C)C50 Varma, M. V. S., Obach, R. S., Rotter, ., et al, J Med Chem 2010, 53,, 1098-1108.
33 Erythromycin 114-07-8 O1C(CC)C(O)(C)C(O)C(C)C(=O)C(CC(O)(C)C(OC2OC(CC(N(C)C)C2O)C)C(C)C(OC2OC(C)C(O)C(OC)(C2)C)C(C)C1=O)C35 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 012, 52, 1132-1137
34 Baclofen 1134-47-0 Clc1ccc(cc1)C(N)CCC(O)=O95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
35 Furosemide 54-31-9 Clc1cc(NCc2occc2)c(C(O)=O)c(S(=O)(=O)N)c161 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
36 Talinolol 38649-73-9 O=C(NC1CCCCC1)Nc2ccc(OCC(O)CNC(C)(C)C)cc265 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
37 Loracarbef 76470-66-1 ClC=1CCC2N(C(=O)C2NCC(N)c2ccccc2)C=1C(O)=O100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
38 Hydrochlorothiazide 58-93-5 Clc1cc2NCNS(=O)(=O)c2cc1S(=O)(=O)N68 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
39 Mannitol 69-65-8 OC(C(O)C(O)CO)C(O)CO19 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
40 Vinblastine 865-21-4 O=C(OC)[C@]4(c2c(c1ccccc1n2)CCN3C[C@](O)(CC)C[C@H](C3)C4)c5c(OC)cc6c(c5)[C@@]89[C@@H](N6C)[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]7(/C=C\CN([C@@H]78)CC9)CC5 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
41 Terbutaline 23031-25-6 Oc1cc(cc(O)c1)C(O)CNC(C)(C)C63 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
42 Amisulpride 71675-85-9 O=S(=O)(c1cc(c(OC)cc1N)C(=O)NCC2N(CC)CCC2)CC100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
43 Atenolol 29122-68-7 O(CC(O)CNC(C)C)c1ccc(cc1)CC(=O)N50 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
44 Methyldopa 555-30-6 Oc1cc(ccc1O)CC(N)(C(O)=O)C50 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
45 Carvedilol 72956-09-3 O(CCNCC(OCc1c2c3c([nH]c2ccc1)cccc3)O)c1ccccc1OC80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
46 Practolol 6673-35-4 OC(CNC(C)C)c1ccc(NC(=O)C)cc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
47 Methotrexate 59-05-2 O=C(O)[C@@H](NC(=O)c1ccc(cc1)N(C)Cc2nc3c(nc2)nc(nc3N)N)CCC(=O)O70 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
48 Ciprofloxacin 85721-33-1 Fc1cc2c(nc1N1CCCCC1)N(C=C(C(O)=O)C2=O)C1CC169 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
49 Netivudine 84558-93-0 O1C(CO)C(O)C(O)C1N1C=C(C#CC)C(=O)NC1=O28 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
50 Doxorubicin 23214-92-8 O1C(C)C(O)C(N)CC1OC1CC(O)(Cc2c1c(O)c1c(C(=O)c3c(C1=O)c(OC)ccc3)c2O)C(=O)CO5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
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51 Nadolol 42200-33-9 O(CC(O)CNC(C)(C)C)c1c2CC(O)C(O)Cc2ccc132 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
52 Digoxin 20830-75-5 O1C(C)C(OC2OC(C)C(O)C(O)C2)C(O)CC1OC1C(OC(OC2CC3CCC4C(CC(O)C5(C)C(CCC45O)C4=CC(OC4)=O)C3(CC2)C)CC1O)C78 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
53 Acebutolol 37517-30-9 O(CC(O)CNC(C)C)c1ccc(NC(=O)CCC)cc1C(=O)C85 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
54 Losartan 114798-26-4 Clc1nc(n(Cc2ccc(cc2)-c2ccccc2-c2[nH]nnn2)c1CO)CCCC80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
55 Doxycycline 564-25-0 O=C3/C(=C(/O)N)C(=O)[C@@]4(O)C(=O)\C2=C(/O)c1c(cccc1O)[C@@H]([C@H]2[C@H](O)[C@H]4[C@@H]3N(C)C)C100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
56 Domperidone 57808-66-9 Clc1cc2NC(=O)N(NC3CCN(CC3)CCCN3c4c(NC3=O)cccc4)c2cc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
57 Sertraline hydrochloride 79559-97-0 Clc1ccc(cc1Cl)[C@H]3c2c(cccc2)[C@@H](NC)CC386 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019839s079,020990s038lbl.pdfEU/EF
58 Dicloxacillin 3116-76-5 O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(onc2c1c(Cl)cccc1Cl)C)[C@H]4SC3(C)C100 Varma, M. V. S., Oba h, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
59 Etoposide 33419-42-0 O1C2C(OC(OC2)C)C(O)C(O)C1OC1C2C(C(c3c1cc1OCOc1c3)c1cc(OC)c(O)c(OC)c1)C(OC2)=O50 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
60 Acrivastine 87848-99-5 OC(=O)\C=C\c1nc(ccc1)/C(=C/CN1CCCC1)/c1ccc(cc1)C88 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
61 Disopyramide 3737-09-5 O=C(N)C(CCN(C(C)C)C(C)C)(c1ccccc1)c1cccnc195 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
62 Amprenavir 161814-49-9 O=C(O[C@H]1CCOC1)N[C@@H](Cc2ccccc2)[C@H](O)CN(CC(C)C)S(=O)(=O)c3ccc(N)cc389 Sadler BM, Chittick GE, Polk RE, et al.,J Clin Pharmacol, 2001, 41, 386-96Extensively metabolised by CYP3A4, Based on mass balance studies, unchanged Amprenavir was below limit of quantification however has been cited to be <2% of the dose. The total recovery (median) was 89% with extensive metabolism, this therfore can be used as the fraction absorbed, mark as uncertain
63 Enalapril 75847-73-3 OC(=O)C1N(CCC1)C(=O)C(NC(CCc1ccccc1)C(O)=O)C63 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
64 Levofloxacin 100986-85-4 C[C@H]1COc2c3n1cc(c(=O)c3cc(c2N4CCN(CC4)C)F)C(=O)O100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
65 Cetirizine 83881-51-0 Clc1ccc(cc1)C(c2ccccc2)N3CCN(CC3)CCOCC(=O)O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
66 Minoxidil 38304-91-5 [O-][n+]1ccc(nc1N)N1CCCCC196 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
67 Dipyridamole 58-32-2 OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO58 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
68 Chloramphenicol 56-75-7 ClC(Cl)C(=O)NC(C(O)c1ccc([N+](=O)[O-])cc1)CO90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
69 Flecainide 54143-55-4 FC(F)(F)COc1ccc(OCC(F)(F)F)cc1C(=O)NCC1NCCCC181 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
70 Amitriptyline 50-48-6 N(CC\C=C/1\c2c(CCc3c\1cccc3)cccc2)(C)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
71 Bosentan 147536-97-8 CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc2c(c(nc(n2)c3ncccn3)OCCO)Oc4ccccc4OC69.8 Weber, C, Gasser, R, Hopfgartner, G, Drug Metab Dispos, 1999, 27, 10-5.EU/EF
72 Nelfinavir 159989-64-7 O=C(c1cccc(O)c1C)N[C@@H](CSc2ccccc2)[C@H](O)CN4[C@H](C(=O)NC(C)(C)C)C[C@@H]3CCCC[C@@H]3C478 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020778s035,020779s056,021503s017lbl.pdf
73 Amiloride 2016-88-8 Clc1nc(C(=O)\N=C(\N)/N)c(nc1N)N50 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
74 Cephalexin 15686-71-2 S1C2N(C(=O)C2NC(=O)C(N)c2ccccc2)C(C(O)=O)=C(C1)C96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
75 Crizotinib 877399-52-5 C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC447 http://www.ac essdata.fda.gov/drugsatfda_docs/label/2013/202570s004lbl.pdfBA/EU/EF
76 Ketoconazole 65277-42-1 Clc1cc(Cl)ccc1C1(OC(CO1)COc1ccc(N2CCN(CC2)C(=O)C)cc1)Cn1ccnc175 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
77 Ofloxacin 82419-36-1 Fc1cc2c3N(C=C(C(O)=O)C2=O)C(COc3c1N1CCN(CC1)C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
78 Chloroquine 54-05-7 Clc1cc2nccc(N(CCCCN(CC)CC)C)c2cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
79 Ritonavir 155213-67-5 CC(C)c4nc(CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1ccccc1)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc3cncs3)cs470 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
80 Fluoxetine 54910-89-3 FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
81 Rifabutin 72559-06-9 CC(C)CN1CCC2(CC1)/N=C\3/c4c6C(=O)[C@@]5(C)O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(\C)C(=O)N\C(=C/3/N2)C(=O)c4c(O)c(C)c6O553 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
82 Prednisolone 50-24-8 OC1(CCC2C3C(C4(C(=CC(=O)C=C4)CC3)C)C(O)CC12C)C(=O)CO99 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
83 Norethindrone 68-22-4 OC1(CCC2C3C(C4C(=CC(=O)CC4)CC3)CCC12C)C#C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
84 Zidovudine 30516-87-1 O1C(CO)C(N=[N+]=[N-])CC1N1[C+]=C(C)C(=O)NC1=O97 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
85 Tacrolimus 104987-11-3 O=C3C(=O)N1CCCC[C@H]1C(=O)O[C@H](C(=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)/C)[C@H](C)[C@@H](O)CC(=O)[C@@H](/C=C(\C[C@@H](C[C@H](OC)[C@H]4O[C@]3(O)[C@H](C)C[C@@H]4OC)C)C)C\C=C15 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
86 Atropine 51-55-8 O(C(=O)C(CO)c1ccccc1)C1CC2N(C(C1)CC2)C94 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
87 Ethinyl_Estradiol 57-63-6 OC1(CCC2C3C(CCC12C)c1c(cc(O)cc1)CC3)C#C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
88 Clozapine 5786-21-0 Clc1cc2N=C(N3CCN(CC3)C)c3c(Nc2cc1)cccc3100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
89 Cisapride 81098-60-4 Clc1cc(C(=O)NC2CCN(CC2OC)CCCOc2ccc(F)cc2)c(OC)cc1N100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
90 Ascorbic_Acid 50-81-7 O1C(C(O)CO)C(O)=C(O)C1=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
91 Fluconazole 86386-73-4 Fc1cc(F)ccc1C(O)(Cn1ncnc1)Cn1ncnc194 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
92 Trimethoprim 738-70-5 O(C)c1c(OC)cc(cc1OC)Cc1cnc(nc1N)N98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
93 Ziprasidone 146939-27-7 Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2c1cccc290 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
94 Terfenadine 50679-08-8 OC(C1CCN(CC1)CCCC(O)c1ccc(cc1)C(C)(C)C)(c1ccccc1)c1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
95 Lovastatin 75330-75-5 O=C(O[C@@H]1[C@H]3C(=C/[C@H](C)C1)\C=C/[C@@H]([C@@H]3CC[C@H]2OC(=O)C[C@H](O)C2)C)[C@@H](C)CC31 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
96 Prazosin 19216-56-9 o1cccc1C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n186 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
97 Haloperidol 52-86-8 Clc1cc(ccc1)C1(O)CCN(CC1)CCCC(=O)c1ccc(F)cc1100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
98 Felodipine 72509-76-3 Clc1c(cccc1Cl)C1C(C(OCC)=O)=C(NC(C)=C1C(OC)=O)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
99 Quinidine 56-54-2 O(C)c1cc2c(nccc2C(O)C2N3CC(C(C2)CC3)C=C)cc180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
100 Glipizide 29094-61-9 S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(cc1)CCNC(=O)c1ncc(nc1)C100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
101 Prednisone 53-03-2 O=C(CO)[C@@]3(O)CC[C@H]2[C@@H]4CC\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4C(=O)C[C@@]23C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-11 7
102 Fluvastatin 93957-54-1 Fc1ccc(cc1)-c1c2c(n(C(C)C)c1\C=C\C(O)CC(O)CC(O)=O)cccc2100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
103 Citalopram 59729-33-8 Fc1ccc(cc1)C1(OCc2c1ccc(c2)C#N)CCCN(C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
104 Methylprednisolone 83-43-2 OC1(CCC2C3C(C4(C(=CC(=O)C=C4)C(C3)C)C)C(O)CC12C)C(=O)CO82 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
105 Propafenone 54063-53-5 O(CC(O)CNCCC)c1ccccc1C(=O)CCc1ccccc195 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
106 Hydroxyzine 68-88-2 Clc1ccc(cc1)C(c2ccccc2)N3CCN(CC3)CCOCCO80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
107 Scopolamine 51-34-3 O1C2C3N(C(CC(OC(=O)C(CO)c4ccccc4)C3)C12)C93 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
108 Theophylline 58-55-9 O=C1N(C)C(=O)N(c2nc[nH]c12)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















110 Imipramine 50-49-7 N(CCCN1c2c(CCc3c1cccc3)cccc2)(C)C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
111 Astemizole 68844-77-9 Fc1ccc(cc1)Cn1c2c(nc1NC1CCN(CC1)CCc1ccc(OC)cc1)cccc2100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
112 Morphine 57-27-2 O1C2C34C(C(N(CC3)C)Cc3c4c1c(O)cc3)C=CC2O90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
113 Labetalol 36894-69-6 Oc1ccc(cc1C(=O)N)C(O)CNC(CCc1ccccc1)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
114 Bromocriptine 25614-03-3 BrC1Nc2c3C1CC1N(CC(C=C1c3ccc2)C(=O)NC1C(C2N(C(CC(C)C)C(=O)N3C2CCC3)C1=O)C(C)C)C28 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
115 Trazodone 19794-93-5 Clc1cc(N2CCN(CC2)CCCN2N=C3N(C=CC=C3)C2=O)ccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
116 Dexamethasone 50-02-2 FC12C(C3CC(C)C(O)(C(=O)CO)C3(CC1O)C)CCC1=CC(=O)C=CC12C90 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
117 Phenazopyridine 94-78-0 n1c(N)c(N=Nc2ccccc2)ccc1N90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
118 Ephedrine 50906-05-3 OC(c1ccccc1)C(NC)C97 Sever, P. S., Dring, L.G., and Williams, R. T., Eur J Clin Pharmacol, 1975, 9, 193-8EU
119 Risperidone 106266-06-2 Fc1cc2onc(c2cc1)C1CCN(CC1)CCC=1C(=O)N2C(=NC=1C)CCCC297 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
120 Zolpidem 82626-48-0 O=C(N(CCC)CCC)Cc1n2C=C(C=Cc2nc1-c1ccc(cc1)C)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
121 Diclofenac 15307-86-5 Clc1cc(Cl)ccc1Nc1ccccc1CC(O)=O00 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
122 Lansoprazole 103577-45-3 S(=O)(Cc1ncc(C)c(OCC(F)(F)F)c1)c1[nH]c2c(n1)cccc285 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
123 Metoprolol 37350-58-6 O(CC(O)CNC(C)C)c1ccc(cc1)CCOC96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
124 Lorazepam 846-49-1 Clc1ccccc1C1=NC(O)C(=O)Nc2c1cc(Cl)cc295 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
125 Mebendazole 31431-39-7 O(C(=O)Nc1[nH]c2cc(ccc2n1)C(=O)c1ccccc1)C6 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
126 Methadone 76-99-3 O=C(C(CC(N(C)C)C)(c1ccccc1)c1ccccc1)CC80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
127 Ketoprofen 22071-15-4 OC(=O)C(C)c1cc(ccc1)C(=O)c1ccccc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
128 Sildenafil 139755-83-2 O=S(=O)(N1CCN(C)CC1)c4cc(C\2=N\C(=O)c3c(N/2)c(nn3C)CCC)c(OCC)cc492 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
129 Loratadine 79794-75-5 Clc1cc2c(cc1)\C(\c1ncccc1CC2)=C\1/CCN(CC/1)C(OCC)=O90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
130 Glyburide 10238-21-8 Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)c(OC)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
131 Flurbiprofen 5104-49-4 Fc1cc(ccc1)-c1ccc(cc1)C(C(O)=O)C95 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
132 Bromazepam 1812-30-2 Brc1cc2c(NC(=O)CN=C2c2ncccc2)cc184 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
133 Naproxen 22204-53-1 O(C)c1cc2c(cc(cc2)C(C(O)=O)C)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
134 Chlorpromazine 50-53-3 Clc1cc2N(c3c(Sc2cc1)cccc3)CCCN(C)C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
135 Repaglinide 135062-02-1 O(CC)c1cc(ccc1C(O)=O)CC(=O)NC(CC(C)C)c1ccccc1N1CCCCC1100 ao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
136 Oxycodone 76-42-6 O1C2C34CCN(C(Cc5c3c1c(OC)cc5)C4(O)CCC2=O)C60 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
137 Phenytoin 57-41-0 O=C1NNC(=O)C1(c1ccccc1)c1ccccc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
138 Lopinavir 192725-17-0 O=C(N[C@@H](Cc1ccccc1)[C@@H](O)C[C@@H](NC(=O)[C@@H](N2C(=O)NCCC2)C(C)C)Cc3ccccc3)COc4c(cccc4C)C80.7 Kumar GN, Jayanti VK, Johnson MK, et al, Pharm Res, 2004, 21, 1622-30EU/EF
139 Pheniramine 86-21-5 n1ccccc1C(CCN(C)C)c1ccccc199 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
140 Oxprenolol 6452-71-7 O(CC(O)CNC(C)C)c1ccccc1OCC=C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
141 Hydrocortisone 50-23-7 OC1(CCC2C3C(C4(C(=CC(=O)CC4)CC3)C)C(O)CC12C)C(=O)CO91 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
142 Caffeine 58-08-2 O=C1N(C)C(=O)N(c2ncn(c12)C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
143 Diflunisal 22494-42-4 Fc1cc(F)ccc1-c1cc(C(O)=O)c(O)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
144 Tolbutamide 64-77-7 S(=O)(=O)(NC(=O)NCCCC)c1ccc(cc1)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
145 Buspirone 36505-84-7 O=C1N(CCCCN2CCN(CC2)c2ncccn2)C(=O)CC2(C1)CCCC2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
146 Triazolam 28911-01-5 Clc1ccccc1C1=NC=C2N(c3c1cc(Cl)cc3)C(=NN2)C85 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
147 Acetaminophen 103-90-2 Oc1ccc(NC(=O)C)cc185 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
148 Ibuprofen 15687-27-1 OC(=O)C(C)c1ccc(cc1)CC(C)C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
149 Diazepam 439-14-5 Clc1cc2c(N(C)C(=O)CN=C2c2ccccc2)cc199 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
150 Oxaprozin 21256-18-8 o1c(c(nc1CCC(O)=O)-c1ccccc1)-c1ccccc198 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
151 Diltiazem 33286-22-5 OC1CC2=CCC3C4CCC(C(CCCC(C)C)C)C4(CCC3C2(CC1)C)C91 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
152 Alprazolam 28981-97-7 Clc1cc2c(-n3c(nnc3C)CN=C2c2ccccc2)cc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
153 Alfentanil 71195-58-9 O=C1N(\N=N/N1CC)CCN3CCC(N(c2ccccc2)C(=O)CC)(CC3)COC100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
154 Naltrexone 16590-41-3 O1C2C34CCN(C(Cc5c3c1c(O)cc5)C4(O)CCC2=O)CC1CC19 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
155 Amantadine 768-94-5 NC12CC3CC(C1)CC(C2)C390 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
156 Promethazine 60-87-7 S1c2c(N(c3c1cccc3)CC(N(C)C)C)cccc288 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
157 Chlorpheniramine 132-22-9 Clc1ccc(N(CCN(C)C)c2ncccc2)cc180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
158 Tacrine 321-64-2 n1c2c(CCCC2)c(N)c2c1cccc295 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
159 Propranolol 525-66-6 OC(C(NC(C)C)C)c1c2c(ccc1)cccc295 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
160 Warfarin 81-81-2 O1c2c(cccc2)C(O)=C(C(CC(=O)C)c2ccccc2)C1=O97 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
161 Alprenolol 13655-52-2 O(CC(O)CNC(C)C)c1ccccc1CC=C93 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
162 Indomethacin 53-86-1 O(C)c1cc2c(n(cc2CC(O)=O)C(=O)c2ccccc2)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
163 Carbamazepine 298-46-4 O=C(N)N1c2c(C=Cc3c1cccc3)cccc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
164 Naloxone 465-65-6 O1C2C34CCN(C(Cc5c3c1c(O)cc5)C4(O)CCC2=O)CC=C91 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
165 Verapamil 52-53-9 O(C)c1cc(ccc1OC)C(C(C)C)(CCCN(CCc1cc(OC)c(OC)cc1)C)C#N95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
166 Midazolam 59467-70-8 Clc1cc2c(-n3c(CN=C2c2ccccc2F)cnc3C)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
167 Clonidine 4205-90-7 Clc1cccc(Cl)c1\N=C/1\NCCN\195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















169 Desipramine 50-47-5 N(CCCN1c2c(CCc3c1cccc3)cccc2)C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
170 Antipyrine 60-80-0 O=C1N(N(C)C(=C1)C)c1ccccc198 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
171 Pindolol 13523-86-9 O(CC(O)CNC(C)C)c1c2c([nH]cc2)ccc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
172 Guanabenz 5051-62-7 Clc1cccc(Cl)c1\C=N\NC(N)=N78 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
173 Nitrendipine 39562-70-4 O(C(=O)C=1C(C(C(OC)=O)=C(NC=1C)C)c1cc([N+](=O)[O-])ccc1)CC88 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
174 Nicardipine 55985-32-5 O(C(=O)c1c(C2C=C(NC(=C2)C)C)c(C(OC)=O)c(cc1[N+](=O)[O-])C)CCN(Cc1ccccc1)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
175 Lidocaine 137-58-6 O=C(Nc1c(cccc1C)C)CN(CC)CC98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
176 Piroxicam 36322-90-4 S1(=O)(=O)N(C)C(C(=O)Nc2ncccc2)=C(O)c2c1cccc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
177 Tamoxifen 10540-29-1 O(CCN(C)C)c1ccc(cc1)\C(=C(\CC)/c1ccccc1)\c1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
178 Nifedipine 21829-25-4 O(C(=O)C)C=1C(C(C(OC)=O)=C(NC=1C)C)c1ccccc1[N+](=O)[O-]90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
179 Lamotrigine 84057-84-1 Clc1c(cccc1Cl)-c1nnc(nc1N)N98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
180 Ondansetron 99614-02-5 O=C1c2c(n(c3c2cccc3)C)CCC1Cn1ccnc1100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
181 Testosterone 58-22-0 OC1CCC2C3C(CCC12C)C1(C(=CC(=O)CC1)CC3)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
182 Bupropion 34841-39-9 Clc1ccc(cc1)C(=O)C(NC(C)(C)C)C87 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
183 Corticosterone 50-22-6 OC1C2C(C3CCC(C(=O)CO)C3(C1)C)CCC1=CC(=O)CCC12C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
184 Progesterone 57-83-0 O=C1CCC2(C3C(C4CCC(C(=O)C)C4(CC3)C)CCC2=C1)C96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
185 Levodopa 59-92-7 Oc1cc(ccc1O)CC(N)C(O)=O86 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
186 Alendronic_Acid 66376-36-1 P(O)(O)(=O)C(P(O)(O)=O)(O)CCCN1 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
187 Deferoxamine 70-51-9 CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O2 ao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
188 HBED 35998-29-9 O=C(O)CN(Cc1ccccc1O)CCN(Cc2ccccc2O)CC(=O)O5 Gunturi, S.B. and Narayanan, R. , QSAR Comb Sci, 2007,  26, 653-668;
Wohnsland F, Faller B., J Med Chem, 2001, 15, 923-30.
189 Clodronate 10596-23-3 ClC(Cl)(P(O)(O)=O)P(O)(O)=O3 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
190 Folinic_Acid 1492-18-8 O=C1N=C(NC=2NCC(N(C1=2)C=O)CNc1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O)N90 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
191 Piperacillin 61477-96-1 O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)NC(=O)N2C(=O)C(=O)N(CC)CC2)[C@H]4SC3(C)C0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
192 Foscarnet 63585-09-1 P(O)(O)(=O)C(O)=O18 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
193 Raffinose 512-69-6 O1C(OC2OC(COC3OC(CO)C(O)C(O)C3O)C(O)C(O)C2O)(CO)C(O)C(O)C1CO0 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
194 Lercanidipine 100427-26-7 [O-][N+](=O)c1cccc(c1)C4C(=C(/N\C(=C4\C(=O)OC(C)(C)CN(CCC(c2ccccc2)c3ccccc3)C)C)C)\C(=O)OC44 Barchielli, M.; Dolfini, E.; Farina, P., et al, J Cardiovas  Pharmacol, 1997, 29, S1-S15BA/EU
195 Cefmetazole 56796-20-4 S1C2N(C(=O)C2(OC)NC(=O)CSCC#N)C(C(O)=O)=C(C1)CSc1nnnn1C10 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
196 Melagatran 192939-46-1 O=C(NCc1ccc(C(=[N@H])N)cc1)[C@H]3N(C(=O)[C@H](NCC(=O)O)C2CCCCC2)CC315 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med hem 2010, 53,, 1098-1108.
197 Ouabain 630-60-4 O1C(C)C(O)C(O)C(O)C1OC1CC2(O)CCC3C(C2(CO)C(O)C1)C(O)CC1(C)C(CCC13O)C1=CC(OC1)=O3 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 20 2, 52, 1132-1137
198 Amphotericin_B 1397-89-3 O1C(C)C(O)C(N)C(O)C1OC1(O)\C=C/C=C/C=C/C=C/C=C\C=C\C=C\C(C)C(O)C(C)C(OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC2(OC(C1)C(C(O)=O)C(O)C2)O)C3 ao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
199 Benazepril 86541-75-5 O=C1N(c2c(CCC1NC(CCc1ccccc1)C(OCC)=O)cccc2)CC(O)=O50 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
200 Fenoterol 13392-18-2 Oc1cc(cc(O)c1)CC(O)NC(Cc1ccc(O)cc1)C60 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
201 Cromolyn 16110-51-3 O=C(O)C=4Oc3cccc(OCC(O)COc2cccc1O/C(=C\C(=O)c12)C(=O)O)c3C(=O)C=41 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
202 Ceftriaxone 73384-59-5 s1cc(nc1N)/C(=N/OC)/C(=O)NC1C2SCC(CSC3=NC(=O)C(O)=NN3C)=C(N2C1=O)C(O)=O1 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
203 Metaproterenol 586-06-1 Oc1cc(cc(O)c1)C(O)CNC(C)C43 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
204 Trospium 10405-02-4 O(C(=O)C(O)(c1ccccc1)c1ccccc1)C1CC([N+]2(CCCC2)C(C1)C)CC10 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
205 Vidarabine 24356-66-9 n2c1c(ncnc1n(c2)[C@@H]3O[C@@H]([C@@H](O)[C@@H]3O)CO)N0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
206 Ribavirin 36791-04-5 c1nc(nn1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N85 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
207 Xamoterol 81801-12-9 O=C(NCCNCC(O)COc1ccc(O)cc1)N2CCOCC27 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
208 Diphenoxylate 915-30-0 N#CC(c1ccccc1)(c2ccccc2)CCN4CCC(c3ccccc3)(C(=O)OCC)CC490 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
209 Acetazolamide 59-66-5 s1c(nnc1S(=O)(=O)N)NC(=O)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137EU/BA
210 Didanosine 69655-05-6 O=C3/N=C\Nc1c3ncn1[C@@H]2O[C@@H](CC2)CO50 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
211 Lactulose 4618-18-2 O1C(O)(CO)C(O)C(OC2OC(CO)C(O)C(O)C2O)C1CO1 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
212 Mesalamine 89-57-6 Oc1ccc(N)cc1C(O)=O80 http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20049-S006_Pentasa_prntlbl.pdfHou 2012 states this is now 25 and BA is not found howev r his information is based on a slow release formulation therefore the fraction absorbed is related to formulation effects. Degree of absorption is high unless formulated. Therefore keeping Hou et al 2007 orginal value based on the FDA label information of the compound on the free drug http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20049-S006_Pentasa_prntlbl.pdf
213 Tiludronic_Acid 89987-06-4 Clc1ccc(cc1)CC(P(O)(O)=O)P(O)(O)=O6 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
214 Oseltamivir_Acid 187227-45-8 O=C(N[C@H]1[C@H](OC(CC)CC)/C=C(/C(=O)O)C[C@@H]1N)C80 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
215 Pimozide 2062-78-4 Fc1ccc(cc1)C(CCN1CCC(N2c3c(NC2=O)cccc3)CC1)c1ccc(F)cc170 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
216 Aztreonam 78110-38-0 s1cc(nc1N)/C(=N/OC(C(O)=O)(C)C)/C(=O)NC1C(N(S(O)(=O)=O)C1=O)C1 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
217 Floxuridine 50-91-9 FC=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)C2)CO90 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137BA
218 Cefatrizine 51627-14-6 S1C2N(C(=O)C2NC(=O)C(N)c2ccc(O)cc2)C(C(O)=O)=C(C1)CSc1nn[nH]c175 Cao, D., Wang, J., Zhou, R. et al, J Chem I fo Model, 2012, 52, 1132-1137
219 Pirenzepine_Hydrochloride 28797-61-7 O=C3c1ccccc1N(C(=O)CN2CCN(C)CC2)c4ncccc4N3>20 Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.EU/EF
220 Ampicillin 69-53-4 S1C2N(C(C(O)=O)C1(C)C)C(=O)C2NC(=O)C(N)c1ccccc162 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
221 Ivermectin 70288-86-7 O1C(C)C(O)C(OC)CC1OC1C(OC(OC2/C(=C/CC3OC4(OC5C(C4)C(C)C5C(CC)C)CC(OC(=O)C4C=C(C)C(O)C5OC\C(=C/C=C/C2C)\C45O)C3)/C)CC1OC)C60 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
222 Ceftibuten 97519-39-6 O=C2N1/C(=C\CS[C@@H]1[C@@H]2NC(=O)C(=C/CC(=O)O)\c3nc(sc3)N)C(=O)O70 Lin, C., Lim, J., Radwanski, E., et al, Antimicrob Agents Chemother, 1995, 39, 359–361
Kohda-Shimizu R, Li, Y.H., Shitara, Y., et al, Int J Pharm, 2001, 220, 119-28EU
223 Cyclosporine_A 59865-13-3 O=C1N(C)C(C(O)C(C\C=C\C)C)C(=O)NC(CC)C(=O)N(CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C1C(C)C)C33 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
224 Tranexamic_Acid 1197-18-8 OC(=O)C1CCC(CC1)CN55 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
225 Methylscopolamine 13265-10-6 O=C(OC1C[C@H]2[N+]([C@@H](C1)[C@@H]3O[C@H]23)(C)C)[C@@H](c4ccccc4)CO17.5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
226 Pentamidine 100-33-4 O(CCCCCOc1ccc(cc1)C(N)=N)c1ccc(cc1)C(N)=N0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















228 Maraviroc 376348-65-1 Cc5nnc(n5[C@@H]1C[C@H]4CC[C@@H](C1)N4CC[C@H](NC(=O)C2CCC(F)(F)CC2)c3ccccc3)C(C)C75 Walker DK, Abel S, Comby P, et al, Drug Metab Dispos, 005, 33, 587-95EU/EF
229 Acamprosate 77337-76-9 S(O)(=O)(=O)CCCNC(=O)C11 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
230 Ginkgolide_B 15291-77-7 CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O90 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
231 Entacapone 130929-57-6 [O-][N+](=O)c1cc(\C=C(/C#N)C(=O)N(CC)CC)cc(O)c1O50 Varma, M. V. S., Oba h, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
232 Creatinine 60-27-5 CN1CC(=O)NC1=N70 Tavelin, S., Taipalensuu, J., Soderberg, L., et al, Pharm Res , 2003,  20, 397-405.
233 Pregabalin 148553-50-8 O=C(O)C[C@H](CC(C)C)CN90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
234 Atazanavir sulfate 198904-31-3 O=S(=O)(O)O.O=C(OC)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)Cc3ccc(c2ncccc2)cc3)C(C)(C)C80 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021567s028lbl.pdfEU/EF
235 Cefixime 79350-37-1 s1c(cnc1N)/C(=N\C(=O)CC(O)=O)/C(=O)NC1C2SCC(C=C)=C(N2C1=O)C(O)=O60 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
236 Metformin 657-24-9 N(C(NC(N)=N)=N)(C)C54 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
237 Bendroflumethiazide 73-48-3 S(=O)(=O)(N)c1cc2S(=O)(=O)NC(Nc2cc1C(F)(F)F)Cc1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
238 Enalaprilat 76420-72-9 O(C(=O)C(NC(C(=O)N1CCCC1C(O)=O)C)CCc1ccccc1)CC10 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
239 Sulfamethizole 144-82-1 s1c(nnc1NS(=O)(=O)c1ccc(N)cc1)C85 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
240 Vildagliptin 274901-16-5 N#C[C@H]4N(C(=O)CNC13CC2CC(C1)CC(O)(C2)C3)CCC485 He YL., lin Pharmacokinet, 2012, 51,147-6BA
241 Cefaclor 53994-73-3 O=C2N1/C(=C(/Cl)CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccccc3)N)C(=O)O90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
242 Penicillin G 61-33-6 S1C2N(C(C(O)=O)C1(C)C)C(=O)C2CC(=O)Cc1ccccc130 Zhao YH, Le J, Abraham MH, Hersey A, et al., J Pharm Sci, 2001, 90,749-84
243 Cefotaxime 63527-52-6 s1cc(nc1N)/C(=N/OC)/C(NC1C2SCC(COC(=O)C)=C(N2C1=O)C(O)=O)=C0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
244 Pravastatin 81093-37-0 O(C(=O)C(CC)C)C1C2C(=CC(O)C1)C=CC(C)C2CCC(O)CC(O)CC(O)=O34 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
245 Folic_Acid 59-30-3 O=C1NC(=Nc2ncc(nc12)CNc1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O)N75 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
246 Octreotide 83150-76-9 C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]5CSSC[C@H](NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc4cnc3ccccc34)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(=O)N5Poor Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.
247 Amlodipine 88150-42-9 Clc1ccccc1C2C(=C(/N/C(=C2/C(=O)OCC)COCCN)C)\C(=O)OC95 Varma, M. V. S., bach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
248 Terbinafine 91161-71-6 N(Cc1c2c(ccc1)cccc2)(C\C=C\C#CC(C)(C)C)C80 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
249 Vardenafil 224785-90-4 CCCc1nc(c2n1nc([nH]c2=O)c3cc(ccc3S(=O)(=O)N4CCN(CC4)CC)OCC)C90 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
250 Cymarin 508-77-0 O1C(C)C(O)C(OC)CC1OC1CC2(O)CCC3C(CCC4(C)C(CCC34O)C3=CC(OC3)=O)C2(CC1)C=C47 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
251 Cephradine 38821-53-3 S1C2N(C(=O)C2NC(=O)C(N)C=2CC=CCC=2)C(C(O)=O)=C(C1)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
252 Ceftazidime 72558-82-8 s1cc(nc1N)/C(=N/OC(C(O)=O)(C)C)/C(=O)NC1C2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
253 Cefamandole_Nafate 34444-01-4 O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@H](OC=O)c3ccccc3)CSc4nnnn4C)C([O-])=O0 Yalkowsky, S.H., Johnson, J.L.H., Sanghvi, T. et al, Pharm Res, 2006, 23, 2475-2481.
254 Raloxifene 84449-90-1 O=C(c1c3ccc(O)cc3sc1c2ccc(O)cc2)c5ccc(OCCN4CCCCC4)cc560 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
255 Valaciclovir 124832-26-4 O=C(OCCOCn1c2N\C(=N/C(=O)c2nc1)N)[C@@H](N)C(C)C36 Fagerholm, U., J Pharm Pharmacol, 2007, 59, 751-757REV 
256 Formoterol_Fumarate 73573-87-2 O=CNc1cc(ccc1O)[C@@H](O)CN[C@H](C)Cc2ccc(OC)cc265 Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.EU/EF
257 Norfloxacin 70458-96-7 Fc1cc2c(N(C=C(C(O)=O)C2=O)CC)cc1N1CCNCC175 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
258 Isoxicam 34552-84-6 S1(=O)(=O)c2c(cccc2)C(O)=C(C(=O)Nc2noc(c2)C)C1C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
259 Zomepirac 33369-31-2 Clc1ccc(cc1)C(=O)c1n(C)c(cc1C)CC(O)=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
260 Aspirin 50-78-2 O(C(=O)C)c1ccccc1C(O)=O91 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
261 Levothyroxine_Sodium 51-48-9 [O-]C(=O)[C@@H](N)Cc2cc(I)c(Oc1cc(I)c(O)c(I)c1)c(I)c260 http://www.ac essdata.fda.gov/drugsatfda_docs/label/2009/021342s016lbl.pdfvariable absorption
262 Cefazolin 25953-19-9 O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cn3nnnc3)CSc4nnc(s4)C)C(=O)O100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
263 Clarithromycin 81103-11-9 CN(C)[C@H]3C[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)OC)[C@@H]3O100 Varma, M. V. S., Obach, R. S., Rotter, ., et al, J Med Chem 2010, 53,, 1098-1108.
264 Lomefloxacin 98079-51-7 Fc1c2N(C=C(C(O)=O)C(=O)c2cc(F)c1N1CC(NCC1)C)CC99 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
265 Abiraterone_Acetate 154229-19-3 O=C(O[C@@H]2C/C1=C/C[C@@H]4[C@@H]([C@@]1(C)CC2)CC[C@@]3(C(=C/C[C@H]34)\c5cccnc5)C)C>45 Acharya M, Gonzalez M, Mannens G., Xenobiotica, 2013, 43, 379-89EF 
266 Rifampin 13292-46-1 O1c2c3c4c(c(O)c2C)c(O)c(NC(=O)\C(=C\C=C\C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C(C)C(OC)\C=C/OC1(C)C3=O)\C)c(\C=N\N1CCN(CC1)C)c4O80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
267 Sorivudine 77181-69-2 Br\C=C\C1CN(C2OC(CO)C(O)C2O)C(=O)NC1=O82 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
268 Norgestrel 6533-00-2 OC1(CCC2C3C(C4C(=CC(=O)CC4)CC3)C=CC12CC)C#C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
269 Ketorolac 74103-06-3 OC(=O)C1CCn2c1ccc2C(=O)c1ccccc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
270 Levocetirizine dihydrochloride 130018-77-8 Clc1ccc(cc1)[C@H](N2CCN(CCOCC(=O)O)CC2)c3ccccc385.4 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022064s024,022157s008lbl.pdfEU
271 Cephalothin 153-61-7 O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cc3sccc3)COC(=O)C)C(=O)O0 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
272 Stavudine 3056-17-5 O1C(C=CC1N1C=C(C)C(=NC1=O)N)CO100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
273 Mibefradil 116644-53-2 Fc1cc2c(cc1)C(C(C)C)C(OC(=O)CC)(CC2)CCN(CCCc1[nH]c2c(n1)cccc2)C69 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
274 Rilpivirine 500287-72-9 N#C\C=C\c1cc(c(c(c1)C)Nc2nc(ncc2)Nc3ccc(C#N)cc3)C75 James C, Preininger L, Sweet M., Am J Health-Syst Ph, 2012, 69, 857-61;
Sanford, M., Drugs, 2012, 72, 525-541EU/EF/REV
275 Metolazone 17560-51-9 Clc1cc2NC(N(c3ccccc3C)C(=O)c2cc1S(=O)(=O)N)C64 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137REV
276 Cinacalcet 226256-56-0 FC(F)(F)c1cccc(c1)CCCN[C@@H](c3c2ccccc2ccc3)C80 Kumar GN, Sproul C, Poppe L, et al, Drug Metab Dispos, 2004, 32, 1491-500EU/EF
277 Enoxacin 74011-58-8 Fc1c(nc2c(c1)C(=O)C(\C(=O)O)=C/N2CC)N3CCNCC389 Chang T, Black A, Dunky A, et al., J Antimicrob Chemoth, 1988, 21, 49-56BA
278 Sulindac 38194-50-2 S(=O)(C)c1ccc(cc1)\C=C/1\c2c(cc(F)cc2)C(CC(O)=O)=C\1C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
279 Cerivastatin 145599-86-6 O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(nc(c(c1c2ccc(F)cc2)COC)C(C)C)C(C)C100 Varma, M. V. S., Obach, R. S., Rotter, ., et al, J Med Chem 2010, 53,, 1098-1108.
280 Albendazole 54965-21-8 O=C(OC)Nc2nc1ccc(SCCC)cc1n25 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
281 UK-294,315 O=C(N1CCCN(CC1)c3cc(N)c4c(c2ccc(F)cc2)c(OC)c(OC)cc4n3)N5CCOCC586 Harrison A, Betts A, Fenner K, et al, Drug Metab Dispos, 2004, 32,197-204.EF 
282 Linezolid 165800-03-3 Fc1cc(N2CC(OC2=O)CNC(=O)C)ccc1N1CCOCC1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
283 Dexloxiglumide 119817-90-2 Clc1ccc(C(=O)N[C@@H](C(=O)N(CCCCC)CCCOC)CCC(=O)O)cc1Cl95 Varma, M. V. S., Obach, R. S., Rotter, ., et al, J Med Chem 2010, 53,, 1098-1108.
284 Sulfadiazine 68-35-9 O=S(=O)(Nc1ncccn1)c2ccc(N)cc293 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
285 Methoxyamphetamine 17862-85-0 O(C)c1cc(ccc1)CC(N)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















287 Rivaroxaban 366789-02-8 c1cc(ccc1N2CCOCC2=O)N3C[C@@H](OC3=O)CNC(=O)c4ccc(s4)Cl66 Weinz C, Schwarz T, Kubitza D, et al, Drug Metab Dispos, 2009, 37, 1056-64. EU/EF 
288 Terazosin 63590-64-7 O1CCCC1C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n190 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
289 Riboflavin 83-88-5 O=C1NC(=O)N=C2N(c3cc(C)c(cc3N=C12)C)CC(O)C(O)C(O)CO80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
290 Tolmetin 26171-23-3 OC(=O)Cc1n(C)c(cc1)C(=O)c1ccc(cc1)C99 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
291 Cefadroxil 66592-87-8 S1C2N(C(=O)C2NC(=O)C(N)c2ccc(O)cc2)C(C(O)=O)=C(C1)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
292 Milnacipran 92623-85-3 O=C(N(CC)CC)C2(c1ccccc1)CC2CN84 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
293 Budesonide 51333-22-3 O1C2(C(OC1CCC)CC1C3C(C4(C(=CC(=O)C=C4)CC3)C)C(O)CC12C)C(=O)CO100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
294 Boceprevir 394730-60-0 O=C(N3[C@H](C(=O)NC(C(=O)C(=O)N)CC1CCC1)[C@H]2C(C)([C@H]2C3)C)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C92 Kiser, J.J., Burton, J.R., Anderson, P.L., et al, Hepatology, 2012, 55, 1620-8EF
295 Olopatadine_Hydrochloride 140462-76-6 O=C(O)Cc2ccc1OCc3c(C(\c1c2)=C\CCN(C)C)cccc370 Tsunoo,M., Momomura, S., Masuo,M., et al., Kiso-to-Rinsho, 1995, 29, 4129–4147 (Japanese);
Ohmori K, Hayashi K, Kaise T,et al, Jpn J Pharmcol, 2002, 88, 379-97.EU/REV
296 Phenylbutazone 50-33-9 O=C1C(N(N(C1=O)c1ccccc1)c1ccccc1)CCCC98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
297 Orphenadrine 83-98-7 O(C(c1ccccc1C)c1ccccc1)CCN(C)C00 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
298 Tegaserod 189188-57-6 CCCCCNC(=N)N\N=C\c2cnc1ccc(cc12)OC

50 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
299 Dapsone 80-08-0 S(=O)(=O)(c1ccc(N)cc1)c1ccc(O)cc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
300 Fenoprofen 31879-05-7 O(c1cc(ccc1)C(C(O)=O)C)c1ccccc185 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
301 Irbesartan 138402-11-6 O=C1N(Cc2ccc(cc2)-c2ccccc2-c2nn[nH]n2)C(=NC12CCCC2)CCCC100 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
302 Gemifloxacin 175463-14-6 Fc2c(nc1N(/C=C(/C(=O)O)C(=O)c1c2)C3CC3)N4C/C(=N\OC)C(C4)CN60 Allen, A., Bird, N., Dixon, R., et al, lin Drug Invest, 2001, 21, 7, 519-526,
Allen A, Bygate E, Oliver S,et al, Antimicrob Agents Chemother, 2000, 44, 1604-8.,
Allen A, Bygate E, Vousden M, et al, Antimicrob Agents Chemother. 2001, 45, 540-5,
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021158s021lbl.pdf
RA/EU/EF
303 Sulfisoxazole 127-69-5 s1nc(C)c(C)c1NS(=O)(=O)c1ccc(N)cc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
304 Spironolactone 52-01-7 S(C(=O)C)C1C2C3CCC4(OC(=O)CC4)C3(CCC2C2(C(C1)=CC(=O)CC2)C)C73 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
305 Tiacrilast 78299-53-3 S(C)c1cc2c(N=CN(\C=C\C(O)=O)C2=O)cc199 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
306 Clopidogrel bisulfate 90055-48-4 COC(=O)[C@H](c1ccccc1Cl)N2CCc3c(ccs3)C2>50 http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20839_Plavix_clinphrmr_P1.pdfEU-EF
307 Dolasetron 115956-13-3 O(C(=O)c1c2c([nH]c1)cccc2)C1CC2N3CC(=O)C(C2)CC3C185 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
308 Flupenthixol 2709-56-0 FC(F)(F)c2cc1C(\c3c(Sc1cc2)cccc3)=C/CCN4CCN(CCO)CC4100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
309 Diethylcarbamazine 90-89-1 O=C(N1CCN(C)CC1)N(CC)CC90 Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.EU/EF
310 Sulfamethoxazole 723-46-6 S(=O)(=O)(Nc1noc(c1)C)c1ccc(N)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
311 Salicylic_Acid 69-72-7 Oc1ccccc1C(O)=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
312 Celecoxib 169590-42-5 O=S(=O)(c3ccc(n1nc(cc1c2ccc(cc2)C)C(F)(F)F)cc3)N97 Paulson, S.K., Hribar, J.D., Liu, N.W., Hajdu, E., et al, Drug Metab Dispos, 2000, 28, 308-14EF
313 Hydralazine 86-54-4 n1ncc2c(cccc2)c1NN00 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
314 Sparfloxacin 110871-86-8 Fc1c(N2CC(NC(C2)C)C)c(F)c2N(C=C(C(O)=O)C(=O)c2c1N)C1CC190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
315 Guanoxan 2165-19-7 O1c2c(OCC1CNC(N)=N)cccc250 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
316 Captopril 62571-86-2 SCC(C(=O)N1CCCC1C(O)=O)C84 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
317 Fleroxacin 79660-72-3 CN1CCN(CC1)c2c(F)c3c(cc2F)C(=O)C(CN3CCF)C(O)=O100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
318 Dofetilide 115256-11-6 S(=O)(=O)(Nc1ccc(cc1)CCN(CCOc1ccc(NS(=O)(=O)C)cc1)C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
319 Bisoprolol 66722-44-9 O(CC(O)CNC(C)C)c1ccc(cc1)COCCOC(C)C96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
320 Cloxacillin 61-72-3 O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(onc2c1ccccc1Cl)C)[C@H]4SC3(C)C75 Varma, M. V. S., Oba h, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
321 Telmisartan 144701-48-4 OC(=O)c1ccccc1-c1ccc(cc1)CN1C2=CC(CC(=C2N=C1CCC)C)c1nc2c(n1C)cccc250 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
322 Propofol 2078-54-8 Oc1c(cccc1C(C)C)C(C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
323 Amrinone 60719-84-8 O=C1NC=C(C=C1N)c1ccncc193 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
324 Meloxicam 71125-38-7 s1c(cnc1NC(=O)C=1N(S(=O)(=O)c2c(cccc2)C=1O)C)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
325 Mefenamic_Acid 61-68-7 OC(=O)c1ccccc1Nc1cccc(C)c1C90 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
326 Brompheniramine_Maleate 86-22-6 Brc1ccc(cc1)C(c2ncccc2)CCN(C)C89 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
327 Darifenacin hydrobromide 133099-04-4 c1ccc(cc1)C(c2ccccc2)([C@@H]3CCN(C3)CCc4ccc5c(c4)OCC5)C(=O)N79 Skerjanec, A., Clin Pharma okinet, 2006, 45, 325-50
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021513s010lbl.pdf
EU/EF
328 Dextrose 50-99-7 O1C(CO)C(O)C(O)C(O)C1O99 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
329 Indacaterol maleate 312753-06-3 O=C4/C=C\c1c(c(O)ccc1[C@@H](O)CNC3Cc2cc(c(cc2C3)CC)CC)N4>45 Kagan M, Dain J, Peng L, et al, Drug Metab Dispos, 2012, 40, 1712-22EF 
330 Cilostazol 73963-72-1 O=C4Nc3c(cc(OCCCCc1nnnn1C2CCCCC2)cc3)CC474 Chapman, T.M. and Goa, K.L., Am J Cardiovasc Drugs , 2003, 3, 117-38.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020863s021lbl.pdfEU/EF
331 Phenylalanine 63-91-2 OC(=O)C(N)Cc1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
332 Gestodene 60282-87-3 OC1(C=CC2C3C(C4C(=CC(=O)CC4)CC3)CCC12CC)C#C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
333 Ruxolitinib 941678-49-5 c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC495 Shilling AD, Nedza FM, Emm T., Drug Metab Dispos, 2010, 38, 2023-31EU/EF
334 Sulfapyridine 144-83-2 O=S(=O)(Nc1ncccc1)c2ccc(N)cc270 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
335 Bicalutamide 90357-06-5 S(=O)(=O)(CC(O)(C(=O)Nc1cc(C(F)(F)F)c(cc1)C#N)C)c1ccc(F)cc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
336 Etodolac 41340-25-4 O1CCC2C(Nc3c2cccc3CC)C1(CC(O)=O)CC(O)=O70 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
337 Rofecoxib 162011-90-7 O=C2OCC(=C2\c1ccccc1)\c3ccc(cc3)S(=O)(=O)C93 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
338 Nicotine 54-11-5 n1cc(ccc1)C1N(CCC1)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
339 Tenoxicam 59804-37-4 s1c2C=C(N(S(=O)(=O)c2cc1)C)C(=O)Nc1ncccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
340 Gliclazide 21187-98-4 S(=O)(=O)(NC(=O)NN1CC2C(CCC2)C1)c1ccc(cc1)C97 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
341 Pefloxacin 70458-92-3 Fc1cc2c(N(C=C(C(O)=O)C2=O)CC)cc1N1CCN(CC1)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
342 Tramadol 27203-92-5 O(C)c1cc(ccc1)C1(O)CCCCC1CN(C)C95 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
343 Temocapril 111902-57-9 O=C(OCC)[C@@H](NC1C(=O)N(C[C@H](SC1)c2sccc2)CC(=O)O)CCc3ccccc360 Püchler K, Sierakowski B, Roots I., Brit J Clin Pharmaco, 1998, 46, 363-7;
Suzuki H, Kawaratani T, Shioya H, et al, Biopharm Drug Dispos , 1993, 14, 41-50;
Izumi, F., Progress in Medicine, 1999, 19, 1093-1098 (Japenese)
EU/EF
344 Lorcaserin_Hydrochloride 616202-92-7 Cl.Clc1cc2c(cc1)CCNC[C@@H]2C92 Bays, H. E., Expet Rev Cardiovasc Ther, 2009, 7, 1429-1445,
Morgan M, Chen W, Anderson C, et al, Annual Meeting of The Obesity Society; October 3–7, 2008; Phoenix, Ariz. Abstract,
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdfEU, REV

















346 Fluorescein 2321-07-5 O1C2(c3c(cccc3)C1=O)c1c(Oc3c2ccc(O)c3)cc(O)cc199 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
347 Topiramate 97240-79-4 S(OCC12OC(OC1C1OC(OC1CO2)(C)C)(C)C)(=O)(=O)N86 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
348 Tinidazole 19387-91-8 S(=O)(=O)(CCn1c(ncc1[N+](=O)[O-])C)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
349 Nevirapine 129618-40-2 O=C2Nc1c(ccnc1N(c3ncccc23)C4CC4)C100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
350 Trovafloxacin 147059-72-1 Fc1cc(F)ccc1N1C=C(C(O)=O)C(=O)c2cc(F)c(nc12)N1CC2C(C1)C2N88 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
351 Glimepiride 93479-97-1 S(=O)(=O)(NC(=O)NC1CCC(CC1)C)c1ccc(cc1)CCNC(=O)N1CC(C)=C(CC)C1=O100 ao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
352 Enzalutamide 915087-33-1 FC(F)(F)c3cc(N2C(=O)C(N(c1cc(F)c(C(=O)NC)cc1)C2=S)(C)C)ccc3C#N85 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203415s001lbl.pdfEU/EF
353 Quinine 130-95-0 O(c4cc1c(nccc1[C@@H](O)[C@H]2N3CC[C@@H](C2)[C@@H](/C=C)C3)cc4)C85 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
354 Pseudoephedrine 90-82-4 OC(C(NC)C)c1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
355 Camazepam 36104-80-0 Clc1cc2c(N(C)C(=O)C(OC(=O)N(C)C)N=C2c2ccccc2)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
356 Papaverine 58-74-2 O(C)c1cc(ccc1OC)Cc1nccc2c1cc(OC)c(OC)c290 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
357 Aminopyrine 58-15-1 N(C)(C)C=1C(=N)N(N(C)C=1C)c1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
358 Ketanserin 74050-98-9 Fc1ccc(cc1)C(=O)C1CCN(CC1)CCN1C(=O)c2c(NC1=O)cccc2100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
359 Phencyclidine 77-10-1 c1ccccc1C3(N2CCCCC2)CCCCC395 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
360 Ethionamide 536-33-4 S=C(N)c1cc(ncc1)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
361 Posaconazole 171228-49-2 CCC(C(C)O)n1c(=O)n(cn1)c2ccc(cc2)N3CCN(CC3)c4ccc(cc4)OCC5CC(OC5)(Cn6cncn6)c7ccc(cc7F)F96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
362 Amphetamine 300-62-9 NC(Cc1ccccc1)C 90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
363 Viloxazine 46817-91-8 O1CC(NCC1)COc1ccccc1OCC99 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
364 Indobufen 63610-08-2 O=C1N(Cc2c1cccc2)c1ccc(cc1)C(CC)C(O)=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
365 Methylphenobarbital 115-38-8 O=C1N(C(=O)NC(=O)C1(c2ccccc2)CC)C50 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
366 Memantine 19982-08-2 NC12CC3(CC(C1)(CC(C2)C3)C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
367 Betaxolol 63659-18-7 O(CC(O)CNC(C)C)c1ccc(cc1)CCOCC1CC190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
368 Praziquantel 55268-74-1 O=C1N2C(c3c(CC2)cccc3)CN(C1)C(=O)C1CCCCC196 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
369 Loxoprofen 68767-14-6 O=C2C(Cc1ccc(cc1)C(C(=O)O)C)CCC258 Choo KS, Kim IW, Jung JK, et al, J. Pharm. Biomed. Anal.,  2001, 25, 639-50.EU
370 Flutamide 13311-84-7 FC(F)(F)c1cc(NC(=O)C(C)C)ccc1[N+](=O)[O-]100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
371 Methimazole 60-56-0 S=C1NC=CN1C 95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
372 Valproic_Acid 99-66-1 OC(=O)C(CCC)CCC98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
373 Tenidap 120210-48-2 Clc1cc2c(N(C(=O)N)C(=O)C2C(=O)c2sccc2)cc189 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
374 Etoricoxib 202409-33-4 Clc1cc(c([n+]([O-])c1)-c1ccc(nc1)C)-c1ccc(S(=O)(=O)C)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
375 Glycine 56-40-6 OC(=O)CN 100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
376 Chlorzoxazone 95-25-0 Clc1cc2NC(Oc2cc1)=O90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
377 Omeprazole 73590-58-6 S(=O)(Cc1ncc(C)c(OC)c1C)c1[nH]c2c(n1)cc(OC)cc280 Cao, D., Wa g, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
378 Coumarin 91-64-5 O1c2c(C=CC1=O)cccc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
379 Codeine 76-57-3 O1C2C34C(C(N(CC3)C)Cc3c4c1c(OC)cc3)C=CC2O95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
380 Biperiden 514-65-8 OC(CCN1CCCCC1)(C1C2CC(C1)C=C2)c1ccccc1100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
381 Isradipine 75695-93-1 o1nc2c(n1)cccc2C1C(C(OC(C)C)=O)=C(NC(C)=C1C(OC)=O)C92 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
382 Propylthiouracil 51-52-5 S=C1NC(=CC(=O)N1)CCC90 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
383 Desmethyldiazepam 1088-11-5 Clc1cc2c(NC(=O)CN=C2c2ccccc2)cc199 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
384 Ketotifen 34580-13-7 s1c2c(cc1)\C(\c1c(CC2=O)cccc1)=C\1/CCN(CC/1)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
385 Oxazepam 604-75-1 Clc1cc2c(NC(=O)C(O)N=C2c2ccccc2)cc197 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
386 Mexiletine 31828-71-4 O(CC(N)C)c1c(cccc1C)C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
387 Carnitine 541-15-1 C[N+](C)(C)CC(O)CC([O-])=O10 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
388 Ethambutol 74-55-5 OCC(NCCNC(CC)CO)CC80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
389 Sirolimus 53123-88-9 O[C@@H]1CC[C@H](C[C@H]1OC)C[C@@H](C)[C@@H]4CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N3CCCC[C@H]3C(=O)O4>90 http://www.accessdata.fda.gov/drugsatfda_docs label/2013/021083s053,021110s067lbl.pdfEU-EF
390 Paroxetine 61869-08-7 Fc1ccc(cc1)C1CCNCC1COc1cc2OCOc2cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
391 Pyridostigmine 155-97-5 O=C(Oc1ccc[n+](c1)C)N(C)C10 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
392 Imatinib 152459-95-5 O=C(Nc1cc(Nc2nc(ccn2)-c2cccnc2)c(cc1)C)c1ccc(cc1)CN1CCN(CC1)C98 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
393 Abacavir 168146-84-7 n3c1c(ncn1[C@H]2/C=C\[C@@H](CO)C2)c(nc3N)NC4CC483 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
394 Minocycline 10118-90-8 CN(C)[C@@H]1C(\O)=C(\C(N)=O)C(=O)[C@@]2(O)C(/O)=C3/C(=O)c4c(O)ccc(c4C[C@H]3C[C@@H]12)N(C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
395 Famciclovir 104227-87-4 O(C(=O)C)CC(CCn1c2nc(ncc2nc1)N)COC(=O)C77 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
396 Nitrofurantoin 67-20-9 o1c(ccc1[N+](=O)[O-])\C=N\N1CC(=O)NC1=O95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
397 Mefloquine 53230-10-7 FC(F)(F)c1c2nc(cc(c2ccc1)C(O)C1NCCCC1)C(F)(F)F78 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
398 Pergolide_Mesilate 66104-23-2 S(C)C[C@@H]2C[C@@H]3c4cccc1c4c(cn1)C[C@H]3N(C2)CCC60 Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.EF 
399 Reboxetine 98769-81-4 O(c1ccccc1OCC)[C@H](c2ccccc2)[C@@H]3OCCNC3100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
400 Pramipexole 104632-26-0 s1c2CC(NCCC)CCc2nc1N95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
401 Guanfacine 29110-47-2 Clc1cccc(Cl)c1CC(=O)\N=C(\N)/N100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
402 Nalbuphine 20594-83-6 O1C2C34CCN(C(Cc5c3c1c(O)cc5)C4(O)CCC2O)CC1CCC1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
403 Itraconazole 84625-61-6 Clc1cc(Cl)ccc1C1(OC(CO1)COc1ccc(N2CCN(CC2)c2ccc(N3C=NN(C(CC)C)C3=O)cc2)cc1)Cn1ncnc180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1 32-1 37

















405 Galantamine 357-70-0 O1c2c3C4(C1CC(O)C=C4)CCN(Cc3ccc2OC)C100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
406 Atomoxetine 83015-26-3 O(c1ccccc1C)[C@@H](c2ccccc2)CCNC100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
407 Methysergide 361-37-5 OCC(NC(=O)C1C=C2C(N(C1)C)Cc1c3c2cccc3n(c1)C)CC100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
408 Metronidazole 443-48-1 OCCn1c(ncc1[N+](=O)[O-])C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
409 Olanzapine 132539-06-1 CN1CCN(CC1)C/2=N/c4ccccc4Nc3sc(C)cc\23100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
410 Tiagabine 115103-54-3 s1ccc(C)c1\C(=C\CCN1CC(CCC1)C(O)=O)\c1sccc1C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
411 Venlafaxine 93413-69-5 O(C)c1ccc(cc1)C(CN(C)C)C1(O)CCCCC195 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
412 Isoniazid 54-85-3 O=C(NN)c1ccncc180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
413 Quetiapine 111974-69-7 S1c2c(cccc2)C(=Nc2c1cccc2)N1CCN(CC1)CCOCCO73 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
414 Propoxyphene 469-62-5 O(C(Cc1ccccc1)(C(CN(C)C)C)c1ccccc1)C(=O)CC95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
415 Tianeptine 66981-73-5 Clc1cc2S(=O)(=O)N(c3c(N(c2cc1)CCCCCCC(O)=O)cccc3)C99 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
416 Mirtazapine 61337-67-5 n1cccc3c1N4C(c2ccccc2C3)CN(C)CC480 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
417 Ethosuximide 77-67-8 O=C1NC(=O)CC1(C)CC93 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
418 Ropinirole 91374-21-9 O=C1Nc2c(C1)c(ccc2)CC(NCCC)NCCC98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
419 Rivastigmine 123441-03-2 O(C(=O)N(CC)C)c1cc(ccc1)C(N(C)C)C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
420 Methylphenidate 113-45-1 O(C(=O)C(C1NCCCC1)c1ccccc1)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
421 Zonisamide 68291-97-4 S(=O)(=O)(N)Cc1noc2c1cccc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
422 Hydrocodone 125-29-1 O=C4[C@@H]5Oc1c2c(ccc1OC)C[C@H]3N(CC[C@]25[C@H]3CC4)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
423 Riluzole 1744-22-5 s1c2cc(OC(F)(F)F)ccc2nc1N90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
424 Perphenazine 58-39-9 Clc1cc2N(c3c(Sc2cc1)cccc3)CCCN1CCN(CC1)CCO100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
425 Clonazepam 1622-61-3 Clc1ccccc1C1=NCC(=O)Nc2c1cc([N+](=O)[O-])cc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
426 Fluvoxamine 54739-18-3 FC(F)(F)c1ccc(cc1)/C(=N/OCCN)/CCCCOC90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
427 Ramelteon 196597-26-9 O=C(NCC[C@H]3c2c(ccc1OCCc12)CC3)CC84 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
428 Nortriptyline 72-69-5 N(CC\C=C/1\c2c(CCc3c\1cccc3)cccc2)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
429 Rosiglitazone 122320-73-4 O=C1NC(=O)SC1Cc3ccc(OCCN(c2ncccc2)C)cc3100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
430 Oxybutynin 5633-20-5 O(C(=O)C(O)(C1CCCCC1)c1ccccc1)CC#CCN(CC)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
431 Moclobemide 71320-77-9 Clc1ccc(cc1)C(=O)NCCN1CCOCC188 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
432 Clomipramine 303-49-1 Clc1cc2N(c3c(CCc2cc1)cccc3)CCCN(C)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
433 Zaleplon 151319-34-5 O=C(N(CC)c1cc(ccc1)C=1n2ncc(c2N=CC=1)C#N)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
434 Nitrazepam 146-22-5 O=C1Nc2c(cc([N+](=O)[O-])cc2)C(=NC1)c1ccccc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
435 Gemfibrozil 25812-30-0 O(CCCC(C(O)=O)(C)C)c1cc(ccc1C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
436 Trimipramine 739-71-9 N(CC(CN1c2c(CCc3c1cccc3)cccc2)C)(C)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
437 Lorcainide 59729-31-6 Clc3ccc(N(C(=O)Cc1ccccc1)C2CCN(C(C)C)CC2)cc370 Varma, M. V. S., Oba h, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
438 Doxapram 309-29-5 O=C4N(CC)CC(CCN1CCOCC1)C4(c2ccccc2)c3ccccc3100 Varma, M. V. S., Oba h, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
439 Maprotiline 10262-69-8 N(CCCC12CCC(c3c1cccc3)c1c2cccc1)C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
440 Phenobarbital 50-06-6 O=C1NC(=O)NC(=O)C1(CC)c1ccccc1100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
441 Doxepin 1668-19-5 O1Cc2c(cccc2)C(c2c1cccc2)CCCN(C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
442 Flumazenil 78755-81-4 Fc1cc2c(-n3c(CN(C)C2=O)c(nc3)C(OCC)=O)cc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
443 Bufuralol 54340-62-4 OC(c2oc1c(cccc1c2)CC)CNC(C)(C)C100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
444 Procyclidine 77-37-2 OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
445 Selegiline 14611-52-0 N(C(Cc1ccccc1)C)(CC#C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
446 Flurazepam 17617-23-1 Clc1cc2c(N(CCN(CC)CC)C(=O)CN=C2c2ccccc2F)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
447 Nalidixic_Acid 389-08-2 O=C1c2ccc(nc2N(CC1C(O)=O)CC)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
448 AAFC flurocitabine 37717-21-8 FC1=CN2C3OC(CO)C(O)C3OC2=NC1=N32 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
449 Acarbose 56180-94-0 O1C(C)C(NC2C=C(CO)C(O)C(O)C2O)C(O)C(O)C1OC1C(O)C(O)C(OC1CO)OC1C(O)C(O)C(OC1CO)O2 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1 32-1137
450 Acenocoumarol 152-72-7 [O-][N+](=O)c1ccc(cc1)C(CC(C)=O)C\2=C(/O)c3ccccc3OC/2=O90 Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.
451 Acetanilide 103-84-4 O=C(Nc1ccccc1)C83 Brodie, B. B. and Axelrod, J., Journal of Pharmacol Exp Ther, 1948, 94, 29–38EU-EF
452 Acetohexamide 968-81-0 S(=O)(=O)(\N=C(/O)\NC1CCCCC1)c1ccc(cc1)C(=O)C80 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
453 Acipimox 51037-30-0 OC(=O)c1ncc([n+]([O-])c1)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
454 Acitretin 55079-83-9 O(C)c1cc(C)c(\C=C\C(=C\C=C\C(=C/C(O)=O)\C)\C)c(C)c1C72 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
455 Adefovir 106941-25-7 P(O)(O)(=O)COCCn1c2ncnc(N)c2nc116 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
456 Adinazolam 37115-32-5 Clc3cc2\C(=N/Cc1nnc(n1c2cc3)CN(C)C)c4ccccc400 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
457 Alcuronium 23214-96-2 OC\C=C/1\C2C=3C4N(C=C5C\6CC7[N+](C/C/6=C\CO)(CCC67C5N(C=3)c3c6cccc3)CC=C)c3c(C45C([N+](C\1)(CC5)CC=C)C2)cccc30 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
458 Alfacalcidol 41294-56-8 OC1CC(O)C\C(=C\C=C/2\C3CCC(C(CCCC(C)C)C)C3(CCC\2)C)\C1=C100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
459 Alizapride 59338-93-1 O=C(c2cc1nnnc1cc2OC)NCC3N(C\C=C)CCC3100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
460 Allopurinol 315-30-0 O=C1NC=Nc2[nH]ncc1280 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
461 Almitrine 27469-53-0 Fc1ccc(cc1)C(N1CCN(CC1)c1nc(nc(n1)NCC=C)NCC=C)c1ccc(F)cc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
462 Almotriptan 154323-57-6 S(=O)(=O)(N1CCCC1)Cc1cc2c([nH]cc2CCN(C)C)cc175 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
463 Alogliptin 850649-62-6 O=C1N(/C(=C\C(=O)N1C)N2CCC[C@@H](N)C2)Cc3ccccc3C#N100 Andukuri, R., Drincic, A. and Rendell, M., Diabetes Metab Syndr Obes Target Ther, 2009, 2, 117–126, 

















464 Amikacin 37517-28-5 O1C(CN)C(O)C(O)C(O)C1OC1C(O)C(OC2OC(CO)C(O)C(N)C2O)C(NC(=O)C(O)CCN)CC1N0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
465 Aminoglutethimide 125-84-8 O=C1NC(=O)CCC1(CC)c1ccc(N)cc100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
466 Amiodarone 1951-25-3 Ic1cc(cc(I)c1OCCN(CC)CC)C(=O)c2c3ccccc3oc2CCCC100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
467 Amobarbital 57-43-2 OC1=NC(O)=NC(=O)C1(CCC(C)C)CC95 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
468 Amosulalol 85320-68-9 S(=O)(=O)(N)c1cc(ccc1C(O)CNCCOc1ccccc1OC)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
469 Amoxapine 14028-44-5 Clc1cc2c(Oc3c(N=C2N2CCNCC2)cccc3)cc195 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
470 Anagrelide 68475-42-3 Clc1c2CN3CC(=O)NC3=Nc2ccc1Cl70 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
471 Anastrozole 120511-73-1 n1cn(nc1)Cc1cc(cc(c1)C(C#N)(C)C)C(C#N)(C)C100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
472 Arbekacin 51025-85-5 O1C(CO)C(O)C(N)C(O)C1OC1C(O)C(OC2OC(CCC2N)CN)C(N)CC1NC(=O)C(O)CCN0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
473 Atovaquone 95233-18-4 O=C1c4ccccc4C(\O)=C(/C1=O)C3CCC(c2ccc(Cl)cc2)CC36 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
474 Atracurium 64228-79-1 O(C)c1cc(ccc1OC)CC1[N+](CCc2c1cc(OC)c(OC)c2)(CCC(OCCCCCOC(=O)CC[N+]1(CCc2c(cc(OC)c(OC)c2)C1Cc1cc(OC)c(OC)cc1)C)=O)C0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
475 Azatadine 3964-81-6 n1c/2c(CCc3c(cccc3)\C\2=C\2/CCN(CC/2)C)ccc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
476 Azathioprine 446-86-6 [O-][N+](=O)c3ncn(c3Sc1ncnc2ncnc12)C87 Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.EF/EU
477 Azelastine 58581-89-8 Clc1ccc(cc1)CC1NN(C2CCCN(CC2)C)C(=O)c2c1cccc290 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020114s023lbl.pdfEF
478 Azimilide 149888-94-8 Clc1ccc(cc1)-c1oc(cc1)\C=N\N1CC(=O)N(CCCCN2CCN(CC2)C)C1=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
479 Azlocillin 37091-66-0 S1C2N(C(C(O)=O)C1(C)C)C(=O)C2NC(=O)C(NC(=O)N1CCNC1=O)c1ccccc10 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
480 Azosemide 27589-33-9 O=S(=O)(N)c2c(Cl)cc(c(c1nnnn1)c2)NCc3sccc320 Suh, O.K., Kim, S.H, Lee, M.G., Biopharm Drug Dispos, 2003, 24, 275-97.REV/BA
481 Bambuterol 81732-65-2 O=C(Oc1cc(cc(OC(=O)N(C)C)c1)C(O)CNC(C)(C)C)N(C)C20 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
482 Benserazide 322-35-0 Oc1c(O)c(O)ccc1CNNC(=O)C(N)CO70 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
483 Benzbromarone 3562-84-3 Brc1cc(cc(Br)c1O)C(=O)c1c2c(oc1CC)cccc273 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
484 Benzydamine 642-72-8 O(CCCN(C)C)c1nn(c2c1cccc2)Cc1ccccc187 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
485 Bepridil 64706-54-3 O(CC(C)C)CC(N(Cc1ccccc1)c1ccccc1)CN1CCCC1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
486 Betahistine 5638-76-6 n1ccccc1CCNC 100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
487 Betazole 105-20-4 n1ccc(n1)CCN 100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
488 Bezafibrate 41859-67-0 O(C(C(O)=O)(C)C)c1ccc(cc1)CCNC(=O)c1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
489 Bifemelane 90293-01-9 O(CCCCNC)c1ccccc1Cc1ccccc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
490 Biotin 58-85-5 S1CC2NC(=O)NC2C1CCCCC(O)=O100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
491 Bornaprine 20448-86-6 O(C(=O)C1(C2CC(C1)CC2)c1ccccc1)CCCN(CC)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
492 Bromfenac 91714-94-2 O=C(c1ccc(Br)cc1)c2cccc(c2N)CC(=O)O00 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
493 Bromhexine 3572-43-8 Brc1cc(Br)cc(CN(C)C2CCCCC2)c1N70 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
494 Buflomedil 55837-25-7 O=C(c1c(OC)cc(OC)cc1OC)CCCN2CCCC2100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
495 Bumetanide 28395-03-1 S(=O)(=O)(N)c1cc(cc(NCCCC)c1Oc1ccccc1)C(O)=O96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
496 Bupivacaine 2180-92-9 O=C(Nc1c(cccc1C)C)C2NCCCC2CCCC90 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
497 Busulfan 55-98-1 O=S(=O)(OCCCCOS(=O)(=O)C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
498 Butylscopolamine 149-64-4 O1C2C3[N+](C(CC(OC(=O)C(CO)c4ccccc4)C3)C12)(CCCC)C10 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
499 Canagliflozin 842133-18-0 Cc1ccc(cc1Cc2ccc(s2)c3ccc(cc3)F)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O84 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdfEU/BA
500 Candoxatril 118785-03-8 O=C(N[C@H]1CC[C@H](CC1)C(O)=O)C4(C[C@@H](COCCOC)C(=O)Oc2cc3CCCc3cc2)CCCC438 Beaumont, K., Webster, R., Gardner, I. et al, Curr Drug Metab, 2003, 4, 461-485.REV
501 Capecitabine 154361-50-9 FC1=CN(C2OC(C)C(O)C2O)C(=O)N=C1NC(OCCCCC)=O96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
502 Capreomycin 11003-38-6a C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O)=C/NC(N)=O)[C@H]1CCN=C(N)N1
50 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
503 Carbimazole 22232-54-8 S=C1N(C=CN1C)C(OCC)=O95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
504 Carboplatin 41575-94-4 C1CC2(C1)C(=O)O[Pt]OC2=O.N.N OR O=C2O[Pt-2](N)(N)OC(=O)C12CCC177 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
505 Carfecillin 27025-49-6 S1C2N(C(C(O)=O)C1(C)C)C(=O)C2NC(=O)C(C(O)=O)c1ccccc199 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
506 Carmustine 154-93-8 ClCCN(N=O)C(=O)NCCCl100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
507 Carprofen 53716-49-7 O=C(O)C(c3ccc2c1cc(Cl)ccc1nc2c3)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
508 Carteolol 51781-06-7 O(CC(O)CNC(C)(C)C)c1c2CCC(=O)Nc2ccc195 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
509 Cefcanel 41952-52-7 O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@H](O)c3ccccc3)CSc4nnc(s4)C)C(=O)O42 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med hem 2010, 53,, 1098-1108.
510 Cefetamet 65052-63-3 O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sc3)N)C)C(=O)O52 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
511 Cefetamet_Pivoxil 65243-33-6 s1cc(nc1N)/C(=N/OC)/C(=O)NC1C2SCC=C(N2C1=O)C(OCOC(=O)C(C)(C)C)=O47 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
512 Cefodizime 69739-16-8 s1c(CC(O)=O)c(nc1SCC=1CSC2N(C(=O)C2NC(=O)\C(=N\OC)\c2nc(sc2)N)C=1C(O)=O)C0 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
513 Ceforanide 60925-61-3 O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cc3ccccc3CN)CSc4nnnn4CC(=O)O)C(=O)O0 Yalkowsky, S.H., Johnson, J.L.H., Sanghvi, T. et al, Pharm Res, 2006, 23, 2475-2481.
514 Cefpirome 84957-29-9 s1cc(nc1N)/C(=N/OC)/C(=O)NC1C2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
515 Cefpodoxime_Proxetil 87239-81-4 s1cc(nc1N)/C(=N/OC)/C(=O)NC1C2SCC(COC)=C(N2C1=O)C(OC(OC(OC(C)C)=O)C)=O50 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
516 Ceftizoxime 68401-81-0 s1cc(nc1N)/C(=N\OC)/C(=O)NC1C2SCC=C(N2C1=O)C(O)=O72 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
517 Cefuroxime_Axetil 64544-07-6 S1C2N(C(=O)C2NC(=O)\C(=N/OC)\c2occc2)C(C(OC(OC(=O)C)C)=O)=C(C1)COC(=O)N44 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
518 Celiprolol 56980-93-9 O(CC(O)CNC(C)(C)C)c1ccc(NC(=O)N(CC)CC)cc1C(=O)C50 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
519 Chloral_Hydrate 302-17-0 ClC(Cl)(Cl)C(O)O 100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
520 Chlorambucil 305-03-3 ClCCN(CCCl)c1ccc(cc1)CCCC(O)=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
521 Chlordiazepoxide 58-25-3 Clc1cc2c(N=C(NC)C[N+]([O-])=C2c2ccccc2)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















523 Chlorphenesin 104-29-0 Clc1ccc(OCC(O)CO)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
524 Chlorpropamide 94-20-2 Clc1ccc(S(=O)(=O)NC(=O)NCCC)cc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
525 Cibenzoline 53267-01-9 N\1=C(\NCC/1)C4CC4(c2ccccc2)c3ccccc3100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
526 Cicaprost 94079-80-8 OC1CC2C(C\C(\C2)=C/COCC(O)=O)C1C#CC(O)C(CC#CCC)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
527 Cidofovir 113852-37-2 O=C1/N=C(\C=C/N1C[C@H](OCP(=O)(O)O)CO)N3 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
528 Cilazapril 92077-78-6 O=C1N2N(CCCC1NC(CCc1ccccc1)C(OCC)=O)CCCC2C(O)=O59 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
529 Cilazaprilat 90139-06-3 O=C1N2N(CCCC1NC(CCc1ccccc1)C(O)=O)CCCC2C(O)=O20 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
530 Cilomilast 153259-65-5 O(c1cc(ccc1OC)C1(CCC(CC1)C(O)=O)C#N)C1CCCC100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
531 Cinchonine 118-10-5 OC(C1N2CC(C(C1)CC2)C=C)c1c2c(ncc1)cccc2100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
532 Cinoxacin 28657-80-9 O1c2c(OC1)cc1N(N=C(C(O)=O)C(=O)c1c2)CC95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
533 Ciprofibrate 52214-84-3 ClC1(Cl)CC1c1ccc(OC(C(O)=O)(C)C)cc199 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
534 Clavulanic_Acid 58001-44-8 O\1C2N(C(C(O)=O)/C/1=C\CO)C(=O)C273 Bolton, G.C, Allen, G. D., Davies, B. E. , Filer, C. W., et al, Xenobiotica. 1986, 16, 853-63EU/EF
535 Clinafloxacin 105956-97-6 Fc2c(c(Cl)c1N(/C=C(/C(=O)O)C(=O)c1c2)C3CC3)N4CCC(N)C4100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
536 Clobazam 22316-47-8 Clc1cc2N(C(=O)CC(=O)N(c2cc1)C)c1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
537 Clofibrate 637-07-0 Clc1ccc(OC(C(OCC)=O)(C)C)cc196 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
538 Clomethiazole 533-45-9 ClCCc1scnc1C 95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
539 Clopidogrel 113665-84-2 COC(=O)[C@H](c1ccccc1Cl)N2CCc3c(ccs3)C250 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
540 Colestipol 50925-79-6 [NH3+]CC[NH2+]CC[NH2+]CC[NH2+]CC[NH3+]0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
541 Conivaptan 210101-16-9 O=C(c2ccccc2c1ccccc1)Nc3ccc(cc3)C(=O)N5c6c(c4nc(nc4CC5)C)cccc6100 Varma, M. V. S., Obach, R. S., Rotter, ., et al, J Med Chem 2010, 53,, 1098-1108.
542 Cotinine 486-56-6 O=C1N(C)C(CC1)c1cccnc197 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
543 Cyclopenthiazide 742-20-1 Clc1cc2NC(NS(=O)(=O)c2cc1S(=O)(=O)N)CN1CCCC1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
544 Cyclophosphamide 50-18-0 O=P1(OCCCN1)N(CCCl)CCCl82.5 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
545 Cyproheptadine 129-03-3 N1(CCC(CC1)=C1c2c(C=Cc3c1cccc3)cccc2)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
546 Cyproterone_Acetate 427-51-0 ClC=1C2=CC(=O)C3C(C3)C2(C2C(C3CCC(OC(=O)C)(C(=O)C)C3(CC2)C)C=1)C98 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
547 Cysteamine 60-23-1 SCCN 0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
548 Dalfampridine 504-24-5 n1ccc(N)cc1 100 Pikoulas, T.E., Fuller, M.A., Ann Pharmacother, 2012, 46, 1010-5REV
549 Dantrolene 7261-97-4 o1c(ccc1\C=N\N1CC(=O)NC1=O)-c1ccc([N+](=O)[O-])cc180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
550 Dapiprazole 72822-12-9 n1nc(n2c1CCCC2)CCN4CCN(c3ccccc3C)CC40 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
551 Delapril 83435-66-9 O=C(OCC)[C@@H](N[C@H](C(=O)N(CC(=O)O)C2Cc1ccccc1C2)C)CCc3ccccc345 Beaumont, K., Webster, R., Gardner, I. et al, Curr Drug Metab, 2003, 4, 461-485.REV 
552 Delmopinol 79874-76-3 O1CC(N(CC1)CCO)CCCC(CCC)CCC95 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
553 Desogestrel 54024-22-5 OC1(CCC2C3C(C4C(CC3)=CCCC4)C(CC12CC)=C)C#C72 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
554 Dextromoramide 357-56-2 O1CCN(CC1)CC(C(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
555 Diazoxide 364-98-7 Clc1cc2S(=O)(=O)NC(=Nc2cc1)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
556 Dicyclomine 77-19-0 O(C(=O)C1(CCCCC1)C1CCCCC1)CCN(CC)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
557 Dienogest 65928-58-7 OC1(CCC2C3C(=C4C(=CC(=O)CC4)CC3)CCC12C)CC#N94 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
558 Diethylpropion 90-84-6 O=C(C(N(CC)CC)C)c1ccccc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
559 Diethylstilbestrol 56-53-1 Oc1ccc(cc1)/C(=C(\CC)/c1ccc(O)cc1)/CC90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
560 Digitoxin 71-63-6 O1C(C)C(OC2OC(C)C(O)C(O)C2)C(O)CC1OC1C(OC(OC2CC3CCC4C(CCC5(C)C(CCC45O)C4=CC(OC4)=O)C3(CC2)C)CC1O)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
561 Dihydrocodeine 125-28-0 O1C2C34C(C(N(CC3)C)Cc3c4c1c(OC)cc3)CCC2O89 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
562 Dihydroergotamine 511-12-6 O1C(NC(=O)C2CC3C(N(C2)C)Cc2c4c3cccc4[nH]c2)(C)C(=O)N2C(Cc3ccccc3)C(=O)N3C(CCC3)C12O5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
563 Diloxanide 3736-81-0 ClC(Cl)C(=O)N(C)c1ccc(O)cc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
564 Diphemanil 15394-62-4 [N+]1(CCC(CC1)=C(c1ccccc1)c1ccccc1)(C)C7 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
565 Diprophylline 479-18-5 O=C2N(c1ncn(c1C(=O)N2C)CC(O)CO)C95 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
566 Distigmine 15876-67-2 O(C(=O)N(CCCCCCN(C(Oc1ccc[n+](c1)C)=O)C)C)c1ccc[n+](c1)C8 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
567 Disulfiram 97-77-8 S(SC(=S)N(CC)CC)C(=S)N(CC)CC97 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
568 Dothiepin 113-53-1 S1Cc2c(cccc2)\C(\c2c1cccc2)=C\CCN(C)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
569 Doxazosin 74191-85-8 O1c2c(OCC1C(=O)N1CCN(CC1)c1nc(N)c3cc(OC)c(OC)cc3n1)cccc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
570 Doxifluridine 3094-09-5 FC=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)C90 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
571 Drotaverine 985-12-6 O(c1ccc(cc1OCC)\C=C3\c2c(cc(OCC)c(OCC)c2)CCN3)CC100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
572 Eflornithine 67037-37-0 FC(F)C(N)(CCCN)C(O)=O55 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
573 Eltrombopag_Olamine 496775-61-2 Cc1ccc(cc1C)N2C(=O)/C(=N\Nc3cccc(c3O)c4cccc(c4)C(=O)O)/C(=N2)C.C(CO)N52 Deng, Y., Madatian, A, Wire, M.B., et al, Drug Metab Dispos, 2011, 39, 1734-46,
Nieto, M., Calvo, G., Hudson, I., et al, Haematologica, 2011, 96, 33-40REV/EU
574 Encainide 66778-36-7 O=C(c1ccc(OC)cc1)Nc2ccccc2CCC3N(C)CCCC395 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
575 Enoximone 77671-31-9 S(C)c1ccc(cc1)C(=O)C=1NC(=O)NC=1C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
576 Entecavir 142217-69-4 C=C3[C@H](CO)[C@@H](O)C[C@@H]3n2cnc1c2\N=C(\N)NC1=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
577 Epristeride 119169-78-7 CC(C)(C)NC(=O)C1CCC2C3C\C=C4\C=C(/CCC4(C)C3CCC12C)C(O)=O93 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
578 Eprosartan 133040-01-4 O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc315 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
579 Ergoloid_Mesylate 8067-24-1 O=C6N7C(C(=O)N1CCCC1C7(O)OC6(NC(=O)C4CC5c2cccc3c2c(cn3)CC5N(C)C4)C(C)C)C(C)(C)CC25 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
580 Ergotamine 113-15-5 O1C(NC(=O)C2C=C3C(N(C2)C)Cc2c4c3cccc4[nH]c2)(C)C(=O)N2C(Cc3ccccc3)C(=O)N3C(CCC3)C12O100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















582 Estramustine 2998-57-4 ClCCN(CCCl)C(Oc1cc2CCC3C4CCC(O)C4(CCC3c2cc1)C)=O90 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
583 Ethacrynic_Acid 58-54-8 Clc1c(Cl)c(OCC(O)=O)ccc1C(=O)C(=O)CC90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
584 Ethanol 64-17-5 OCC 100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
585 Ethynodiol_Diacetate 297-76-7 O(C(=O)C)C1(CCC2C3C(C4C(=CC(OC(=O)C)CC4)CC3)CCC12C)C#C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
586 Etidronate 2809-21-4 P(O)(O)(=O)C(P(O)(O)=O)(O)C5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
587 Etilefrine 709-55-7 OC(c1cc(O)ccc1)CNCC100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
588 Etravirine 269055-15-4 N#Cc3cc(c(Oc1nc(nc(c1Br)N)Nc2ccc(C#N)cc2)c(c3)C)C16 Hussar, D.A. and Campoli, K.E., JAPhA, 2003, 48, 428-31
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022187s010lbl.pdfREV/EF
589 Ezogabine 150812-12-7 O=C(OCC)Nc1ccc(cc1N)NCc2ccc(F)cc284 Borlak, J., Gasparic, A., Locher, M., et al, Metabolism, 2006, 55, 711-21.EU 
590 Febuxostat 144060-53-7 N#Cc1c(OCC(C)C)ccc(c1)c2nc(c(s2)C(=O)O)C89 Grabowski, B.A., Khosravan, R., Vernillet, L., et al, J Clin Pharmacol, 2011, 51, 189-201EU/EF
591 Felbamate 25451-15-4 O(CC(COC(=O)N)c1ccccc1)C(=O)N90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
592 Fenclofenac 34645-84-6 Clc1cc(Cl)ccc1Oc1ccccc1CC(O)=O00 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
593 Fenfluramine 458-24-2 FC(F)(F)c1cc(ccc1)C(CNCC)C95 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
594 Fenofibrate 49562-28-9 O=C(c1ccc(Cl)cc1)c2ccc(OC(C(=O)OC(C)C)(C)C)cc290 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
595 Fenspiride 5053-08-7 O=C3OC1(CCN(CC1)CCc2ccccc2)CN3100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
596 Feprazone 30748-29-9 O=C1N(N(C(=O)C1C\C=C(\C)/C)c1ccccc1)c1ccccc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
597 Fidaxomicin 873857-62-6 Clc1c(c(c(O)c(Cl)c1O)C(=O)O[C@H]2[C@H](O)[C@H](OC)[C@@H](O[C@@H]2C)OCC=4C(=O)O[C@H]([C@H](O)C)C\C=C(\C=C(\[C@H](O[C@@H]3OC([C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]3O)(C)C)[C@H](\C=C(/C)[C@@H](O)C\C=C\C=4)CC)C)C)CC8 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201699s000lbl.pdfEF
598 Finasteride 98319-26-7 O=C1NC2CCC3C4CCC(C(=O)NC(C)(C)C)C4(CCC3C2(C=C1)C)C100 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
599 Flucloxacillin 5250-39-5 O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(onc2c1c(F)cccc1Cl)C)[C@H]4SC3(C)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
600 Flucytosine 2022-85-7 FC1=CNC(=O)N=C1N100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
601 Fludrocortisone_Acetate 514-36-3 FC12C(C3CCC(O)(C(=O)COC(=O)C)C3(CC1O)C)CCC1=CC(=O)CCC12C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
602 Flunarizine 52468-60-7 Fc1ccc(cc1)C(N1CCN(CC1)CCCc1ccccc1)c1ccc(F)cc180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
603 Flunisolide 3385-03-3 FC1C2=CC(=O)C=CC2(C2C(C3CC4OC(OC4(C(=O)CO)C3(CC2O)C)(C)C)C1)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
604 Fluoxymesterone 76-43-7 O=C4\C=C3/[C@]([C@@]2(F)[C@@H](O)C[C@]1([C@@H](CC[C@@]1(O)C)[C@@H]2CC3)C)(C)CC444 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
605 Flupirtine 56995-20-1 Fc1ccc(cc1)CNc2nc(N)c(NC(=O)OCC)cc2100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
606 Fomepizole 7554-65-6 n1cc(cn1)C 100 Marraffa J, Forrest A, Grant W, et al, Clin Toxicol (Phila), 2008, 46, 181-6
607 Fosfomycin 23155-02-4 P(O)(O)(=O)C1OC1C36 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
608 Fosinopril 98048-97-6 P(OC(OC(=O)CC)C(C)C)(=O)(CCCCc1ccccc1)CC(=O)N1CC(CC1C(O)=O)C1CCCCC135 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
609 Fosmidomycin 66508-53-0 P(O)(O)(=O)CCCN(O)C=O30 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
610 Frovatriptan 158747-02-5 O=C(N)c3ccc1c(c2c(n1)CC[C@@H](NC)C2)c340 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
611 Fructose 57-48-7 O1CC(O)C(O)C(O)C1(O)CO100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
612 Fusidic_Acid 6990-06-3 O(C(=O)C)C/1CC2(C(CC(O)C3C2(CCC2C(C)C(O)CCC23C)C)\C\1=C(/CC\C=C(\C)/C)\C(O)=O)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
613 Gallopamil 16662-47-8 O(C)c1c(OC)cc(cc1OC)C(C(C)C)(CCCN(CCc1cc(OC)c(OC)cc1)C)C#N97 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
614 Gatifloxacin 112811-59-3 Fc1cc2c(N(C=C(C(O)=O)C2=O)C2CC2)c(OC)c1N1CC(NCC1)C96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
615 Genaconazole 121650-83-7 S(=O)(=O)(C(C(O)(Cn1ncnc1)c1ccc(F)cc1F)C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
616 Gentamicin_C1 1403-66-3 O1C(OC2C(O)C(OC3OCC(O)(C)C(NC)C3O)C(N)CC2N)C(N)CCC1C(NC)C0 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
617 Gentamicin_C1A 548-62-9 O1C(OC2C(O)C(OC3OCC(O)(C)C(NC)C3O)C(N)CC2N)C(N)CCC1CC0 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
618 Ginkgolide_A 15291-75-5 CC1C(=O)OC2C1(C34C(=O)OC5C3(C2)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O90 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
619 Glibornuride 26944-48-9 S(=O)(=O)(NC(=O)NC1C2CCC(C)(C1O)C2(C)C)c1ccc(cc1)C98 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
620 Gliquidone 33342-05-1 S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(cc1)CCN1C(=O)C(c2c(cc(OC)cc2)C1=O)(C)C95 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
621 Glycopyrrolate 596-51-0 O(C(=O)C(O)(C1CCCC1)c1ccccc1)C1CC[N+](C1)(C)C18 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
622 Glymidine 339-44-6 S(=O)(=O)(Nc1ncc(OCCOC)cn1)c1ccccc195 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
623 Granisetron 109889-09-0 O=C(NC1CC2N(C(C1)CCC2)C)c1nn(c2c1cccc2)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
624 Guanadrel 40580-59-4 O1C(COC12CCCCC2)CNC(N)=N80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
625 Hexobarbital 56-29-1 OC1=NC(=O)C(C)(C=2CCCCC=2)C(=O)N1C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
626 Hydroflumethiazide 135-09-1 S(=O)(=O)(N)c1cc2S(=O)(=O)NCNc2cc1C(F)(F)F67 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
627 Hydromorphone hydrochloride 466-99-9 O=C4[C@@H]5Oc1c2c(ccc1O)C[C@H]3N(CC[C@]25[C@H]3CC4)C87 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021217s005lbl.pdfEU-EF
628 Hydroxychloroquine 118-42-3 Clc1cc2nccc(NC(CCN(CCO)CC)C)c2cc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
629 Hydroxyprogesterone_Caproate 630-56-8 O(C(=O)CCCCC)C1(CCC2C3C(CCC12C)C1(C(=CC(=O)CC1)C=C3)C)C(=O)C90 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
630 Hydroxyurea 127-07-1 O=C(N)NO 100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
631 Ibutilide 122647-31-8 S(=O)(=O)(Nc1ccc(cc1)C(O)CCCN(CCCCCCC)CC)C82 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
632 Idazoxan 79944-56-2 O1c3c(OCC1C/2=N/CCN\2)cccc395 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
633 Ifosfamide 3778-73-2 O=P1(OCCCN1CCCl)NCCCl100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
634 Imidapril 89396-94-1 O=C(O)[C@H]2N(C(=O)[C@@H](N[C@H](C(=O)OCC)CCc1ccccc1)C)C(=O)N(C)C270 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
635 Imipenem 74431-23-5 S(CC\N=C\N)C=1CC2N(C(=O)C2C(O)C)C=1C(O)=O5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
636 Indecainide 74517-78-5 O=C(N)C3(c1ccccc1c2c3cccc2)CCCNC(C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
637 Indoprofen 31842-01-0 O=C1N(Cc2c1cccc2)c1ccc(cc1)C(C(O)=O)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
638 Iothalamatesodium 1225-20-3 Ic1c(C(=O)NC)c(I)c(NC(=O)C)c(I)c1C(O)=O2 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
639 Isosorbide_Dinitrate 87-33-2 O1C2C(OCC2O[N+](=O)[O-])C(O[N+](=O)[O-])C190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















641 Isotretinoin 4759-48-2 OC(=O)\C=C(\C=C\C=C(\C=C/C=1C(CCCC=1C)(C)C)/C)/C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
642 Isoxepac 55453-87-7 O1Cc2c(cccc2)C(=O)c2cc(ccc12)CC(O)=O98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
643 Kanamycin 59-01-8 O1C(CNC(=O)C)C(O)C(O)C(O)C1OC1C(O)C(OC2OC(CO)C(O)C(N)C2O)C(N)CC1N1 ao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
644 Ketazolam 27223-35-4 Clc1cc2c(N(C)C(=O)CN3C2(OC(=CC3=O)C)c2ccccc2)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
645 K-Strophanthoside 33279-57-1 O1C(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C(O)C1OC1C(OC)CC(OC1O)OC1CC2(O)CCC3C(CCC4(C)C(CCC34O)C3=CC(OC3)=O)C2(CC1)C=O16 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
646 Lacidipine 103890-78-4 O(C(=O)C=1C(C(C(OCC)=O)=C(NC=1C)C)c1ccccc1\C=C\C(OC(C)(C)C)=O)CC98 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
647 Lacosamide 175481-36-4 O=C(N[C@@H](C(=O)NCc1ccccc1)COC)C100 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022255lbl.pdfBA 
648 Lenalidomide 191732-72-6 O=C1NC(=O)CCC1N3C(=O)c2cccc(c2C3)N90 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021880s029s033lbl.pdfEU
649 Letrozole 112809-51-5 n1cn(nc1)C(c1ccc(cc1)C#N)c1ccc(cc1)C#N100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
650 Levamisole 14769-73-4 S1CCN2CC(N=C12)c1ccccc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
651 Levetiracetam 102767-28-2 O=C1N(CCC1)C(CC)C(=O)N100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
652 Levobunolol 47141-42-4 O(CC(O)CNC(C)(C)C)c1c2c(ccc1)C(=O)CCC2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
653 Levomepromazine 60-99-1 O(c2cc1N(c3c(Sc1cc2)cccc3)CC(C)CN(C)C)C53 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
654 Levonorgestrel 797-63-7 OC1(CCC2C3C(C4C(=CC(=O)CC4)CC3)CCC12CC)C#C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
655 Levoprotiline 76496-68-9 O[C@@H](CNC)CC34c1ccccc1C(c2ccccc23)CC4100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
656 Levosimendan 141505-33-1 O=C1NN=C(C(C1)C)c1ccc(N\N=C(\C#N)/C#N)cc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
657 Liothyronine 6893-02-3 O=C(O)C(N)Cc2cc(I)c(Oc1cc(I)c(O)cc1)c(I)c295 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
658 Lisuride 18016-80-3 O=C(NC1C=C2C(N(C1)C)Cc1c3c2cccc3[nH]c1)N(CC)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
659 Lodoxamide_Trometamol 63610-09-3 Clc1c(cc(C#N)cc1NC(=O)C(=O)O)NC(=O)C(=O)O.OCC(N)(CO)CO70 Therapeutic drugs, 2ed (1999 , Edinburgh : Churchill Livingstone, Dollery, C.
660 Lomustine 13010-47-4 O=C(NC1CCCCC1)N(N=O)CCCl100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
661 Lormetazepam 848-75-9 Clc1ccccc1C1=NC(O)C(=O)N(c2c1cc(Cl)cc2)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
662 Lornoxicam 70374-39-9 Clc1sc2c(S(=O)(=O)N(C)C(C(=O)Nc3ncccc3)=C2O)c1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
663 Loxiglumide 107097-80-3 Clc1ccc(C(=O)NC(C(=O)N(CCCCC)CCCOC)CCC(=O)O)cc1Cl100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
664 Lymecycline 992-21-2 OC(=O)[C@@H](N)CCCCNCNC(=O)\C3=C(/O)[C@@H](N(C)C)[C@@H]4C[C@H]2C(\C(=O)c1c(O)cccc1[C@@]2(C)O)=C(\O)[C@]4(O)C3=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
665 Lynestrenol 52-76-6 OC1(CCC2C3C(C4C(CC3)=CCCC4)CCC12C)C#C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
666 Mebeverine 2753-45-9 O(C)c1cc(ccc1OC)C(OCCCCN(C(Cc1ccc(OC)cc1)C)CC)=O90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
667 Meclofenamic_Acid 644-62-2 Clc1c(Nc2ccccc2C(O)=O)c(Cl)ccc1C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
668 Megestrol_Acetate 3562-63-8 O(C(=O)C)C1(CCC2C3C(CCC12C)C1(C(=CC(=O)CC1)C(=C3)C)C)C(=O)C100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
669 Meperidine 57-42-1 O(C(=O)C1(CCN(CC1)C)c1ccccc1)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
670 Meptazinol 54340-58-8 Oc1cc(ccc1)C1(CCCCN(C1)C)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
671 Mercaptopurine 50-44-2 S=C2/N=C\Nc1ncnc1250 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
672 Meropenem 119478-56-7 S(C=1C(C2N(C(=O)C2C(O)C)C=1C(O)=O)C)C1NC(CC1)C(=O)N(C)C0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
673 Mesna 19767-45-4 S(O)(=O)(=O)CCS 77 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
674 Mestranol 72-33-3 O(C)c1cc2CCC3C4CCC(O)(C#C)C4(CCC3c2cc1)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
675 Methocarbamol 532-03-6 O(CC(O)COC(=O)N)c1ccccc1OC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
676 Methsuximide 77-41-8 O=C1N(C)C(=O)CC1(C)c1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
677 Methylergonovine 113-42-8 OCC(NC(=O)C1C=C2C(N(C1)C)Cc1c3c2cccc3[nH]c1)CC100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
678 Metyrapone 54-36-4 O=C(C(C)(C)c1cccnc1)c1cccnc180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
679 Mezlocillin 51481-65-3 S1C2N(C(C(O)=O)C1(C)C)C(=O)C2NC(=O)C(NC(=O)N1CCN(S(=O)(=O)C)C1=O)c1ccccc10 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
680 Mianserin 24219-97-4 N12C(c3c(Cc4c1cccc4)cccc3)CN(CC2)C70 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
681 Miconazole 22916-47-8 Clc1cc(Cl)ccc1C(OCc1ccc(Cl)cc1Cl)Cn1ccnc199 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
682 Mifepristone 84371-65-3 OC1(CCC2C3C(=C4C(CC(=O)CC4)CC3)C(CC12C)c1ccc(N(C)C)cc1)C#C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
683 Mifobate 76541-72-5 Clc1ccc(cc1)C(P(OC)(OC)=O)CP(OC)(OC)=O82 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
684 Miglitol 72432-03-2 OCCN1[C@@H]([C@@H](O)[C@H](O)[C@@H](O)C1)CO100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137The 100% value is based on a low dose of 2 mg, dose dependancy at higher doses saturation occurs > 50 mg absorption saturation occurs
Ref: Pharmacokinetics of miglitol : Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man, AHR H.-J., (1997), increasing the dose can reduce the FA down in the region of 50-70%
685 Miglustat 72599-27-0 OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
686 Milrinone 78415-72-2 O=C1NC(C)=C(C=C1C#N)c1ccncc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
687 Misoprostol 59122-46-2 OC1CC(=O)C(CCCCCCC(OC)=O)C1\C=C/CC(O)(CCCC)C88 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
688 Mitotane 53-19-0 Clc1ccccc1C(c2ccc(Cl)cc2)C(Cl)Cl40 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
689 Mivacurium 106791-40-6 O(C)c1c(OC)cc(cc1OC)CC1[N+](CCc2c1cc(OC)c(OC)c2)(CCCOC(=O)CC\C=C\CCC(OCCC[N+]1(CCc2c(cc(OC)c(OC)c2)C1Cc1cc(OC)c(OC)c(OC)c1)C)=O)C0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
690 Modafinil 68693-11-8 S(=O)(C(c1ccccc1)c1ccccc1)CC(=O)N80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
691 Moexipril 103775-10-6 O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)Cc1c(cc(OC)c(OC)c1)C2)C)CCc3ccccc323 Beaumont, K., Webster, R., Gardner, I. et al, Curr Drug Metab, 2003, 4, 461-485.REV
692 Molsidomine 25717-80-0 o1n[n+](N2CCOCC2)cc1NC(OCC)=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
693 Montelukast 158966-92-8 O=C(O)CC1(CC1)CS[C@@H](c2cccc(c2)\C=C\c3nc4cc(Cl)ccc4cc3)CCc5ccccc5C(O)(C)C80 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
694 Moricizine 31883-05-3 S1c2c(N(c3c1cccc3)C(=O)CCN1CCOCC1)cc(NC(OCC)=O)cc288 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
695 Moxalactam 64952-97-2 S(CC=1COC2N(C(=O)C2(OC)NC(=O)C(C(O)=O)c2ccc(O)cc2)C=1C(O)=O)c1nnnn1C3 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
696 Moxifloxacin 354812-41-2 Fc1cc2c(c(OC)c1N1CC3C(NCCC3)C1)C(NC1CC1)C=C(C(O)=O)C2=O90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
697 Moxisylyte 54-32-0 O(C(=O)C)c1cc(C(C)C)c(OCCN(C)C)cc1C70 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
698 Moxonidine 75438-57-2 Clc1nc(nc(OC)c1NC=1NCCN=1)C88 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















700 Nabumetone 42924-53-8 O(C)c1cc2c(cc(cc2)CCC(=O)C)cc180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
701 Nafarelin 76932-56-4 NC(=O)CNC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(Cc2cc3ccccc3cc2)NC(=O)C(Cc4ccc(O)cc4)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc5cncn5)NC(=O)C6CCC(=O)N6)Cc8cnc7ccccc780 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
702 Nafronyl 31329-57-4 O1CCCC1CC(Cc1cc2c(cc1)cccc2)C(OCCN(CC)CC)=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
703 Naratriptan 121679-13-8 S(=O)(=O)(NC)CCc1cc2cc([nH]c2cc1)C1CCN(CC1)C70 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
704 Nateglinide 105816-04-4 OC(=O)C(NC(=O)C1CCC(CC1)C(C)C)Cc1ccccc183 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
705 Nedocromil 69049-73-6 O1c2c(cc3c(N(CC)C(=CC3=O)C(O)=O)c2CCC)C(=O)C=C1C(O)=O3 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
706 Nefazodone 83366-66-9 Clc1cc(N2CCN(CC2)CCCN2N=C(N(CCOc3ccccc3)C2=O)CC)ccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
707 Nefopam 13669-70-0 O1CCN(Cc2c(cccc2)C1c1ccccc1)C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
708 Neomycin 1404-04-2 O1C(COC2C(O)C(OC2CO)OC2C(OC3OC(CN)C(O)C(O)C3N)C(N)CC(N)C2O)C(N)C(O)C(O)C1CN3 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 132-1137
709 Netilmicin 56391-56-1 O1C(=CC(N)CC1OC1C(O)C(OC2OCC(O)(C)C(NC)C2O)C(NCC)CC1N)CN0 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
710 Niacin 59-67-6 c1cc(cnc1)C(=O)O94 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
711 Nicorandil 65141-46-0 O([N+](=O)[O-])CCNC(=O)c1cccnc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
712 Nilutamide 63612-50-0 FC(F)(F)c1cc(N2C(=O)C(NC2=O)(C)C)ccc1[N+](=O)[O-]100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
713 Nilvadipine 75530-68-6 O(C(=O)C=1C(C(C(OC)=O)=C(NC=1C)C#N)c1cc([N+](=O)[O-])ccc1)C(C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
714 Nisoldipine 63675-72-9 O(C(=O)C=1C(C(C(OC)=O)=C(NC=1C)C)c1ccccc1[N+](=O)[O-])CC(C)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
715 Nitroxoline 4008-48-4 Oc1c2ncccc2c([N+](=O)[O-])cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
716 Nizatidine 76963-41-2 s1cc(nc1CN(C)C)CSCCN\C(\NC)=C\[N+](=O)[O-]95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
717 Nomifensine 24526-64-5 c1ccc2c(c1N)CN(CC2c3ccccc3)C100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
718 Norgestimate 35189-28-7 O(C(=O)C)C1(CCC2C3C(C4C(=C/C(=N/O)/CC4)CC3)CCC12CC)C#C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
719 Orlistat 96829-58-2 O=C(O[C@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)CCCCCCCCCCC)[C@@H](NC=O)CC(C)C17 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020766s029lbl.pdfEF
720 Oxamniquine 21738-42-1 OCc1cc2CCC(Nc2cc1[N+](=O)[O-])CNC(C)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
721 Oxatomide 60607-34-3 O=C1Nc2c(N1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1)cccc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
722 Oxcarbazepine 28721-07-5 O=C(N)N1c2c(cccc2)C(=N)Cc2c1cccc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
723 Oxiracetam 62613-82-5 O=C(N)CN1C(=O)CC(O)C175 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
724 Oxitropium 30286-75-0 O1C2C3[N+](C(CC(OC(=O)C(CO)c4ccccc4)C3)C12)(CC)C16 Wahl D, van Wayjen RG, van den Ende AA., Arzneimittelforschung, 1985,35, 266-72. (German)
725 Oxyfedrine 15687-41-9 O(C)c1cc(ccc1)C(=O)CCNC(C(O)c1ccccc1)C85 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
726 Oxyphenbutazone 129-20-4 Oc1ccc(N2N(C(=O)C(CCCC)C2=O)c2ccccc2)cc1100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
727 Oxytetracycline 79-57-2 OC12C(C(N(C)C)C(O)=C(C(=O)N)C1=O)C(O)C1C(C2=O)=C(O)c2c(cccc2O)C1(O)C58 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
728 Pafenolol 75949-61-0 O=C(NC(C)C)NCCc1ccc(OCC(O)CNC(C)C)cc129 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
729 Pancuronium 16974-53-1 O(C(=O)C)C1C2(C(CC1[N+]1(CCCCC1)C)C1C(CC2)C2(CC([N+]3(CCCCC3)C)C(OC(=O)C)CC2CC1)C)C0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
730 Pantoprazole 102625-70-7 S(=O)(Cc1nccc(OC)c1OC)c1[nH]c2c(n1)cc(OC(F)F)cc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
731 Paromomycin 1263-89-4 O([C@H]3[C@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@H]1O[C@@H](CN)[C@@H](O)[C@H](O)[C@H]1N)[C@H]2O)[C@@H](O)[C@H](N)C[C@@H]3N)[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4N)CO0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
732 Pelrinone 94386-65-9 O=C1NC(=NC(NCc2cccnc2)=C1C#N)C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
733 Penbutolol 36507-48-9 O(CC(O)CNC(C)(C)C)c1ccccc1C1CCCC1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
734 Penciclovir 39809-25-1 O=C2/N=C(\Nc1n(cnc12)CCC(CO)CO)N10 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
735 Pentazocine 359-83-1 Oc1cc2c(CC3N(CCC2(C)C3C)C\C=C(\C)/C)cc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
736 Pentobarbital 76-74-4 O=C1NC(=O)NC(=O)C1(C(CCC)C)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
737 Pentoxifylline 6493-05-6 O=C1N(CCCCC(=O)C)C(=O)N(c2ncn(c12)C)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
738 Perhexiline 6621-47-2 N3C(CC(C1CCCCC1)C2CCCCC2)CCCC380 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
739 Perindopril_Erbumine 107133-36-8 O(C(=O)C(NC(C(=O)N1C2C(CC1C(O)=O)CCCC2)C)CCC)CC95 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
740 Phenacemide 63-98-9 O=C(NC(=O)N)Cc1ccccc100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
741 Phenglutarimide 1156-05-4 O=C1NC(=O)CCC1(CCN(CC)CC)c1ccccc100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
742 Phenindione 83-12-5 O=C1c2c(cccc2)C(=O)C1c1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
743 Phenprocoumon 435-97-2 O1c2c(cccc2)C(O)=C(C(CC)c2ccccc2)C1=O95 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
744 Phensuximide 86-34-0 O=C2N(C(=O)CC2c1ccccc1)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
745 Phenylpropanolamine 14838-15-4 OC(C(N)C)c1ccccc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
746 Phthalylsulfathiazole 85-73-4 s1ccnc1NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc15 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
747 Physostigmine 57-47-6 O=C(Oc1cc2c(cc1)N([C@H]3N(CC[C@@]23C)C)C)NC5 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
748 Pirbuterol 38029-10-6 Oc1ccc(nc1CO)C(O)CNC(C)(C)C60 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
749 Piretanide 55837-27-9 S(=O)(=O)(N)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O85 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
750 Pirmenol 68252-19-7 n1ccccc1C(O)(c2ccccc2)CCCN3C(CCCC3C)C95 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
751 Piroximone 84490-12-0 O=C1NC(C(=O)c2ccncc2)=C(N1)CC81 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
752 Pizotyline 15574-96-6 s1c2c(cc1)/C(/c1c(CC2)cccc1)=C\1/CCN(CC/1)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
753 Polythiazide 346-18-9 Clc1cc2NC(N(S(=O)(=O)c2cc1S(=O)(=O)N)C)CSCC(F)(F)F100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
754 Pomalidomide 19171-19-8 O=C3NC(=O)CCC3N1C(=O)c2c(C1=O)cccc2N83 http://www.a essdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdfEU-EF
755 Pralidoxime 6735-59-7 O\N=C\c1[n+](cccc1)C30 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
756 Pranlukast 103177-37-3 O=C(c2ccc(OCCCCc1ccccc1)cc2)Nc5cccc3c5O/C(=C\C3=O)c4nnnn420 Yoneda K, Matsumoto I, Sutoh F, et al, Biol Pharmaceut Bull, 2009, 32, 688-93.
757 Primidone 125-33-7 O=C1NCNC(=O)C1(CC)c1ccccc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















759 Probucol 23288-49-5 S(c1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C(Sc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(C)C7 ao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137
760 Procainamide 51-06-9 O=C(c1ccc(N)cc1)NCCN(CC)CC85 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
761 Procarbazine 671-16-9 O=C(NC(C)C)c1ccc(cc1)CNNC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
762 Propiverine 54556-98-8 O(C(=O)C(OCCC)(c1ccccc1)c1ccccc1)C1CCN(CC1)C84 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
763 Prothionamide 14222-60-7 S=C(N)c1cc(ncc1)CCC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
764 Protriptyline 438-60-8 N(CCCC1c2c(C=Cc3c1cccc3)cccc2)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
765 Proxyphylline 603-00-9 O=C1N(C)C(=O)N(c2ncn(c12)CC(O)C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
766 Pyrazinamide 98-96-4 O=C(N)c1nccnc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
767 Pyrimethamine 58-14-0 Clc2ccc(c1c(nc(nc1CC)N)N)cc2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
768 Quinagolide 87056-78-8 S(=O)(=O)(NC1CC2C(N(C1)CCC)Cc1c(C2)c(O)ccc1)N(CC)CC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
769 Quinalbarbitone 76-73-3 OC=1NC(=C)C(C(CCC)C)(CC=C)C(=O)N=190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
770 Quinapril 85441-61-8 O(C(=O)C(NC(C(=O)N1c2c(CCC1C(O)=O)cccc2)C)CCc1ccccc1)CC60 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
771 Quinaprilat 82768-85-2 O=C(O)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)Cc1c(cccc1)C2)C)CCc3ccccc361 Varma, M. V. S., Obach, R. S., Rotter, ., et al, J Med Chem 2010, 53,, 1098-1108.
772 Rabeprazole 117976-89-3 S(=O)(Cc1nccc(OCCCOC)c1C)c1[nH]c2c(n1)cccc290 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
773 Ramipril 87333-19-5 O(C(=O)C(NC(C(=O)N1C2C(CC1C(O)=O)CCC2)C)CCc1ccccc1)CC60 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
774 Recainam 74738-24-2 O=C(Nc1c(cccc1C)C)NCCCNC(C)C71 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
775 Remoxipride 117591-79-4 Brc1ccc(OC)c(C(=O)NCC2N(CCC2)CC)c1OC100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
776 Reproterol 54063-54-6 Oc1cc(cc(O)c1)C(O)CNCCCn1c2c(nc1)N(C)C(=O)N(C)C2=O60 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
777 Rimiterol 32953-89-2 Oc1cc(ccc1O)C(O)C1NCCCC148 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
778 Ritodrine 26652-09-5 Oc1ccc(cc1)C(O)C(NCCc1ccc(O)cc1)C95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
779 Rizatriptan 145202-66-0 [nH]1cc(c2cc(ccc12)Cn1ncnc1)CCN(C)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
780 Roquinimex 84088-42-6 CN(c1ccccc1)C(=O)C\3=C(/O)c2ccccc2N(C)C/3=O100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
781 Rufinamide 106308-44-5 O=C(c1nnn(c1)Cc2c(F)cccc2F)N85 Perucca E, Cloyd J, Critchley D, et al, Epilepsia. 2008, 49, 1123-41REV 
782 Saccharin 81-07-2 S1(=O)(=O)NC(=O)c2c1cccc288 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
783 Salbutamol 18559-94-9 OCc1cc(ccc1O)C(O)CNC(C)(C)C83 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
784 Salsalate 552-94-3 O(C(=O)c1ccccc1O)c1ccccc1C(O)=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
785 Saxagliptin 361442-04-8 O=C(N1[C@H](C#N)C[C@@H]2C[C@H]12)[C@@H](N)C35CC4CC(C3)CC(O)(C4)C575 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022350s004lbl.pdfEU/EF
786 Sematilide 101526-62-9 O=S(=O)(Nc1ccc(cc1)C(=O)NCCN(CC)CC)C65 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
787 Sibutramine 106650-56-0 Clc1ccc(cc1)C1(CCC1)C(N(C)C)CC(C)C77 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
788 Sitafloxacin 127254-12-0 F[C@H]5C[C@H]5N2/C=C(/C(=O)O)C(=O)c1cc(F)c(c(Cl)c12)N4C[C@@H](N)C3(CC3)C495 Varma, M. V. S., Obach, R. S., Rotter, ., et al, J Med Chem 2010, 53,, 1098-1108.
789 Sitagliptin 486460-32-6 Fc1cc(c(F)cc1F)C[C@@H](N)CC(=O)N3Cc2nnc(n2CC3)C(F)(F)F95 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
790 Solifenacin 242478-38-2 O=C(O[C@@H]2C1CCN(CC1)C2)N5[C@@H](c3ccccc3)c4ccccc4CC5100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
791 Spirapril 83647-97-6 O=C(OCC)[C@@H](N[C@H](C(=O)N2[C@H](C(=O)O)CC1(SCCS1)C2)C)CCc3ccccc360 Hayduk K and Kraul H.,J Cardiovas Pharm. 1999, 4, S19-23REV 
792 Streptomycin 57-92-1 O1C(CO)C(O)C(O)C(NC)C1OC1C(O)(C=O)C(OC1OC1C(NC(N)=N)C(O)C(NC(N)=N)C(O)C1O)C1 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
793 Streptozocin 18883-66-4 O1C(CO)C(O)C(O)C(NC(=O)N(N=O)C)C1O21.5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
794 Succinylsulfathiazole 116-43-8 s1ccnc1NS(=O)(=O)c1ccc(NC(=O)CCC(O)=O)cc15 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
795 Sudoxicam 34042-85-8 s1ccnc1NC(=O)C=1N(S(=O)(=O)c2c(cccc2)C=1O)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
796 Sufentanil 56030-54-7 O=C(N(c1ccccc1)C2(COC)CCN(CC2)CCc3sccc3)CC90 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
797 Sulbactam 68373-14-8 S1(=O)(=O)C2N(C(C(O)=O)C1(C)C)C(=O)C25 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
798 Sulfamethazine 57-68-1 S(=O)(=O)(Nc1nc(cc(n1)C)C)c1ccc(N)cc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
799 Sulfinpyrazone 57-96-5 S(=O)(CCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1)c1ccccc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
800 Sulfisomidine 515-64-0 S(=O)(=O)(Nc1nc(nc(c1)C)C)c1ccc(N)cc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
801 Sultopride 53583-79-2 S(=O)(=O)(CC)c1cc(C(=O)NCC2N(CCC2)CC)c(OC)cc189 Kobari T, Namekawa H, Kato Y, et al, Xenobiotica, 1985,15,469-76.EU
802 Suprofen 40828-46-4 O=C(c1ccc(cc1)C(C(=O)O)C)c2sccc292 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
803 Suramin 145-63-1 O=C(Nc1cc(ccc1C)C(=O)Nc3c2c(cc(cc2c(cc3)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)c8cccc(NC(=O)Nc7cc(C(=O)Nc6cc(C(=O)Nc5c4c(cc(cc4c(cc5)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)ccc6C)ccc7)c80 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
804 Tamsulosin 106133-20-4 S(=O)(=O)(N)c1cc(ccc1OC)CC(NCCOc1ccccc1OCC)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
805 Tapentadol 175591-23-8 Oc1cc(ccc1)[C@@H]([C@@H](C)CN(C)C)CC99 Terlinden, R., Ossig, J., Fliegert, F., et al , Eur J Drug Metab Ph, 2007, 32, 163-169EU
806 Teicoplanin_A2_1 91032-34-7 Clc1c2Oc3cc4C(NC(=O)C5NC(=O)C(NC(=O)C(N)c6cc(Oc7cc(O)cc5c7)c(O)cc6)Cc5cc(Cl)c(Oc(c4)c3OC3OC(CO)C(O)C(O)C3NC(=O)CC\C=C\CCCCC)cc5)C(=O)NC3c4cc(-c5c(cc(O)cc5OC5OC(CO)C(O)C(O)C5O)C(NC(=O)C(NC3=O)C(OC3OC(CO)C(O)C(O)C3NC(=O)C)c(c1)cc2)C(O)=O)c(O)cc40 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
807 Temazepam 846-50-4 Clc1cc2c(N(C)C(=O)C(O)N=C2c2ccccc2)cc195 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
808 Temozolomide 85622-93-1 O=C(c1ncn2C(=O)N(\N=N/c12)C)N100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
809 Terodiline 15793-40-5 c1ccccc1C(c2ccccc2)CC(NC(C)(C)C)C100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
810 Tesaglitazar 251565-85-2 S(Oc1ccc(cc1)CCOc1ccc(cc1)CC(OCC)C(O)=O)(=O)(=O)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
811 Thiabendazole 148-79-8 s1cc(nc1)-c1[nH]c2c(n1)cccc290 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
812 Thioridazine 50-52-2 S(c2cc1N(c3c(Sc1cc2)cccc3)CCC4N(C)CCCC4)C60 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
813 Tibolone 5630-53-5 OC1(CCC2C3C(C4=C(CC3C)CC(=O)CC4)CCC12C)C#C90 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
814 Ticarcillin 34787-01-4 S1C2N(C(C(O)=O)C1(C)C)C(=O)C2NC(=O)C(C(O)=O)c1ccsc10 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
815 Ticlopidine 55142-85-3 Clc1ccccc1CN1CCc2sccc2C180 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
816 Tilidine 51931-66-9 O=C(CCC)C1(CCC=CC1N(C)C)c1ccccc1100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137

















818 Tobramycin 32986-56-4 O1C(CO)C(O)C(N)C(O)C1OC1C(O)C(OC2OC(CN)C(O)CC2N)C(N)CC1N0 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
819 Tocainide 41708-72-9 O=C(Nc1c(cccc1C)C)C(N)C100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
820 Tolazoline 59-98-3 N1CCN=C1Cc1ccccc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
821 Tolmesoxide 38452-29-8 S(=O)(C)c1cc(OC)c(OC)cc1C98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
822 Tolrestat 82964-04-3 S=C(N(CC(O)=O)C)c1c2c(cc(OC)cc2)c(cc1)C(F)(F)F66 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
823 Tolterodine 124937-51-5 Oc1ccc(cc1C(CCN(C(C)C)C(C)C)c1ccccc1)C77 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
824 Toremifene 89778-26-7 ClCC\C(=C(\c1ccc(OCCN(C)C)cc1)/c1ccccc1)\c1ccccc1100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
825 Torsemide 56211-40-6 S(=O)(=O)(NC(=O)NC(C)C)c1cnccc1Nc1cc(ccc1)C96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
826 Trandolapril 87679-37-6 O(C(=O)C(NC(C(=O)N1C2C(CC1C(O)=O)CCCC2)C)CCc1ccccc1)CC50 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
827 Trapidil 15421-84-8 n12ncnc1N=C(C=C2N(CC)CC)C96 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
828 Triamcinolone 124-94-7 FC12C(C3CC(O)C(O)(C(=O)CO)C3(CC1O)C)CCC1=CC(=O)C=CC12C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
829 Triamcinolone_Acetonide 76-25-5 FC12C(C3CC4OC(OC4(C(=O)CO)C3(CC1O)C)(C)C)CCC=1C2C=CC(=O)C=190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
830 Trifluoperazine 117-89-5 S1c2c(N(c3c1cccc3)CCCN1CCN(CC1)C)cc(cc2)C(F)(F)F100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
831 Trihexyphenidyl 144-11-6 OC(CCN1CCCCC1)(C1CCCCC1)c1ccccc1100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
832 Trimeprazine 84-96-8 S1c2c(N(c3c1cccc3)CC(CN(C)C)C)cccc280 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
833 Trofosfamide 22089-22-1 ClCCN1P(OCCC1)(=O)N(CCCl)CCCl100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
834 Tropisetron 89565-68-4 CN4[C@@H]1CC[C@H]4C[C@H](C1)OC(=O)c3cnc2ccccc2395 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
835 Tubocurarine 57-95-4 O1c2cc3C([N+](CCc3cc2OC)(C)C)Cc2ccc(Oc3c4C([N+](CCc4cc(OC)c3O)(C)C)Cc3cc1c(O)cc3)cc20 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
836 Urapidil 34661-75-1 O(C)c1ccccc1N1CCN(CC1)CCCNC=1N(C)C(=O)N(C)C(=O)C=1100 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.
837 Vancomycin 1404-90-6 Clc1c2Oc3cc4C(NC(=O)C(NC(=O)C(NC(=O)C(NC)CC(C)C)C(O)c(c1)cc2)CC(=O)N)C(=O)NC1c2cc(-c5c(cc(O)cc5O)C(NC(=O)C(NC1=O)C(O)c1cc(Cl)c(Oc(c4)c3OC3OC(CO)C(O)C(O)C3OC3OC(C)C(O)C(N)(C3)C)cc1)C(O)=O)c(O)cc20 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 132-1137
838 Varenicline tartrate 375815-87-5 n1c2cc3c(cc2ncc1)[C@@H]4CNC[C@H]3C492 Obach RS, Reed-Hagen AE, Krueger SS, et al,Drug Metab Dispos, 2006, 34, 121-30EU
839 Vecuronium 50700-72-6 O(C(=O)C)C1C2(C(CC1[N+]1(CCCCC1)C)C1C(CC2)C2(CC(N3CCCCC3)C(OC(=O)C)CC2CC1)C)C0 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 201 , 52, 1132-1137
840 Vigabatrin 60643-86-9 O=C(O)CCC(\C=C)N100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
841 Vilazodone 163521-12-8 Cl.N#Cc1ccc2c(c1)c(cn2)CCCCN5CCN(c4cc3c(oc(c3)C(=O)N)cc4)CC598 Frampton JE., CNS Drugs, 2011, 25, 615-27REV/EF/EU
842 Vitamin_A 68-26-8 OC\C=C(\C=C\C=C(\C=C\C=1C(CCCC=1C)(C)C)/C)/C80 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
843 Vitamin_E 59-02-9 Cc1c(c2c(c(c1O)C)CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C65 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
844 Ximoprofen 56187-89-4 OC(=O)C(C)c1ccc(cc1)C1C\C(=N\O)\CCC198 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
845 Xipamide 14293-44-8 O=S(=O)(c1cc(c(O)cc1Cl)C(=O)Nc2c(cccc2C)C)N80 Therapeuti  drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.
846 Zalcitabine 7481-89-2 O1C(CCC1N1C=CC(=NC1=O)N)CO85 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
847 Zanamivir 139110-80-8 O1C(C(O)C(O)CO)C(NC(=O)C)C(NC(N)=N)C=C1C(O)=O2 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
848 Zatebradine 85175-67-3 O(C)c1cc(ccc1OC)CCN(CCCN1CCc2cc(OC)c(OC)cc2CC1=O)C79 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
849 Zileuton 132880-11-6 s1c2c(cc1C(N(O)C(=O)N)C)cccc2100 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
850 Zopiclone 43200-80-2 Clc1ccc(nc1)N1C(OC(=O)N2CCN(CC2)C)c2nccnc2C1=O98 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
851 Zotepine 26615-21-4 Clc1cc2c(Sc3c(C=C2OCCN(C)C)cccc3)cc1100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
852 Auranofin 34031-32-8 CC(=O)OC[C@H]1O[C@@H](S[Au]=P(CC)(CC)CC)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O>23 Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, .EU
853 Ethylmorphine 76-58-4 O1C2C34C5C1=C(O)C=CC5CC(N(CC3)CC)C4C=CC2O48 Hedenmalm K, Sundgren M, Granberg K, et al, Ther Drug Monit, 1997, 19, 643-9.;
Popa C, Beck O, Brodin K., et al, J Anal Toxicol, 1998, 22, 142-7;
Gerdin E, Rane A., Brit J Clin Pharmaco, 1992, 34, 250-5
EU
854 Isocarboxazid 59-63-2 o1nc(cc1C)C(=O)NNCc1ccccc156 Koechlin,BA., Schwartz, MA., and Oberhaensli, WE., J Pharm Exp Ther, JPET, 1962, 138, 11-20EU
855 Vismodegib 879085-55-9 CS(=O)(=O)c1ccc(c(c1)Cl)C(=O)Nc2ccc(c(c2)c3ccccn3)Cl69.3 Graham RA, Lum BL, Morrison G, Drug Metab Dispos, 2011, 39, 1460-7EF 
856 Apricitabine 160707-69-7 O=C1/N=C(/N)\C=C/N1[C@@H]2S[C@@H](OC2)CO80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
857 Clenbuterol 37148-27-9 Clc1cc(cc(Cl)c1N)C(O)CNC(C)(C)C80 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
858 Etofylline 519-37-9 O=C2N(c1ncn(c1C(=O)N2C)CCO)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
859 Flunitrazepam 1622-62-4 [O-][N+](=O)c3cc\1c(N(C(=O)C/N=C/1c2ccccc2F)C)cc380 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
860 Leflunomide 75706-12-6 O=C(Nc1ccc(cc1)C(F)(F)F)c2c(onc2)C80 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
861 Trimethobenzamide 138-56-7 O=C(c1cc(OC)c(OC)c(OC)c1)NCc2ccc(OCCN(C)C)cc280 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
862 Desvenlafaxine_Succinate 93413-62-8 OC2(C(c1ccc(O)cc1)CN(C)C)CCCCC280.5 Parker, VD., Richards,LS., Nichols, AI., et al, Clin Pharmacol Ther, 2005, 77, 47;
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204150s000lbl.pdfBA
863 Sulfamerazine 127-79-7 O=S(=O)(Nc1nc(ccn1)C)c2ccc(N)cc281 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
864 Chlorthalidone 77-36-1 Clc1ccc(cc1S(=O)(=O)N)C1(O)NC(=O)c2c1cccc282 Varma, M. V. S., Obach, R. S., Rotter, C., et al, J Med Chem 2010, 53,, 1098-1108.BA
865 Mepindolol 23694-81-7 OC(CNC(C)C)COc1cccc2c1cc(n2)C82 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
866 Mycophenolic_Acid 24280-93-1 O=C1OCc2c1c(O)c(c(OC)c2C)C\C=C(/C)CCC(=O)O82.5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
867 N_Acetylprocainamide 32795-44-1 O=C(Nc1ccc(cc1)C(=O)NCCN(CC)CC)C83 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
868 Pioglitazone 111025-46-8 O=C1NC(=O)SC1Cc3ccc(OCCc2ncc(cc2)CC)cc38 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
869 Valdecoxib 81695-72-7 O=S(=O)(N)c3ccc(c2c(onc2c1ccccc1)C)cc383 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
870 Aprindine 37640-71-4 c1cccc3c1CC(N(c2ccccc2)CCCN(CC)CC)C385 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
871 Delavirdine 136817-59-9 O=S(=O)(Nc1cc2cc(nc2cc1)C(=O)N4CCN(c3ncccc3NC(C)C)CC4)C85 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
872 Norfenfluramine 1886-26-6 FC(F)(F)c1cccc(c1)CC(N)C85 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
873 Aripiprazole 129722-12-9 Clc4cccc(N3CCN(CCCCOc2ccc1c(NC(=O)CC1)c2)CC3)c4Cl87 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
874 Clindamycin 18323-44-9 ClC(C(NC(=O)C1N(CC(C1)CCC)C)C1OC(SC)C(O)C(O)C1O)C87 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
875 Chloroxine 773-76-2 Clc1c(O)c2ncccc2c(Cl)c189 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA

















877 Carbazepine10_11Epoxide NC(=O)N1C2=C(C=CC=C2)C2OC2C2=C1C=CC=C290 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
878 Clomifene 911-45-5 Cl/C(c1ccccc1)=C(/c2ccc(OCCN(CC)CC)cc2)c3ccccc390 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
879 Droxidopa 23651-95-8 O=C(O)C(N)C(O)c1cc(O)c(O)cc190 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
880 Ertapenem 153832-46-3 O=C(O)c1cc(ccc1)NC(=O)[C@H]4NC[C@@H](S\C3=C(\N2C(=O)[C@H]([C@H](O)C)[C@H]2[C@H]3C)C(=O)O)C490 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
881 Nitisinone 104206-65-7 O=C(c1ccc(cc1[N+]([O-])=O)C(F)(F)F)C2C(=O)CCCC2=O90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
882 Fluocortolone 152-97-6 O=C\1\C=C/[C@]4(/C(=C/1)[C@@H](F)C[C@@H]2[C@@H]4[C@@H](O)C[C@@]3([C@@H](C(=O)CO)[C@@H](C[C@@H]23)C)C)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
883 Indapamide 26807-65-8 O=S(=O)(N)c1c(Cl)ccc(c1)C(=O)NN3c2ccccc2CC3C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
884 Lofexidine 31036-80-3 Clc2c(OC(C/1=N/CCN\1)C)c(Cl)ccc290 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
885 Toliprolol 2933-94-0 O(c1cc(ccc1)C)CC(O)CNC(C)C90 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
886 Clorazepate 23887-31-2 Clc3cc\1c(NC(=O)C(/N=C/1c2ccccc2)C(=O)O)cc391 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
887 Phenylethylmalonamide 7206-76-0 CCC(C(N)=O)(C(N)=O)C1=CC=CC=C191 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
888 Emtricitabine 143491-57-0 FC=1\C(=N/C(=O)N(C=1)[C@H]2O[C@H](SC2)CO)\N93 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
889 Estazolam 29975-16-4 Clc3cc2\C(=N/Cc1nncn1c2cc3)c4ccccc493 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
890 Mazindol 22232-71-9 Clc1ccc(cc1)C4(O)c2c(cccc2)/C3=N/CCN3493 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
891 Midodrine 133163-28-7 O=C(NCC(O)c1cc(OC)ccc1OC)CN93 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
892 Pipemidic_Acid 51940-44-4 O=C(O)\C2=C\N(c1nc(ncc1C2=O)N3CCNCC3)CC93 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
893 Pirazolac 71002-09-0 Clc3ccc(c1cn(nc1CC(=O)O)c2ccc(F)cc2)cc393.5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
894 Cefprozil 92665-29-7 O=C2N1/C(=C(/C=C/C)CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccc(O)cc3)N)C(=O)O95 Therapeutic drugs, ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.BA
895 Cinolazepam 75696-02-5 Fc3ccccc3C/2=N/C(O)C(=O)N(c1c\2cc(Cl)cc1)CCC#N95 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
896 Gitoxin 4562-36-1 O=C\1OC/C(=C/1)[C@H]2[C@@H](O)C[C@@]8(O)[C@]2(C)CC[C@H]7[C@H]8CC[C@H]6[C@]7(C)CC[C@H](O[C@@H]5O[C@H](C)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@@H]3O[C@@H]([C@@H](O)[C@@H](O)C3)C)[C@@H](O)C4)C)[C@@H](O)C5)C695 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137BA
897 Zuclopenthixol 53772-83-1 Clc2cc1C(\c3c(Sc1cc2)cccc3)=C/CCN4CCN(CCO)CC495 Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.BA
898 Oxandrolone 53-39-4 O=C3OC[C@@]2([C@H]1CC[C@@]4(C)[C@H]([C@@H]1CC[C@H]2C3)CC[C@@]4(O)C)C97 Cao, D., Wang, J., Zhou, R. et al, J hem Info Model, 2012, 52, 1132-1137BA
899 Palonosetron 135729-61-2 O=C5N([C@H]2C1CCN(CC1)C2)C[C@@H]4c3c5cccc3CCC497 ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
900 Treosulfan 299-75-2 O=S(=O)(OCC(O)C(O)COS(=O)(=O)C)C97 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
901 Antrafenine 55300-29-3 FC(F)(F)c5ccc1c(nccc1Nc2ccccc2C(=O)OCCN4CCN(c3cc(ccc3)C(F)(F)F)CC4)c5100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
902 Chlormezanone 80-77-3 O=S2(=O)CCC(=O)N(C2c1ccc(Cl)cc1)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
903 Cicloprolol 63659-12-1 O(c1ccc(OCC(O)CNC(C)C)cc1)CCOCC2CC2100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
904 Amifostine 20537-88-6 O=P(O)(O)SCCNCCCN100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
905 Benorylate 5003-48-5 O(C(=O)C)c1ccccc1C(Oc1ccc(NC(=O)C)cc1)=O100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137;
Robertson, A., Glynn, JP., and A. K. Watson, AK.,  Xenobiotica, 1972, 2, 339-347
906 Calcitriol 32222-06-3 O[C@@H]1CC(\C(=C)[C@@H](O)C1)=C\C=C2/CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)CCCC(O)(C)C)C100 Therapeutic drugs, ed (1999), Edinburgh : Churchill Livingstone, Dollery, .
907 Chenodeoxycholic_Acid 474-25-9 C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C100 Therapeutic drugs, 2ed 1999), Edinburgh : hurchill Livingstone, Dollery, C.
908 Oxtriphylline 146-71-4 [O-]/C2=C1\N=C/N=C1N(C(=O)N2C)C100 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137BA
909 Ursodeoxycholic_Acid 128-13-2 O=C(O)CCC(C)[C@H]4CC[C@@H]1[C@]4(C)CC[C@@H]2[C@@]3(C)CC[C@@H](O)C[C@H]3C[C@H](O)[C@@H]12100 Therapeutic drugs, 2ed (1999), Edinburgh : hurchill Livingstone, Dollery, C.
910 Ezetimibe 163222-33-1 Fc1ccc(cc1)[C@@H](O)CC[C@H]4C(=O)N(c2ccc(F)cc2)[C@@H]4c3ccc(O)cc3>31 Patrick JE, Kosoglou T, Stauber KL., Drug Metab Dispos, 2002, 30, 430-7EU, EF, EUB
911 Carglumic _Acid 1188-38-1 O=C(O)CC[C@H](NC(=O)N)C(=O)O>40 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022562lbl.pdfEF 
912 Deferasirox 201530-41-8 OC(=O)c1ccc(cc1)n2nc(nc2c3ccccc3O)c4ccccc4O81 Waldmeier F, Bruin GJ, Glaenzel U, et al., Drug Metab Dispos,  2010, 38, 808-1BA, EU, EF
913 Ticagrelor 274693-27-5 Fc1ccc(cc1F)[C@@H]5C[C@H]5Nc4nc(nc2c4nnn2[C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)SCCC>73 Teng R, Oliver S, Hayes MA, et al., Drug Metab Dispos, 2010, 38, 1514-21EU, EF, EUB
914 Tetrabenazine 58-46-8 O(C)c1cc2C3N(CC(CC(C)C)C(=O)C3)CCc2cc1OC>75 http://www.ac essdata.fda.gov/drugsatfda_docs/label/2011/021894s004lbl.pdfEU
915 Altretamine 645-05-6 n1c(nc(nc1N(C)C)N(C)C)N(C)C>87 Ames MM, Powis G, Kovach JS, et al., Cancer Res, 1979, 39, 5016-21;
Worzalla, JF., Kaiman, BD., Johnson, BM., et al., Cancer Res, 1974, 34, 2669EU
916 Amdinocillin 32887-01-7 O=C(O)[C@@H]2N3C(=O)[C@@H](/N=C/N1CCCCCC1)[C@H]3SC2(C)CPoor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
917 Amygdalin 29883-15-6 O1C(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C(O)C1OC(C#N)c1ccccc1Poor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
918 Bephenium 7181-73-9 O(CC[N+](Cc1ccccc1)(C)C)c1ccccc1Poor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
919 Bethanechol 674-38-4 O(C(C[N+](C)(C)C)C)C(=O)NPoor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
920 Chlorhexidine 55-56-1 Clc1ccc(NC(NC(NCCCCNC(NC(Nc2ccc(Cl)cc2)=N)=N)=N)=N)cc1Poor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
921 Diatrizoate 117-96-4 Ic1c(C(O)=O)c(I)c(NC(=O)C)c(I)c1NC(=O)CPoor ao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
922 Edetic_Acid/EDTA 60-00-4 OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=OPoor Bradberry S, Vale A., Clin Toxicol (Phila), 2009, 47, 841-58;
Foreman H, Trujillo TT., J Lab Clin Med, 1954, 43, 566-71.
923 Iohexol 66108-95-0 Ic1c(C(=O)NCC(O)CO)c(I)c(N(C(=O)C)CC(O)CO)c(I)c1C(=O)NCC(O)COPoor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
924 Iotroxate 72704-51-9 O=C(Nc1c(c(I)cc(I)c1I)C(=O)O)COCCOCCOCC(=O)Nc2c(C(=O)O)c(I)cc(I)c2IPoor Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.
925 Iotroxic_Acid 51022-74-3 Ic1c(C(O)=O)c(I)cc(I)c1NC(=O)COCCOCCOCC(=O)Nc1c(I)c(C(O)=O)c(I)cc1IPoor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
926 Ipratropium 60205-81-4 O(C(=O)C(CO)c1ccccc1)C1CC2[N+](C(C1)CC2)(C(C)C)CPoor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
927 Obidoxime 114-90-9 O(C[n+]1ccc(cc1)\C=N\O)C[n+]1ccc(cc1)\C=N\OPoor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
928 Pamidronic_Acid 40391-99-9 P(O)(O)(=O)C(P(O)(O)=O)(O)CCNPoor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
929 Pentolinium 52-62-0 [N+]1(CCCC1)(CCCCC[N+]1(CCCC1)C)CPoor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
930 Poldine 596-50-9 O(CC1[N+](CCC1)(C)C)C(=O)C(O)(c1ccccc1)c1ccccc1Poor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
931 Propantheline 298-50-0 O1c2c(cccc2)C(c2c1cccc2)C(OCC[N+](C(C)C)(C(C)C)C)=OPoor Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137
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0.0000115 AQUASOL dATAbASE 6th edition25 1000 mg British National Formulary, BNF 64, September 2012Tablet (AS SODIUM)
MDR1-MDCK II 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS HYDROCHLORIDE)
MDR1-MDCK II 1500 mg British National Formulary, BNF 64, September 2012Solution (IV INFUSION/INJECTION, IM)
0.24 Hazardous Substances Data Bank (HSDB)pH1.8 500 mg British National Formulary, BNF 64, September 2012Tablet as potassium salt
MDR1-MDCK II 8 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
MDR1-MDCK II 2 mg/ml British National Formulary, BNF 64, September 2012Solution (AS HYDROCHLORIDE)
>0.0622 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) tosylate salt50 g/ml Benet LZ, Broccatelli F, Opre  TI., AAPS J. 2011 Dec;13(4):519-47; FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution (IV AS TOSYL TE)
4 AQUASOL dATAbASE 6th edition 1000 mg British National Formulary, BNF 64, September 2012Tablet
MDR1-MDCK II 2.5 mg British National Formulary, BNF 64, September 2012Tablet  
1.817 AQUASOL dATAbASE 6th edition25 800 mg British National Formulary, BNF 64, September 2012Tablet
320 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
70 AQUASOL dATAbASE 6th editionRT 300 mg British National Formulary, BNF 64, September 2012Tablet
MDR1-MDCK (strain not stated) 400 mg British National Formulary, BNF 64, September 2012Tablet
97 The Merck Index: 12th edition 1996 80 mg British National Formulary, BNF 64, September 2012Tablet (AS DIHYDRATE)
MDR1-MDCK (strain not stated) 75 mg British National Formulary, BNF 64, September 2012Capsule (AS PHOSPHATE)
MDCK (Strain not stated) 800 mg British National Formulary, BNF 64, September 2012Tablet
0.055 AQUASOL dATAbASE 6th editionmesylate (25) 1000 mg British National Formulary, BNF 64, September 2012Tablet (AS MESILATE)
800 mg British National Formulary, BNF 64, September 2012Tablet
3.37 AQUASOL dATAbASE 6th edition25 500 mg British National Formulary, BNF 64, September 2012Solution (IV INFUSION AS SODIUM SALT)
0.01 AQUASOL dATAbASE 6th edition 2000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.08499 AQUASOL dATAbASE 6th edition25 320 mg British National Formulary, BNF 64, September 2012Tablet
9.3 AQUASOL dATAbASE 6th editionIntrinsic (25) 800 mg British National Formulary, BNF 64, September 2012Tablet
101 Balaguer-Fernández C, Femenía-Font A, Del Rio-Sancho S., et al., J Pharm Sci. 2008 Jun;97(6):2102-9succinate salt (20) 100 mg B itish National Formulary, BNF 64, September 2012Tablet (AS SUCCINATE)
1000 AQUASOL dATAbASE 6th edition 2.5 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INJECTION)
550 Kortejarvi, H.,  Yliperttula,M., Dressman, JB., et al., J Pharm Sci, 2005, Aug 94 (8):1617-1625pH 1–7.4, Hydrochloride300 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
<0.003 Oh YK, Nix DE, Straubinger RM., Antimicrob Agents Chemother. 1995 Sep;39(9):2104-111000 mg British National Formulary, BNF 64, September 2012Tablet (AS MONOHYDRATE HEMI-ETHANOLATE)
0.0011 AQUASOL dATAbASE 6th edition25 40 mg British National Formulary, BNF 64, September 2012Tablet
500 mg British National Formulary, BNF 64, September 2012Capsule
0.44 AQUASOL dATAbASE 6th edition25 500 mg British National Formulary, BNF 64, September 2012Tablet (Coated AS HYDROCHLORIDE)
0.2827 AQUASOL dATAbASE 6th edition25 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
MDCK II/ MDCK (strain not stated)
MDR1-MDCK (strain not stated) 40 mg British National Formulary, BNF 64, September 2012Tablet (AS CALCIUM SALT)
0.528 AQUASOL dATAbASE 6th editiondihydrate (30) 500 mg British National Formulary, BNF 64, September 2012Tablet
4.549 AQUASOL dATAbASE 6th edition25 20 mg British National Formulary, BNF 64, September 2012Tablet
0.0062 AQUASOL dATAbASE 6th edition25 80 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.02 Ghai D, Sinha VR., Nanomedicine. 2012 Jul;8(5):618-26100 mg Krueger M, Achenbach H, Terhaag B, et al., Int J Clin Pharmacol Ther. 2001 Feb;39(2):61-6Tablet
MDCK (Strain not stated) 400 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
0.605 AQUASOL dATAbASE 6th edition25 50 mg British National Formulary, BNF 64, September 2012Tablet (Coadminstered wi h Timolol and amiloride
209.2 AQUASOL dATAbASE 6th edition 40 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (inhalation)
MDR1-MDCK II 1 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INJECTION AS SULFATE)
90 Reverchon E, Della Porta G., Int J Pharm. 2003 Jun 4;258(1-2):1-95 mg British National Formulary, BNF 64, September 2012Tablet (AS SULFATE)
MDR1-MDCK (strain not stated) 400 mg British National Formulary, BNF 64, September 2012Tablet
0.0135 AQUASOL dATAbASE 6th editionIntrinsic (25) 100 mg British National Formulary, BNF 64, September 2012Tablet
10 AQUASOL dATAbASE 6th edition25 500 mg British National Formulary, BNF 64, September 2012Tablet (anh drous)
0.00045 AQUASOL dATAbASE 6th edition22.5 50 mg British National Formulary, BNF 64, September 2012Tablet
MDR1-MDCK II/ MDCK (strain not stated) 400 mg Hunt D, McRae C, Ramshaw J, et al., Aust N Z J Med. 1977 Apr;7(2):111-3Tablet
MDR1-MDCK II/ MDCKII 30 mg British National Formulary, BNF 64, September 2012Tablet
0.086 AQUASOL dATAbASE 6th edition25 750 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
MDCK (Strain not stated) 200 mg Fillastre JP, Godin M, Legallicier B., et al., J Antimicrob Chemother. 1996 May;37(5):965-74Tablet

















8.3 AQUASOL dATAbASE 6th edition25 240 mg British National Formulary, BNF 64, September 2012Tablet
0.0464 AQUASOL dATAbASE 6th edition25 0.25 mg British National Formulary, BNF 64, September 2012Tablet
0.711 Hopfinger AJ, Esposito EX, Llinàs A., et al., J Chem Inf Model. 2009 Jan;49(1):1-5Intrinsic 400 mg British National Formulary, BNF 64, September 2012Capsule as hydrochloride
150 mg British National Formulary, BNF 64, September 2012Tablet (AS POTASSIUM)
1087 AQUASOL dATAbASE 6th edition25 200 mg British National Formulary, BNF 64, September 2012Capsule (AS HYCLATE)
0.0171 AQUASOL dATAbASE 6th editionpH 6.5 (22) 20 mg British National Formulary, BNF 64, September 2012Tablet (AS MALEATE)
4.24 Deák K, Takács-Novák K, Tihanyi K, et al., Med Chem. 2006 Jul;2(4):385-950 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS SODIUM)
0.1145 AQUASOL dATAbASE 6th edition25 200 mg British National Formulary, BNF 64, September 2012Capsule 1.9m^2 averag  male 100 per m^2 therefore 200mg
0.7 Gu X, Li H, Macnair KR, et al., J Pharm Biomed Anal. 2005 Apr 1;37(4):663-7pH 6.8, 25 8 mg British National Formulary, BNF 64, September 2012Capsule
0.00617 AQUASOL dATAbASE 6th edition22.5 300 mg British National Formulary, BNF 64, September 2012Capsule
0.04 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-113725 600 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdfCap ule
21 AQUASOL dATAbASE 6th editionMaleate (25) 40 mg British National Formulary, BNF 64, September 2012Tablet (AS MALEATE)
500 mg British National Formulary, BNF 64, September 2012Tablet
MDR1-MDCK II/MDCKII 10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
2.2 SRC PHYSPROP 50 mg British National Formulary, BNF 64, September 2012Tablet
0.00346 Hopfinger AJ, Esposito EX, Llinàs A., et al., J Chem Inf Model. 2009 Jan;49(1):1-5Intrinsic 150 mg British National Formulary, BNF 64, September 2012Tablet
3.19 AQUASOL dATAbASE 6th edition25 1750 mg British National Formulary, BNF 64, September 2012Capsule (25mg/kg at 70 kg adult)
MDR1-MDCK (strain not stated) 200 mg British National Formulary, BNF 64, September 2012Tablet (AS ACETATE)
0.0097 SRC PHYSPROP 24 200 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
MDCK (Strain not stated) 250 mg British National Formulary, BNF 64, September 2012Tablet (AS MONOHYDRATE)
4.5 AQUASOL dATAbASE 6th edition 1250 mg British National Formulary, BNF 64, September 2012Tablet (AS MESILATE)
659 AQUASOL dATAbASE 6th edition25 10 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
4.62 AQUASOL dATAbASE 6th edition25 750 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
Average of different concentration, MDCK wild type used 250 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202570s004lbl.pdfCap ule
0.01 AQUASOL dATAbASE 6th editionambi nt temp 400 mg British National Formulary, BNF 64, September 2012Tablet
2.75 Ross, DL., Riley, CM., Int J Pharm, 1990, 63, 30 Sept, 237–250Intrinsic (25) 400 mg British National Formulary, BNF 64, September 2012Tablet
50 http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Product_Information_Sheet/c6628pis.Par.0001.File.tmp/c6628pis.pdfDip osphate salt in water310 mg British National Formulary, BNF 64, September 2012Tablet as base 250mg
0.01 AQUASOL dATAbASE 6th edition 600 mg British National Formulary, BNF 64, September 2012Tablet  
14 http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/018936s064lbl.pdfHydrochl ri e salt  60 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
0.19 AQUASOL dATAbASE 6th edition 600 mg British National Formulary, BNF 64, September 2012Capsule
0.212 AQUASOL dATAbASE 6th edition25 5 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.00633 AQUASOL dATAbASE 6th edition25 5 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (AS ACETATE)
20.1 SRC PHYSPROP 25 300 mg British National Formulary, BNF 64, September 2012Capsule
0.00122 AQUASOL dATAbASE 6th edition25 0.10 % British National Formulary, BNF 64, September 2012Topical (AS MO OHYDRATE)
3.322 AQUASOL dATAbASE 6th edition25 0.6 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INJECTION AS SULFATE)
0.0113 SRC PHYSPROP 0.5 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.1889 Hopfinger AJ, Esposito EX, Llinàs A., et al., J Chem Inf Model. 2009 Jan;49(1):1-5Intrinsic 200 mg British National Formulary, BNF 64, September 2012Tablet
0.009319 AQUASOL dATAbASE 6th editionpH 8.2 (25) 40 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
249 AQUASOL dATAbASE 6th edition25 2000 mg Levine GN, Frei B, Koulouris SN., et al., Circulation. 1996 Mar 15;93(6):1107-13Tablet
1 AQUASOL dATAbASE 6th edition 800 mg British National Formulary, BNF 64, September 2012Capsule
0.403 AQUASOL dATAbASE 6th edition25 200 mg British National Formulary, BNF 64, September 2012Tablet
0.0004336 Alelyunas YW, Liu R, Pelosi-Kilby L, et al., Eur J Pharm Sci. 2009 May 12;37(2):172-82pH7.4 80 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
0.0000001 AQUASOL dATAbASE 6th edition25 120 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.0004 Hazardous Substances Data Bank (HSDB) 80 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.0032 AQUASOL dATAbASE 6th edition22.5 5 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.002058 AQUASOL dATAbASE 6th edition22.5 20 mg British National Formulary, BNF 64, September 2012Tablet
0.00453 AQUASOL dATAbASE 6th edition22 10 mg British National Formulary, BNF 64, September 2012Tablet
0.14 AQUASOL dATAbASE 6th edition25 400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS SULFATE)
0.00145 Llinàs A, Glen RC, Goodman JM., J Chem Inf Model. 2008 Jul;48(7):1289-303Intrinsic (25) 15 mg British National Formulary, BNF 64, September 2012Tablet
0.115 AQUASOL dATAbASE 6th edition25 20 mg British National Formulary, BNF 64, September 2012Tablet
40 mg British National Formulary, BNF 64, September 2012Capsule (AS SODIUM SALT)
MDR1-MDCK (strain not stated) 40 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROBROMIDE)
0.539 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Tablet
0.0007599 AQUASOL dATAbASE 6th edition22.5 300 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
25 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
100 AQUASOL dATAbASE 6th edition 0.3 mg British National Formulary, BNF 64, September 2012Tablet (Chewable)
7.55 AQUASOL dATAbASE 6th edition25 500 mg British National Formulary, BNF 64, September 2012Tablet (Modified releas )

















0.01823 AQUASOL dATAbASE 6th edition24 150 mg British National Formulary, BNF 64, September 2012Tablet (S HYDROCHLORIDE)
0.321 AQUASOL dATAbASE 6th editionpH 5.8 (30) 10 mg Lefebvre RA, Van Peer A, Woestenborghs R., Br J Clin Pharmacol. 1997 Mar;43(3):319-22T blet
0.345 AQUASOL dATAbASE 6th edition25 50 mg British National Formulary, BNF 64, September 2012Tablet (AS SULFATE)
0.117 SRC PHYSPROP 25 400 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.00207 AQUASOL dATAbASE 6th edition 4.8 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020866s002lbl.pdfCap ule (AS MESYLATE)
0.127 Hopfinger AJ, Esposito EX, Llinàs A., et al., J Chem Inf Model. 2009 Jan;49(1):1-5Intrinsic 400 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
0.0985 AQUASOL dATAbASE 6th edition25 2 mg British National Formulary, BNF 64, September 2012Tablet
0.0137 Llinàs A, Glen RC, Goodman JM., J Chem Inf Model. 2008 Jul;48(7):1289-303.25 200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (co-administered with PHENAZOPYRIDIN  HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM)
52.3 AQUASOL dATAbASE 6th edition25 1 mg/ml British National Formulary, BNF 64, September 2012Solution (IM)
0.04474 AQUASOL dATAbASE 6th edition25 6 mg British National Formulary, BNF 64, September 2012Tablet
<0.01 AQUASOL dATAbASE 6th editionTartrate (25) 10 mg British National Formulary, BNF 64, September 2012Tablet (AS TARTRATE)
0.0035 AQUASOL dATAbASE 6th edition32 50 mg British National Formulary, BNF 64, September 2012Tablet (AS SODIUM OR POTASSIUM)
60 mg British National Formulary, BNF 64, September 2012Capsule
43 AQUASOL dATAbASE 6th editiontartrate (25) 200 mg British National Formulary, BNF 64, September 2012Tablet (AS TARTRATE)
0.054 AQUASOL dATAbASE 6th edition 2.5 mg British National Formulary, BNF 64, September 2012Tablet
0.0388 AQUASOL dATAbASE 6th edition25 (differe t polymorphs)100 mg British National Formulary, BNF 64, September 2012Tablet (chewable)
MDR1-MDCK (strain not stated) 10 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.051 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Capsule
3.488 AQUASOL dATAbASE 6th editioncitrate 100 mg British National Formulary, BNF 64, September 2012Tablet (AS CITRATE)
0.01 Janssens F, Leenaerts J, Diels G., et al., J Med Chem. 2005 Mar 24;48(6):2154-6610 mg British National Formulary, BNF 64, September 2012Tablet
0.031 AQUASOL dATAbASE 6th edition25 10 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, London; FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
0.0325 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Tablet
0.17 Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-473 mg Oda M, Kotegawa T, Tsutsumi K., et al., Eur J Clin Pharmacol. 2003 Nov;59(8-9):615-9Tablet
0.0159 AQUASOL dATAbASE 6th edition25 500 mg British National Formulary, BNF 64, September 2012Tablet
0.0025500 SRC PHYSPROP 24 100 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
0.08999 AQUASOL dATAbASE 6th edition25 4 mg British National Formulary, BNF 64, September 2012Tablet
142.9 AQUASOL dATAbASE 6th editionhydrochloride salt 20 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
0.014 AQUASOL dATAbASE 6th editionpH 1-7 (25) 300 mg British National Formulary, BNF 64, September 2012Capsule (AS SODIUM)
0.007 DeGoey DA, Grampovnik DJ, Flosi WJ., et al., J Med Chem. 2009 May 14;52(9):2964-70800 mg British National Formulary, BNF 64, September 2012Tablet (WITH RITONAVIR)
11.05 AQUASOL dATAbASE 6th editionMaleate (37.5) 45.3 mg http://www.medicines.org.au/files/swpavilt.pdfTablet
MDR1-MDCK II 160 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.33 AQUASOL dATAbASE 6th edition25 20 mg British National Formulary, BNF 64, September 2012Tablet
21.6 AQUASOL dATAbASE 6th edition25 200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online);
Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.0061860 AQUASOL dATAbASE 6th editionpH 2 (24.9) 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.125 AQUASOL dATAbASE 6th edition24 2000 mg British National Formulary, BNF 64, September 2012Tablet
MDR1-MDCK II, MDCKII, MDCK-MDR1 (strain not stated) 10 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.03 AQUASOL dATAbASE 6th editionambi nt temp 0.5 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
14.475 AQUASOL dATAbASE 6th edition25 1000 mg British National Formulary, BNF 64, September 2012Tablet
0.0138 AQUASOL dATAbASE 6th edition25 800 mg British National Formulary, BNF 64, September 2012Tablet
0.0468 AQUASOL dATAbASE 6th edition25 15 mg British National Formulary, BNF 64, September 2012Tablet
0.004 AQUASOL dATAbASE 6th edition37 1200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.51 AQUASOL dATAbASE 6th editionhydrochloride salt (25) 300 mg British National Formulary, BNF 64, September 2012Capsule (modified release AS HYDROCHLORIDE)
0.07 AQUASOL dATAbASE 6th editionambi nt temp 500 mg British National Formulary, BNF 64, September 2012Tablet 
MDR1-MDCK (strain not stated) 5 mg/ml British National Formulary, BNF 64, September 2012Solution (IV AS HYDROCHLORIDE INJECTION)
MDR1-MDCK II 150 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
2.119 Sköld C, Winiwarter S, Wernevik J., et al., J Med Chem. 2006 Nov 16;49(23):6660-71Intrinsic 100 mg British National Formulary, BNF 64, September 2012Capsule
0.01564 AQUASOL dATAbASE 6th edition24 25 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
5.496 AQUASOL dATAbASE 6th edition37.5 4 mg British National Formulary, BNF 64, September 2012Tablet (AS MALEATE)
0.92 Lee J, Park TG, Choi H., Int J Pharm. 2000 Feb 25;196(1):75-83.Hydrochloride 40 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
0.08099 AQUASOL dATAbASE 6th edition25 160 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.017 SRC PHYSPROP 20 10 mg British National Formulary, BNF 64, September 2012Tablet (AS SODIUM)
0.3669 AQUASOL dATAbASE 6th edition22.5 200 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Tablet
0.41 Hopfinger AJ, Esposito EX, Llinàs A., et al., J Chem Inf Model. 2009 Jan;49(1):1-5Intrinsic (25) 50 mg British National Formulary, BNF 64, September 2012Capsule
0.15 AQUASOL dATAbASE 6th edition25 400 mg British National Formulary, BNF 64, September 2012Tablet
0.414 Llinàs A, Glen RC, Goodman JM., J Chem Inf Model. 2008 Jul;48(7):1289-303Intrinsic (25) 1 mg/ml British National Formulary, BNF 64, September 2012Solution (IV)
0.7205 Bergström CA, Luthman K, Artursson P., Eur J Pharm Sci. 2004 Aug;22(5):387-98240 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.054 AQUASOL dATAbASE 6th edition24 5 mg/ml British National Formulary, BNF 64, September 2012Solution (IV AS HYDROCHLORIDE)
182.767 Bergström CA, Wassvik CM, Norinder U., et al., J Chem Inf Comput Sci. 2004 Jul-Aug;44(4):1477-88hydrochloride salt 0.075 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)

















0.0586 SRC PHYSPROP 24 300 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
637 AQUASOL dATAbASE 6th edition25 500 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Tablet
0.033 AQUASOL dATAbASE 6th edition22.5 15 mg British National Formulary, BNF 64, September 2012Tablet
11 Hazardous Substances Data Bank (HSDB)Acetate (25) 32 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, London; FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
MDR1-MDCK II 20 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
MDR1-MDCK II 40 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDDE)
3.85 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Solution (IV INJECTION)
0.084 AQUASOL dATAbASE 6th edition25 20 mg British National Formulary, BNF 64, September 2012Tablet
0.1 Gao S, Singh J., J. Control Release, 1998, 51 (2–3), 193–19980 mg British National Formulary, BNF 64, September 2012Tablet (AS CITRATE)
0.0058 AQUASOL dATAbASE 6th edition25 20 mg British National Formulary, BNF 64, September 2012Capsule
0.17 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020241s050,020764s043,022251s013lbl.pdf25 100 mg British National Formulary, BNF 64, September 2012Tablet
0.035208 Alelyunas YW, Liu R, Pelosi-Kilby L, et al., Eur J Pharm Sci. 2009 May 12;37(2):172-82pH 7.4 8 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.0279 AQUASOL dATAbASE 6th edition25 40 mg British National Formulary, BNF 64, September 2012Capsule (AS UNDECANOATE OILY SOLUTION)
78.7 Alelyunas YW, Empfield JR, McCarthy D., Bioorg Med Chem Lett. 2010 Dec 15;20(24):7312-6150 mg British National Formulary, BNF 64, September 2012Tablet
0.2405 AQUASOL dATAbASE 6th edition37
0.0089 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Capsule (Micronized)
3.79 AQUASOL dATAbASE 6th edition25 200 mg British National Formulary, BNF 64, September 2012Capsule (Co administer d with benserazide hydrochloride)
70 mg British National Formulary, BNF 64, September 2012Tablet (AS SODIUM FORM)
12 SRC PHYSPROP 20 2000 mg British National Formulary, BNF 64, September 2012Powder (IV INFUSION) AS MESILATE
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 1600 mg British National Formulary, BNF 64, September 2012Capsule (AS SODIUM SALT)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 25 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS CALCIUM SALT)
0.119 www.toku-e.com/ConvertHtmlToPdf.axd?product=45040000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IV INJECTION/INFUSION)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 24 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INFUSION AS SODIUM)
229.8 AQUASOL dATAbASE 6th edition25
0.005 US Patent 2006/0073200 A1, Serial number EP1807059 A1 20 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 2000 mg Ko H, Cathcart KS, Griffith DL., et al., Antimicrob Agents Chemother. 1989 Mar;33(3):356-61;
Tan, JS., Salstrom, SJ., Signs, SA., et al., Antimicrob Agents Chemother. 1989 June; 33(6): 924–927Solution (IV AS SODIUM INFUSION)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 3 mg Evans HC, Perry CM, Faulds D., Drugs. 2004;64(6):649-78Powder (SC)
13 AQUASOL dATAbASE 6th edition25 24 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.75 AQUASOL dATAbASE 6th edition28 100 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, London; FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Powder (IV INJECTION/ORAL SUSPENSION)
2.76 Thomas S, Brightman F, Gill H., et al., J Pharm Sci. 2008 Oct;97(10):4557-74pH 7.4, ydrochloride salt40 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019851s044lbl.pdfTablet (AS HYDROCHLORIDE)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 5 mg Dudenhausen JW, Hermer M, Rominger KL., Geburtshilfe Frauenheilkd. 1989 Mar;49(3):234-6 (German)Tablet
>100 Hazardous Substances Data Bank (HSDB)20 200 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 4000 mg British National Formulary, BNF 64, September 2012Solution (IV INFUSION AS SODIUM)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 20 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS SULFATE)
500 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021595s007lbl.pdfChloride 20 mg British National Formulary, BNF 64, September 2012Tablet (AS CHLORIDE)
0.5135 AQUASOL dATAbASE 6th edition 187.4 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution (IV)
142 Hazardous Substances Data Bank (HSDB)25 600 mg British National Formulary, BNF 64, September 2012Tablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 200 mg Bastain W, Boyce MJ, Stafford LE., et al., Eur J Clin Pharmacol. 1988;34(5):469-73Tablet
0.8 SRC PHYSPROP 25 10 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE WITH ATROPINE SULFATE)
0.7112 AQUASOL dATAbASE 6th edition25 500 mg British National Formulary, BNF 64, September 2012Tablet/Capsule - extended release
27.3 AQUASOL dATAbASE 6th edition25 400 mg British National Formulary, BNF 64, September 2012Capsule (granules)
764 SRC PHYSPROP 30 20000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (ORAL)
1.41 French, DL., Mauger, JW., Pharm Res, 1993 Sept; 10(9), 1285-129037 4800 mg British National Formulary, BNF 64, September 2012Tablet
400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
Ogihara T, Kano T, Wagatsuma T, Wada S., Drug Metab Dispos. 2009 Aug;37(8):1676-81
0.0029 AQUASOL dATAbASE 6th edition30 20 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
2000 mg British National Formulary, BNF 64, September 2012Solution (IV INJECTION)
500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IV INJECTION)
16 Kurochkina VB, Sklyarenko AV, Satarova JE., et al., Bioprocess Biosyst Eng. 2011 Nov;34(9):1103-17For propylene glycolate, recalculated to main substance (25oC, H2O)500 mg Mastrandrea V, Ripa S, La Rosa F., et al., Int J Clin Pharmacol Res. 1985;5(5):319-23Capsule
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 50 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
13.9 AQUASOL dATAbASE 6th edition25 1000 mg British National Formulary, BNF 64, September 2012Capsule
0.004 AQUASOL dATAbASE 6th edition 12 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
0.04 AQUASOL dATAbASE 6th edition25 1000 mg British National Formulary, BNF 64, September 2012Capsule
167 SRC PHYSPROP 1500 mg British National Formulary, BNF 64, September 2012Tablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 20 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS BROMIDE)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 300 mg British National Formulary, BNF 64, September 2012Powder (IV AS ISETIONATE)

















Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 300 mg British National Formulary, BNF 64, September 2012Tablet
Zornoza T, Cano-Cebrián MJ, Nalda-Molina R, European J Pharm Sci, 2004, 22, 347-56 666 mg British National Formulary, BNF 64, September 2012Tablet (AS CALCIUM)
200 mg British National Formulary, BNF 64, September 2012Tablet
80.1 AQUASOL dATAbASE 6th edition1
32.1 US Patent 2005/0171,203 Serial number A1 11/016,511300 mg British National Formulary, BNF 64, September 2012Tablet
4.5 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021567s028lbl.pdf24 400 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021567s028lbl.pdf
200 mg British National Formulary, BNF 64, September 2012Tablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 850 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.1083 AQUASOL dATAbASE 6th edition25 10 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Tablet (Co-administered NADOLOL)
10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (acti  metabolite)
0.529 AQUASOL dATAbASE 6th edition20 1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
>50 He H, Tran P, Yin H., et al., Drug Metab Dispos. 2009 Mar;37(3):545-54Unpublished results from the reference50 mg British National Formulary, BNF 64, September 2012Tablet
10 AQUASOL dATAbASE 6th edition 500 mg British National Formulary, BNF 64, September 2012Capsule (AS MONOHYDRATE)
2.675 AQUASOL dATAbASE 6th edition25 2400 mg British National Formulary, BNF 64, September 2012Powder (IV INJECTION/INFUSION AS SODIUM SALT)
4000 mg British National Formulary, BNF 64, September 2012Powder (IV INJECTION AS SODIUM SALT)
40 mg British National Formulary, BNF 64, September 2012Tablet (AS SODIUM)
0.0016 AQUASOL dATAbASE 6th edition25 5 mg British National Formulary, BNF 64, September 2012Tablet
0.5 mg/ml British National Formulary, BNF 64, September 2012Solution (IV AS ACETATE)
<0.01 AQUASOL dATAbASE 6th editionRT 10 mg British National Formulary, BNF 64, September 2012Tablet (AS MALEATE OR MESILATE)
0.00532 Kumar, N., Jain, AK., Singh, C., et al., Asian journal of pharmaceutics, 2008, 2 (3 ), 154-158Hydrochloride (27) 250 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
20 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
21.3 AQUASOL dATAbASE 6th edition 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
5 Chen XQ, Cho SJ, Li Y., et al., J Pharm Sci. 2002 Aug;91(8):1838-523000 mg British National Formulary, BNF 64, September 2012Powder for IV recon as sodium salt
10000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution (IV INJECTION)
0.00025 Hazardous Substances Data Bank (HSDB) 60 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
174 http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm072850.pdfHydrochloride 1000 mg British National Form lary, BNF 64, September 2012Tabl t
0.024 mg British National Formulary, BNF 64, September 2012Powder for inhalation
0.19 AQUASOL dATAbASE 6th edition25 400 mg British National Formulary, BNF 64, September 2012Tablet
0.0339 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 200 mg Ballerini R, Casini A, Chinol M, et al., Drugs Exp Clin Res. 1985;11(8):517-21.Caps le
100 mg Smith, PC., McDonagh, AF., Benet, LZ., J Clin Invest. 1986 March; 77(3): 934–939. Tablet (AS dihydrate of the sodium salt)
4.46 AQUASOL dATAbASE 6th edition25 (differe t forms used)900 mg British National Formulary, BNF 64, September 2012Tablet
0.0428 Sköld C, Winiwarter S, Wernevik J., et al., J Med Chem. 2006 Nov 16;49(23):6660-710.2 mg British National Formulary, BNF 64, September 2012Tablet
10000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution (IV INJECTION)
0.09948 AQUASOL dATAbASE 6th editionEFG (20) 500 mg British National Formulary, BNF 64, September 2012Tablet
1.03 Ross, DL., Riley, CM., Int J Pharm, 1990, 63, 30 Sept, 237–250Intrinsic (25) 400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000ClinPharmR.pdf 1000 mg British National Formulary, BNF 64, September 2012Tablet  
2.792 AQUASOL dATAbASE 6th editionpH 7.5 (RT) 300 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
150 mg Kanamitsu SI, Ito K, Okuda H., et al., Drug Metab Dispos. 2000 Apr;28(4):467-74Tablet
0.01 AQUASOL dATAbASE 6th edition 1.5 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
0.183 AQUASOL dATAbASE 6th edition32 10 mg British National Formulary, BNF 64, September 2012Tablet
94.6 http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm072485.pdf5 mg British National Form lary, BNF 64, September 2012Tabl t
0.457 Llinàs A, Glen RC, Goodman JM., J Chem Inf Model. 2008 Jul;48(7):1289-303Intrinsic (25) 1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV INFUSION/INJECTION)
85 AQUASOL dATAbASE 6th edition24.8 40 mg British National Formulary, BNF 64, September 2012Capsule
250 mg Welker HA., J Pharm Pharmacol. 1998 Sep;50(9):983-7;
Welker HA, Wiltshire H, Bullingham R., Clin Pharmacokinet. 1998 Dec;35(6):405-23Tablet
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202022Orig1s000ClinPharmR.pdf 25 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.0603 AQUASOL dATAbASE 6th edition25 5 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_BioPharmr.pdf 90 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.383 Ross, DL., Riley, CM., Int J Pharm, 1990, 63, 30 Sept, 237–250Intrinsic (25) 400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.007 AQUASOL dATAbASE 6th edition37 200 mg British National Formulary, BNF 64, September 2012Tablet
Kivistö KT, Zukunft J, Hofmann U., Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):124-30 0.8 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20740S19lbl.pdfTablet (AS SODIUM)
0.01 AQUASOL dATAbASE 6th edition 400 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdfTablet
0.74 Harrison A, Betts A, Fenner K, et al, Drug Metab Dispos, 2004, 32,197-204.
Nti-Addae KW, Guarino VR, Dalwadi G, et al., J Pharm Sci. 2012 Sep;101(9):3134-41 600 mg British National Formulary, BNF 64, September 2012Tablet
0.533 Tolle-Sander S, Grill A, Joshi H., et al., J Pharm Sci. 2003 Oct;92(10):1968-80pH 7.5 200 mg Roy P, Jakate AS, Patel A., et al., J Clin Pharmacol. 2005 Mar;45(3):329-36Tablet
0.0721 AQUASOL dATAbASE 6th edition25 1000 mg British National Formulary, BNF 64, September 2012Tablet
Caco-2 cell line with high expression of P-gp transporter, used value where ph gradient (6 to 7.4 from A-B sides taken)

















Gnoth MJ, Buetehorn U, Muenster U., et al., J Pharmacol Exp Ther. 2011 Jul;338(1):372-80 20 mg British National Formulary, BNF 64, September 2012Tablet
0.0306 AQUASOL dATAbASE 6th edition22.5 10 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.08468 AQUASOL dATAbASE 6th edition25 4 mg British National Formulary, BNF 64, September 2012Tablet
0.02 AQUASOL dATAbASE 6th edition37 600 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
1000 mg British National Formulary, BNF 64, September 2012Capsule
100 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (AS HYDROCHLORIDE)
0.02153 AQUASOL dATAbASE 6th edition 3 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Capsule
~0.0015 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258orig1s000clinpharmr.pdf800 mg B tish Natio al Formulary, BNF 64, September 2012Capsules
1 mg/ml British National Formulary, BNF 64, September 2012OPHTHALMIC (AS HYDROCHLORIDE)
0.034 AQUASOL dATAbASE 6th edition25 200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet/Capsule
0.001801 AQUASOL dATAbASE 6th edition22.5 100 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.0176 Srivijaya,R., Vishweshwar, P., Sreekanth, BR., et al., 2008, CrystEngComm, 3, (online)6 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.15 AQUASOL dATAbASE 6th editionpH 7.4 (25) 100 mg British National Formulary, BNF 64, September 2012Tablet
0.1 AQUASOL dATAbASE 6th edition37 600 mg British National Formulary, BNF 64, September 2012Tablet (AS CALCIUM SALT)
300 mg British National Formulary, BNF 64, September 2012Tablet
0.35 http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021158s007lbl.pdfpH 7 (37) 320 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.292 AQUASOL dATAbASE 6th edition37 1000 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.0213 AQUASOL dATAbASE 6th edition25 200 mg British National Formulary, BNF 64, September 2012Tablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 750 mg Massarella JW, Silvestri TM, Keigher N., et al., Int J Clin Pharmacol Res. 1987;7(2):121-7Capsule
300 mg British National Formulary, BNF 64, September 2012Tablet (AS BISULFATE)
200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS MESILATE)
Sköld C, Winiwarter S, Wernevik J., et al., J Med Chem. 2006 Nov 16;49(23):6660-71 2 mg British National Formulary, BNF 64, September 2012Tablet (AS DIHYDROCHLORIDE)
Kogan A, Kesselman E, Danino D., Colloids Surf B Biointerfaces. 2008 Oct 1;66(1):1-12 150 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS CITRATE)
0.4383 AQUASOL dATAbASE 6th edition25 2000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
2.18 AQUASOL dATAbASE 6th edition25 Active metabolite
0.007 AQUASOL dATAbASE 6th edition25 400 mg British National Formulary, BNF 64, September 2012Capsules
0.0048 AQUASOL dATAbASE 6th edition22.5 50 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
280 Llinàs A, Glen RC, Goodman JM., J Chem Inf Model. 2008 Jul;48(7):1289-303Intrinsic (25) 300 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 10 mg Sloan TP, Mahgoub A, Lancaster R., et al., Br Med J. 1978 Sep 2;2(6138):655-7Tablet (AS SULFATE)
119.0 AQUASOL dATAbASE 6th edition 50 mg British National Formulary, BNF 64, September 2012Tablet
0.691 Ross, DL., Riley, CM., Int J Pharm, 1990, 63, 30 Sept, 237–250Intrinsic (25) 400 mg Naber KG, Theuretzbacher U, Kinzig M., et al., Antimicrob Agents Chemother. 1998 Jul;42(7):1659-65Tablet
In the presence of 5 uM cyclosporin A as a nonspecific inhibitor of cell transporters. 0.5 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
0.0000055 AQUASOL dATAbASE 6th edition100 10 mg British National Formulary, BNF 64, September 2012Tablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 80 mg British National Formulary, BNF 64, September 2012Tablet
0.16 AQUASOL dATAbASE 6th editionambi nt temp 20 mg/ml British National Formulary, BNF 64, September 2012Emulson (IV INJECTION)
>0.0281 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4 (22.5-24.5) 75 mg Park GB, Kershner RP, Angellotti J., et al., J Pharm Sci. 1983 Jul;72(7):817-9.Caps le no longer presecribed as oral now only IV
0.012 AQUASOL dATAbASE 6th edition25 15 mg British National Formulary, BNF 64, September 2012Tablet
0.02 SRC PHYSPROP 30 500 mg British National Formulary, BNF 64, September 2012Tablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 12 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS MALEATE)
15 mg British National Formulary, BNF 64, September 2012Tablet
450.5 AQUASOL dATAbASE 6th edition25 100 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution (IV)
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf 0.3 mg British National Formulary, BNF 64, September 2012Inhalation powder/hard capsul  (AS MALEATE)
0.000101 Patel, SG., and Rajput., SJ., AAPS PharmSciTech. 2009 June; 10(2): 660–66937 100 mg British National Formulary, BNF 64, September 2012Tablet
27 AQUASOL dATAbASE 6th edition25 500 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
Faassen, F., Kelder, J., Lenders, J., et al., Pharm Res February 2003, Volume 20, Issue 2, pp 177-186 0.075 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (co-administered with ethinylestradiol)
2.7 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202192s001lbl.pdf25 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
0.265 AQUASOL dATAbASE 6th edition25 1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
<0.005 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137150 mg British National Formulary, BNF 64, September 2012Tablet
0.04 AQUASOL dATAbASE 6th edition37 600 mg British National Formulary, BNF 64, September 2012Tablets
0.009 AQUASOL dATAbASE 6th edition25 50 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
1000 SRC PHYSPROP 4 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)INHALANT CARTRIDGE
0.0619 AQUASOL dATAbASE 6th edition32 20 mg British National Formulary, BNF 64, September 2012Tablet
0.025 Grbic S, Parojcic J, Ibric S, et al., AAPS PharmSciTech. 2011 Mar;12(1):165-71pH 4.37 160 mg British National Formulary, BNF 64, September 2012Tablet
0.197 McGuirk PR, Jefson MR, Mann DD., et al., J Med Chem. 1992 Feb 21;35(4):611-20pH 7.2 800 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 100 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
When temocapril was applied to the apical side, the Papp of temocapril was calculated from the total concentrations of temocapril and temocaprilat on the receiver side.10 mg Püchler K, Sierakowski B, Roots I., Brit J Clin Pharmaco, 1998, 46, 363-7.Tablet
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000ClinPharmR.pdf 10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet

















0.05 Hazardous Substances Data Bank (HSDB)20 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IV)
9.705 AQUASOL dATAbASE 6th edition 200 mg British National Formulary, BNF 64, September 2012Tablet 
Sköld C, Winiwarter S, Wernevik J., et al., J Med Chem. 2006 Nov 16;49(23):6660-71 2000 mg British National Formulary, BNF 64, September 2012Tablet
0.1708 AQUASOL dATAbASE 6th editionpH 7 400 mg British National Formulary, BNF 64, September 2012Tablet
0.0123 SRC PHYSPROP 25 200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
>0.0736 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 6 mg British National Formulary, BNF 64, September 2012Tablet
0.002 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000ClinPharmR.pdf160 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203415s001lbl.pdfCap ule
0.5497 AQUASOL dATAbASE 6th editionhydrochloride (25) 600 mg British National Formulary, BNF 64, September 2012Tablet (AS SULFATE)
<0.5 AQUASOL dATAbASE 6th editionRT 60 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
30 mg Ferrillo F, Balestra V, Carta F., et al., Neuropsychobiology. 1984;11(1):72-6.Tablet
0.03733 AQUASOL dATAbASE 6th edition37.5 600 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS HYDROCHLORIDE)
50.3 AQUASOL dATAbASE 6th edition25 300 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Tablet
0.01 SRC PHYSPROP 25 40 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385
1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
<0.002 US Patent 2008/0171,013 A1 Serial number 12/014,39140 mg/ml British National Formulary, BNF 64, September 2012Suspension
10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (AS SULFATE)
300 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
200 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.15 AQUASOL dATAbASE 6th edition25 200 mg The Treatment of Epilepsy, 2009, 3rd Ed, Edited by Shorvon SD., Perucca,E., Engel, J Jr. , pg 600, Wiley-Blackwell, West SussexTablet
38.6 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021627s000_namenda_clinpharmr.pdfpH 6.99 20 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 20 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47; FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online), 365Tablet (AS HYDROCHLORIDE)
0.4 AQUASOL dATAbASE 6th edition 2400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
60 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385
~200 Hazardous Substances Data Bank (HSDB) 60 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
1.65 AQUASOL dATAbASE 6th edition 500 mg British National Formulary, BNF 64, September 2012Tablet (AS SEMISODIUM VALPROATE)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 120 mg Coates PE, Mesure R., Br J Clin Pharmacol. 1995;39 Suppl 1:17S-19SCapsule (AS SODIUM)
0.0767 Nayak, AM., and Panigrahi, PP., ISRN Physical Chemistry, Volume 2012 (2012), 1-5RT 120 mg British National Formulary, BNF 64, September 2012Capsule
218 AQUASOL dATAbASE 6th edition25 15 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution
>0.0254 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 750 mg FDA Ora ge Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.1 Pilbrant, A., Cederberg, C., Scand J Gastroentero, 1985, 20, 113-120 60 mg British National Formulary, BNF 64, September 2012Capsule
2.494 AQUASOL dATAbASE 6th edition25 10 mg Merkel U, Sigusch H, Hoffmann A., Eur J Clin Pharmacol. 1994;46(2):175-7.Capsule
10.69 AQUASOL dATAbASE 6th edition25 60 mg British National Formulary, BNF 64, September 2012Tablet (AS PHOSPHATE)
Abalos IS, Rodríguez YI, Lozano V, Environ Toxicol Pharmacol. 2012 Sep;34(2):223-7 2 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47; FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online), 365Tablet (AS HYDROCHLORIDE)
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 10 mg British National Formulary, BNF 64, September 2012Tablet
1.204 AQUASOL dATAbASE 6th editionIntrinsic (25) 50 mg British National Formulary, BNF 64, September 2012Tablet
>0.0406 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 10 mg Greenblatt DJ, Divoll MK, Soong MH., et al., J Clin Pharmacol. 1988 Sep;28(9):853-9Tablet
Pham The, H., González-Álvarez, I., Bermejo, M., et al, Mol Inform, 2011, 30, 376–385 2 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROGEN FUMARATE)
0.035 AQUASOL dATAbASE 6th edition22 50 mg British National Formulary, BNF 64, September 2012Tablet
400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS HYDROCHLORIDE)
Strain not stated 7000 mg British National Formulary, BNF 64, September 2012Tablet 200mg/kg daily in 2-4 divided doses
649 Becker C, Dressman JB, Amidon GL., et al ., J Pharm Sci. 2008 Apr;97(4):1350-60dihydrochloride salt 400 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.0026 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)25 6 mg British National Formulary, BNF 64, September 2012Tablet
6.213 Kwon JW, Armbrust KL., Bull Environ Contam Toxicol. 2008 Aug;81(2):128-3560 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
MDR1-MDCK II 120 mg British National Formulary, BNF 64, September 2012Tablet (AS BROMIDE)
0.049 Hazardous Substances Data Bank (HSDB)Mesyl te pH 7.4 400 mg British National Formulary, BNF 64, September 2012Tablet (AS MESILATE)
0.0000017 AQUASOL dATAbASE 6th edition32 600 mg British National Formulary, BNF 64, September 2012Tablet (AS SULFATE)
52 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Tablet
20 Harnden MR, Jarvest RL, Boyd MR., et al., J Med Chem. 1989 Aug;32(8):1738-43750 mg British National Formulary, BNF 64, September 2012Tablet
0.124 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Tablet
MDCK-MDR1 (strain not stated) 250 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
MDR1-MDCK (strain not stated) 1 mg British National Formulary, BNF 64, September 2012Tablet (AS MESILATE)
250 US Patent 2009/0143,387 A1 Serial number 12/339,212Mesylate 4 mg British National Formulary, BNF 64, September 2012Tablet (AS MESILATE)
>10 US Patent 2010/0086, 589, Serial number 12/630,271 pH 7.4 0.7 mg British National Formulary, BNF 64, September 2012Tablet
MDR1-MDCK II 2 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, London; FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
MDR1-MDCK II 20 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV AS HYDROCHLORIDE)
0.004 Ghazal, H. S.; Dyas, A. M.; Ford, J. L.; Hutcheon, G. A., Int. J. Pharm. 2009, 366, 117–123.pH 1 200 mg British National Formulary, BNF 64, September 2012Capsule (enclosed beads)

















31 http://www.janssen.com.au/files/Products/Reminyl_PI.pdfHBr s lt 12 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROBROMIDE)
27.8 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-1137hydrochloride salt 120 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
MDR1-MDCK II 4 mg British National Formulary, BNF 64, September 2012Tablet (AS MALEATE)
10.3 AQUASOL dATAbASE 6th edition25 500 mg British National Formulary, BNF 64, September 2012Tablet
MDR1-MDCK (strain not stated) 20 mg British National Formulary, BNF 64, September 2012Tablet
MDR1-MDCK (strain not stated) 15 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
<0.1 AQUASOL dATAbASE 6th editionRT 187.5 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
122.8 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Tablet
2.37 http://www.medicines.org.au/files/appserxr.pdfFumarate salt 400 mg British National Formulary, BNF 64, September 2012Tablet (AS FUMARATE)
0.0037 AQUASOL dATAbASE 6th editionhydrochloride, intrinsic (25)100 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS NAPSYLATE)
MDR1-MDCK (strain not stated) 12.5 mg http://www.servier.com.cn/pdf/dtlen200612260.pdfTabl t (AS SODIUM)
MDR1-MDCK (strain not stated) 45 mg British National Formulary, BNF 64, September 2012Tablet
190 AQUASOL dATAbASE 6th editionpH 3-7.9 (25) 750 mg British National Formulary, BNF 64, September 2012Capsule
133 http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020658s018s020s021lbl.pdfHydrochl ri e 8 mg British National Formulary, BNF 64, September 2012Ta et (AS HYDROCHLORIDE)
MDR1-MDCK (strain not stated) 6 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROGEN TATRATE)
MDR1-MDCK (strain not stated) 50 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.8 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020789s012lbl.pdf200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
MDR1-MDCK (strain not stated) 10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS BITARTRATE co-administer d with ACETAMINOPHEN)
MDR1-MDCK (strain not stated) 50 mg British National Formulary, BNF 64, September 2012Tablet
0.02828 AQUASOL dATAbASE 6th edition24 8 mg British National Formulary, BNF 64, September 2012Tablet
0.1 SRC PHYSPROP 25 2 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
14.869 Henry TB, Kwon JW, Armbrust KL., et al., Environ Toxicol Chem. 2004 Sep;23(9):2229-33.22 150 mg British National Formulary, BNF 64, September 2012Tablet (AS MALEATE)
0.21 http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500064663.pdf8 mg FDA Orange Book: Approv d D ug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonT blet
0.025 Llinàs A, Glen RC, Goodman JM., J Chem Inf Model. 2008 Jul;48(7):1289-303Intrinsic (25) 100 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
8 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.8 Miyamoto, E; Kawashima, S; Yoshifumi, M., et al, The Analyst, 1994, 119, (7), 1489pH 6 5 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
MDR1-MDCK (strain not stated) 300 mg British National Formulary, BNF 64, September 2012Tablet
MDR1-MDCK II 150 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS HYDROCHLORIDE)
MDR1-MDCK (strain not stated) 10 mg British National Formulary, BNF 64, September 2012Tablet
0.043 AQUASOL dATAbASE 6th edition30 10 mg British National Formulary, BNF 64, September 2012Tablet
>0.5 AQUASOL dATAbASE 6th edition 600 mg British National Formulary, BNF 64, September 2012Tablet
0.0048 Llinàs A, Glen RC, Goodman JM., J Chem Inf odel. 2008 Jul;48(7):1289-303Intrinsic (25) 75 mg British National Formulary, BNF 64, September 2012Capsule (AS MALEATE)
100 mg Amery WK, Heykants J, Bruyneel K., et al., Eur J Clin Pharmacol. 1983;24(4):517-9Table
MDR1-MDCK II 20 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INJECTION AS HYDROCHLORIDE)
0.0008334 AQUASOL dATAbASE 6th edition22.5 75 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
1.13 AQUASOL dATAbASE 6th edition25 180 mg British National Formulary, BNF 64, September 2012Tablet
0.03157 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
MDR1-MDCK II 0.3 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INJECTION)
MDR1-MDCK II 60 mg Dayer P, Balant L, Kupfer A., et al., Eur J Clin Pharmacol. 1985;28(3):317-20Tablet
0.001055 AQUASOL dATAbASE 6th edition22.5 30 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
MDR1-MDCK II 10 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
500 Hazardous Substances Data Bank (HSDB)Dihydrochloride salt 30 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
0.1 AQUASOL dATAbASE 6th edition23 900 mg British National Formulary, BNF 64, September 2012Suspension
200 mg British National Formulary, BNF 64, September 2012Tablet
0.00939 Hazardous Substances Data Bank (HSDB)20-25 8 mg British National Formulary, BNF 64, September 2012Tablet
5.84 AQUASOL dATAbASE 6th edition25 3500 mg Buchanan,N., Davis,MD., Henderson, DB., et al., Br J Clin Pharmacol. 1980 May; 9(5): 525–526;
Cunningham, JL., Bullen,MF., Price Evans., DA.,Eur J Clin Pharmacol, 1974, 7(6), 461-466;
McKay J, Rawlings MD, Cobden I, et al.,  Br J Clin Pharmacol. 1982 Oct;14(4):501-4;
Wynne HA, Cope LH, James OF., et al., Age Ageing. 1989 Nov;18(6):415-8.
Capsule, Based on 50/mg/kg being dosed and the average man being 70kg of metabolic active mass
0.25 AQUASOL dATAbASE 6th editionEFG, pH 6.5 (25) 500 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Tablet
250 mg British National Formulary, BNF 64, September 2012;
Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
75 mg British National Formulary, BNF 64, September 2012Tablet
10 mg British National Formulary, BNF 64, September 2012Tablet (AS DIPIVOXIL FORM)
30 mg Fleishaker JC, Hulst LK, Ekernäs SA., et al ., J Clin Psychopharmacol. 1992 Dec;12(6):403-14.Tablet (AS mesylate), never made to market
17.5 mg Diefenbach C, Künzer T, Buzello W., et al., Anesth Analg. 1995 Feb;80(2):373-7;
Walker J, Shanks CA, Triggs EJ., Eur J Clin Pharmacol. 1980 Jun;17(6):449-57Solution (IV 0.25 mg/kg INFUSION) based on average human being 70kg
0.001 mg British National Formulary, BNF 64, September 2012Capsule
50 mg Depierre A, Lebeau B, d'Allens H., Oncology. 1992;49(4):305-11.Tablet
0.525 AQUASOL dATAbASE 6th edition25 300 mg British National Formulary, BNF 64, September 2012Tablet
200 mg Stavchansky S, Doluisio JT, Macleod CM., et al., Biopharm Drug Dispos. 1989 May-Jun;10(3):229-37;
Simonneau G, Meignan M, Denjean A., et al., Chest. 1986 Feb;89(2):174-9Caps le (AS BISMESYLATE)


















185 AQUASOL dATAbASE 6th editionpH 10.4 (25) 525 mg British National Formulary, BNF 64, September 2012Solution (IV/IM AS SULFATE INJECTION/INFUSION) based on average human being 70kg
500 mg Thompson TA, Vermeulen JD, Wagner WE Jr., et al., J Pharm Sci. 1981 Sep;70(9):1040-3Tablet
0.7164 AQUASOL dATAbASE 6th edition25 200 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.59 AQUASOL dATAbASE 6th edition25 200 mg Hart J, Hill HM, Bye CE, et al., Br J Clin Pharmacol. 1976 Apr;3(2):289-98;
Irvine RE, Grove J, Toseland PA, et al., Br J Clin Pharmacol. 1974 Feb;1(1):41-3Capsule (AS SODIUM)
150 mg Nakashima M, Asano M, Ohguchi S., et al., Clin Pharmacol Ther. 1984 Oct;36(4):436-43Tablet
0.0344 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4 (22.5-24.5), Hydrochloride salt150 mg Benet LZ, Broccatelli F, Opre  TI., AAPS J. 2011 Dec;13(4):519-47; FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
0.0012 US Patent 2004/6,811,794, serial number US 10/027,349pH 4-8 (25) 2.5 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
0.5 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-11371 mg British National Formulary, BNF 64, September 2012Tablets
200 mg Sato,R, Tanigawara,Y, Kaku, M., et al., Antimicrob Agents Chemother. 2006 November; 50(11): 3763–3769;
Tanigawara, Y, Sato, R., Morita, K., et al., Antimicrob. Agents Chemother. 2006. November; 50(11) 3754-3762Powder (IV/IM INJECTION)
<0.0001 Charman WN, Porter CJ, Mithani S., et al., J Pharm Sci. 1997 Mar;86(3):269-821000 mg British National Formulary, BNF 64, September 2012Tablet (with Proguanil hydrochloride) if taken as oral suspension 150mg/mL
10 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INJECTION AS BESILATE)
2 mg Hillas JL, Somerfield SD, Wilson JD., et al., Br J Clin Pharmacol. 1980 Dec;10(6):573-7Tablet (AS MALEATE)
0.13 AQUASOL dATAbASE 6th edition25 100 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016324s034s035lbl.pdfTablet
0.457 mg/ml Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Solution (AS HYDROCHLORIDE Ophthalmic
150 mg Corey AE, Agnew JR, Valentine SN., et al., J Clin Pharmacol. 1999 Dec;39(12):1272-6Capsule
50 http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Product_Information_Sheet/a7926pis.Par.0001.File.tmp/a7926pis.pdfSodium salt 5000 mg Ellis CJ, Geddes AM, Davey PG., et al., J Antimicrob Chemother. 1979 Sep;5(5):517-25Powder (IV INJECTION)
80 mg Suh, O.K., Kim, S.H, Lee, M.G., Biopharm Drug Dispos, 2003, 24, 275-97.Tablet
20 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
50 mg Keller GA, Czerniuk P, Bertuola R., et al., Clin Ther. 2011 Apr;33(4):500-10Tablet (Co-administered Levodopa)
>0.042 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 100 mg Uchida S, Shimada K, Misaka S., et al., Drug Metab Pharmacokinet. 2010;25(6):605-10;
Lee MH, Graham GG, Williams KM., et al., Drug Saf. 2008;31(8):643-65T blet
100 mg Chasseaud LF, Catanese B., Int J Tissue React. 1985;7(3):195-204;
Catanese B, Lagana A, Marino A., et al., Pharmacol Res Commun. 1986 Apr;18(4):385-403Tablet
7.43 AQUASOL dATAbASE 6th edition37 200 mg Taguchi M, Fujiki A, Iwamoto J., et al., Biol Pharm Bull. 2006 Mar;29(3):517-21Tablet
16 mg British National Formulary, BNF 64, September 2012Tablet (AS DIHYDROCHLORIDE)
>0.0543 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 200 mg British National Formulary, BNF 64, September 2012Tablet (modified releas  value increases to 400mg)
50 mg Shigemitsu T, Majima Y., et al, Clin Ther. 1996 Jan-Feb;18(1):106-13Tablet (AS HYDROCHLORIDE)
0.257 AQUASOL dATAbASE 6th edition25 5 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Tablet
0.10 % Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonOphthalmic (AS SODIUM)
8 mg Yang LL, Yuan YS, Tu XD., Se Pu. 2000 Nov;18(6):543-5 (Chinese);
Liu J, Chen X, Hu Y., et al., J Pharm Biomed Anal. 2010 Apr 6;51(5):1134-41Capsule (AS HYDROCHLORIDE)
300 mg Tseng CH, Tai TY, Wu HP., et al., Diabetes Res Clin Pract. 1992 May;16(2):117-22ablet (AS HYDROCHLORIDE)
>0.0547 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 5 mg British National Formulary, BNF 64, September 2012Tablet
0.1015 AQUASOL dATAbASE 6th edition25 5 mg/ml British National Formulary, BNF 64, September 2012Solution (IV AS ANHYDROUS HYDROCHLORIDE)
0.1 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Scientific_Discussion/human/000472/WC500052062.pdf2 mg British National Formulary, BNF 64, September 2012Tablet
20 mg Tytgat GN., Drugs. 2007;67(9):1343-57.Tablet
300 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdfTablet
200 mg Northridge DB, Currie PF, Newby DE., et al., Eur J Heart Fail. 1999 Mar;1(1):67-72Capsul
26 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-113720 2800 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020896s026lbl.pdfTablet base  on surface rea
1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (AS SULFATE)
20 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
14.85 Harrap KR., Cancer Treat Rev. 1985 Sep;12 Suppl A:21-3310 mg/ml British National Formulary, BNF 64, September 2012Solution (IV)
1000 mg Wilkinson PJ, Reeves DS, Wise R, et al., Br Med J. 1975 May 3;2(5965):250-2Tablet
4 SRC PHYSPROP 25 7.7 mg British National Formulary, BNF 64, September 2012Implant
0.00511 Llinàs A, Glen RC, Goodman JM., J Chem Inf Model. 2008 Jul;48(7):1289-303Intrinsic (25) 150 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
10 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Tablet (AS HYDROCHLORIDE)
515 mg Kneer, J., Tam, YK., Blouin, RA., et al., Antimicrob Agents Chemother. 1989 November; 33(11): 1952–1957;
Hayton WL, Kneer J, Blouin RA., et al., Antimicrob Agents Chemother. 1990 Jul;34(7):1318-22;
Blouin RA, Kneer J, Stoeckel K., et al., Antimicrob Agents Chemother. 1989 Mar;33(3):291-6.Solution (IV INFUSION)
0.16 Koup JR, Dubach UC, Brandt R., et al., Antimicrob Agents Chemother. 1988 Apr;32(4):573-9pH 5-6 1000 mg Kneer, J., Tam, YK., Blouin, RA., et al., Antimicrob Agents Chemother. 1989 November; 33(11): 1952–1957;
Hayton WL, Kneer J, Blouin RA., et al., Antimicrob Agents Chemother. 1990 Jul;34(7):1318-22;
Blouin RA, Kneer J, Stoeckel K., et al., Antimicrob Agents Chemother. 1989 Mar;33(3):291-6.Tablet
164.41 Auda SH, Mrestani Y, Nies DH., et al., J Pharm Pharmacol. 2009 Jun;61(6):753-8. Di sodium salt 3000 mg Lenfant B, Namour F, Logeais C., et al., Antimicrob Agents Chemother. 1995 Sep;39(9):2037-41Sol tion (IV INFUSION)
2000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV INFUSION/INJECTION)
2000 mg Sauermann,R., Delle-Karth, G., Marsik, C., Antimicrob Agents Chemother. 2005 February; 49(2): 650–655;
Meyer BH, Muller FO, Luus HG., et al., J Antimicrob Chemother. 1992 Apr;29 Suppl A:63-70Solution (IV INFUSION)
0.4 Khan F, Katara R, Ramteke S., AAPS PharmSciTech. 2010 Sep;11(3):1368-75200 mg British National Formulary, BNF 64, September 2012Tablet
4000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV INFUSION, IM INJECTION AS SODIUM)
500 mg British National Formulary, BNF 64, September 2012Tablet
0.0229 AQUASOL dATAbASE 6th edition20 400 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
793 AQUASOL dATAbASE 6th editionRT 500 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Capsule
>0.0456 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4 (22.5-24.5) 10 mg British National Formulary, BNF 64, September 2012Tablet
2 AQUASOL dATAbASE 6th editionRT 50 mg British National Formulary, BNF 64, September 2012Capsule

















<10 SRC PHYSPROP 500 mg Yu JY, Song HH, Kim BG., et al., Clin Ther. 2009 Nov;31(11):2735-43Tablet (AS CARBAMATE)
0.8913 AQUASOL dATAbASE 6th edition25 250 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
200 mg Massarella J, Silvestri T, Lin A., et al, J Pharm Sci. 1986 Sep;75(9):894-6;
Hamada M, Shigematsu Y, Ikeda S., et al., Circulation. 1997 Sep 2;96(5):1520-4Table
0.05 mg Belch JJ, McLaren M, Lau CS., et al, Br J Clin Pharmacol. 1993 Jun;35(6):643-7;
Hildebrand M, Staks T, Nieuweboer B., et al., Eur J Clin Pharmacol. 1990;39(2):149-53;
Lau CS, Belch JJ, Madhok R., et al., Clin Exp Rheumatol. 1993 Jan-Feb;11(1):35-40.Tablet
>=170 Hazardous Substances Data Bank (HSDB)pH 6-8 75 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INFUSION)
5 mg British National Formulary, BNF 64, September 2012Tablet
Active metabolite
20 mg Zussman BD, Benincosa LJ, Webber DM, et al., J Clin Pharmacol. 2001 Sep;41(9):950-8;
Giembycz MA., Expert Opin Investig Drugs. 2001 Jul;10(7):1361-79Tablet
0.2724 AQUASOL dATAbASE 6th edition25
0.0367 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 500 mg FDA Ora ge Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCaps le
100 mg British National Formulary, BNF 64, September 2012Tablet
200 mg British National Formulary, BNF 64, September 2012Powder (IV) co administered with with ticarcillin
200 mg Bron NJ, Dorr MB, Mant TG., et al., J Antimicrob Chemother. 1996 Dec;38(6):1023-9;
Randinitis EJ, Brodfuehrer JI, Eiseman I., et al., Antimicrob Agents Chemother. 2001 Sep;45(9):2529-35Capsule
30 mg British National Formulary, BNF 64, September 2012Tablet
0.09708 AQUASOL dATAbASE 6th editionRT 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Capsule
768 mg British National Formulary, BNF 64, September 2012Capsule (AS OILY BASE)
0.0151 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 300 mg British National Formulary, BNF 64, September 2012Tablet (AS SULFATE)
30000 mg British National Formulary, BNF 64, September 2012Granules (AS HYDROCHLORIDE)
<0.001 Crombie AL, Antrilli TM, Campbell BA., et al , Bioorg Med Chem Lett. 2010 Jun 15;20(12):3742-520 mg FDA Ora ge Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IV INFUSION AS HYDROCHLORIDE)
20 mg Curvall M, Elwin CE, Kazemi-Vala E, et al., Eur J Clin Pharmacol. 1990;38(3):281-7.
0.05 AQUASOL dATAbASE 6th editionRT 1 mg British National Formulary, BNF 64, September 2012Tablet
40 AQUASOL dATAbASE 6th edition 50 mg British National Formulary, BNF 64, September 2012Tablet (AS ANHYDROU )
0.0003176 AQUASOL dATAbASE 6th edition22.5 4 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
50 mg British National Formulary, BNF 64, September 2012Tablet
500 mg British National Formulary, BNF 64, September 2012Capsules (AS BITARTRATE)
83.3 SRC PHYSPROP 20 10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (Extended release)
100 mg British National Formulary, BNF 64, September 2012Capsule (AS SODIUM)
0.50 % FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)OPHTHALMIC 
30 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, London;
Stockis A, De Bruyn S, Gengler C., Arzneimittelforschung. 2003;53(8):554-61Tablet
2 mg/ml Eriksson B, Ottersgård Brorsson AK, Hallström G, Xenobiotica. 1998 Nov;28(11):1075-81Solutionn (Mouthwash)
0.15 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (Co administered with ethinyl estradiol)
7.5 mg Demoen PJ., J Pharm Sci. 1961 Jan;50:79-82;
Pagani I, Barzaghi N, Crema F., et al., Fundam Clin Pharmacol. 1989;3(1):27-35Tablet
0.1 Llinàs A, Glen RC, Goodman JM., J Chem Inf Model. 2008 Jul;48(7):1289-303Intrinsic (25) 200 mg British National Formulary, BNF 64, September 2012Tablet
76.9 Hazardous Substances Data Bank (HSDB) 20 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS HYDROCHLORIDE)
3 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (Co administered with estradiol v lera e)
75 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
0.012 AQUASOL dATAbASE 6th edition25 20 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.0141 AQUASOL dATAbASE 6th edition25 0.2 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
40 mg British National Formulary, BNF 64, September 2012Tablets (AS DIHYDROCODEINE TARTRATE)
1 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution (IM, SC AS MESYLATE)
500 mg British National Formulary, BNF 64, September 2012Tablet (AS FUROATE)
100 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
333 SRC PHYSPROP 800 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet 15mg/kg based n body weig t
5 mg British National Formulary, BNF 64, September 2012Tablet (AS BROMIDE)
0.2 AQUASOL dATAbASE 6th edition25 800 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
75 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
16 mg British National Formulary, BNF 64, September 2012Tablets (AS MESILATE)
750 mg Lencioni M, Falcone A, Allegrini G., et al., Oncology. 2000 Sep;59(3):204-9Tablet
13.75 AQUASOL dATAbASE 6th editionhydrochloride (37) 80 mg Mahaparale S, Telekone RS, Raut RP., Indian J Pharm Sci. 2010 Jan;72(1):133-6Tab t (AS HYD OCHLORIDE Co-adminsitered with paracetemol)
7000 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonPowder (IV INFUSION)  
75 mg British National Formulary, BNF 64, September 2012Tablet (AS OLAMINE)
50 mg Antonaccio MJ, Verjee S., Am J Cardiol. 1986 Aug 29;58(5):114C-116C.
0.014 Dage RC, Kariya T, Hsieh CP., et al., Am J Cardiol. 1987 Aug 14;60(5):10C-14C5 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INJECTION)
2.4 Cao, D., Wang, J., Zhou, R. et al, J Chem Info Model, 2012, 52, 1132-113725 1 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
5 mg Benincosa LJ, Audet PR, Lundberg D., et al., Biopharm Drug Dispos. 1996 Apr;17(3):249-58.Tabl
600 mg British National Formulary, BNF 64, September 2012Tablet (AS MESILATE)
1 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
2 mg British National Formulary, BNF 64, September 2012Tablet (sublingual AS TARTRATE)

















~0.001 AQUASOL dATAbASE 6th edition30 140 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS PHOSPHATE)
50 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
1000 SRC PHYSPROP 62 mg/ml Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Solution
0.0014 AQUASOL dATAbASE 6th edition25 2 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
690 SRC PHYSPROP 20 400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.0189 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 10 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
200 mg British National Formulary, BNF 64, September 2012Tablet
400 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022345s001lbl.pdfTablet
0.0129 Khosravan,R.,  Grabowski, B.,  Wu, JT., et al., Br J Clin Pharmacol. 2008 March; 65(3): 355–363120 mg British National Formulary, BNF 64, September 2012Tablet
900 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdfTablet
0.00842 AQUASOL dATAbASE 6th edition25 600 mg Henson R, Lloyd-Jones JG, Nichols JD., et al., Eur J Drug Metab Pharmacokinet. 1980;5(4):217-23Tablet
20 mg Caccia S, Conforti I, Duchier J., et al., Eur J Clin Pharmacol. 1985;29(2):221-4Tablet (AS HYDROCHLORIDE)
0.0008 AQUASOL dATAbASE 6th edition25 267 mg British National Formulary, BNF 64, September 2012Capsule (micronised)
80 mg Montes B, Catalan M, Roces A., et al., Eur J Clin Pharmacol. 1993;45(2):169-72Tablet
150 mg Fletcher MR, Loebl W, Scott JT., Ann Rheum Dis. 1975 Apr;34(2):190-4Capsule
0.015 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM249354.pdfNeutral pH 200 mg British Nation l Formulary, BNF 64, S ptember 2012Tablet
0.040 AQUASOL dATAbASE 6th editionambi nt temp 1 mg British National Formulary, BNF 64, September 2012Tablet
500 mg British National Formulary, BNF 64, September 2012Capsule (AS SODIUM SALT)
15 SRC PHYSPROP 25 10 mg/ml British National Formulary, BNF 64, September 2012Solution (IV INFUSION)
0.3 mg British National Formulary, BNF 64, September 2012Tablet (AS ACETATE)
0.0165 Marına,TM., Margarita, VM., Salcedo, GE., Il Farmaco 57 (2002) 723 /72720 mg Holmes B, Brogden RN, Heel RC., et al., Drugs. 1984 Jan;27(1):6-44Tablet
78 mg/inhalation FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)AEROSOL, METERED; INHALATION 
20 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
1 AQUASOL dATAbASE 6th edition 100 mg Singal, R., Gupta, P., Jain., N., et al., Maedica (Buchar). 2012 June; 7(2): 163–166C psule (AS MALEATE)
1000 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV INFUSION)
3000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonGranules (ORAL SUSPENSION)
40 mg British National Formulary, BNF 64, September 2012Tablet (AS SODIUM SALT)
1200 mg Na-Bangchang K, Ruengweerayut R, Karbwang J., et al., Malar J. 2007 May 25;6:70Capsul
2.5 mg British National Formulary, BNF 64, September 2012Tablet (AS SUCCINATE)
778 AQUASOL dATAbASE 6th edition25
50 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
400 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonOral
200 mg Lin C, Kim H, Radwanski E., et al., Antimicrob Agents Chemother. 1996 Jan;40(1):92-6Capsule
40 mg/ml Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Solution (IV)
4 SRC PHYSPROP 25
50 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.0695 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 180 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
2 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, London; FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (AS BROMIDE)
500 mg Gillespie, Drug Ther Bull. 1967 May 26;5(11):42-3Tabl t
2 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
76 Hazardous Substances Data Bank (HSDB)sulf te (25) 25 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
0.4347 AQUASOL dATAbASE 6th edition25 500 mg Smith, DA., Chandler, MH., Shedlofsky, SI., et al., Br J Clin Pharmacol. 1991 December; 32(6): 735–739Tablet
0.3299 AQUASOL dATAbASE 6th editionRT 100 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
1.931 Hazardous Substances Data Bank (HSDB) 1.3 mg British National Formulary, BNF 64, September 2012Capsule
400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS SULFATE)
500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IM)
1000 SRC PHYSPROP 25 1000 mg British National Formulary, BNF 64, September 2012Capsule
0.1 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV INFUSION AS FUMARATE)
40 mg Glue P, White E, Wilson S., et al., Psychopharmacology (Berl). 1991;105(3):368-73Capsu e
3000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonP wder (IV INFUSION)
20 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
10 SRC PHYSPROP 1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonP wder (IV AS co-adminsitered CILASTATIN SODIUM)
100 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (AS HYDROCHLORIDE EXTENDED RELEASE)
200 mg Tamassia, V., Corvi, G., Moro, E., et al., Eur J Clin Pharmacol, 1976, 10(3-4), 257-262Tablet
6000 Hazardous Substances Data Bank (HSDB)20 60 % FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV)
0.5497 AQUASOL dATAbASE 6th edition25 30 mg British National Formulary, BNF 64, September 2012Tablet

















20 mg British National Formulary, BNF 64, September 2012Capsule
200 mg Honig WJ, Pelgrom R, Chadha DR., J Clin Pharmacol. 1982 Feb-Mar;22(2-3):82-8Tablet
1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS SULFATE)
60 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
0.25 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonPowder (IV)
6 mg British National Formulary, BNF 64, September 2012Tablet
~30 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022253s000_022254s000_ChemR.pdf25 200 mg British National Formulary, BNF 64, September 2012Tablet
0.45 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021880s006s016s017lbl.pdf25 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTa et
2.5 mg British National Formulary, BNF 64, September 2012Tablet
150 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
1040 http://www.ucb.com/_up/ucb_com_products/documents/Keppra%20tabs%20and%20oral%20sol%20April%202009.pdf750 mg British Natio al Formulary, BNF 64, September 2012Tablet
0.50 % FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonOPHTHALMIC (AS HYDROCHLORIDE)
0.02 AQUASOL dATAbASE 6th edition25 50 mg British National Formulary, BNF 64, September 2012Tablet (AS MALEATE)
1.5 mg British National Formulary, BNF 64, September 2012Tablet
50 mg Dieterle W, Faigle JW, Imhof P., et al., Xenobiotica. 1984 Apr;14(4):303-10Tablet
2 mg Sundberg S, Antila S, Scheinin H., et al., Int J Clin Pharmacol Ther. 1998 Dec;36(12):629-35Tablet/Capsule
0.003958 AQUASOL dATAbASE 6th edition37 30 mg British National Formulary, BNF 64, September 2012Tablet (AS SODIUM SALT)
0.02 mg Krause W, Mager T, Kühne G., et al., Eur J Clin Pharmacol. 1991;40(4):399-403Tablet
0.10 % FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonOPHTHALMIC (AS TROMETHAMINE)
<0.05 Hazardous Substances Data Bank (HSDB) 250 mg British National Formulary, BNF 64, September 2012Capsule
1.5 mg British National Formulary, BNF 64, September 2012Tablet
0.0155 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 8 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
800 mg Corazziari E, Ricci R, Biliotti D, et al., Dig Dis Sci. 1990 Jan;35(1):50-4Tablet
408 mg British National Formulary, BNF 64, September 2012Capsule
2.5 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (Co administ d with an oestrog n)
150 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.03 SRC PHYSPROP 100 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
0.002 Kawabata,Y., Wada, K., Nakatani, M., et al ., Int J Pharm, 2011, Nov; 420 (1), Pages 1–10160 mg British National Formulary, BNF 64, September 2012Tablet
6.55 AQUASOL dATAbASE 6th edition25 150 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
200 mg British National Formulary, BNF 64, September 2012Tablet
0.124 AQUASOL dATAbASE 6th edition25 100 mg British National Formulary, BNF 64, September 2012Tablet
1000 mg British National Formulary, BNF 64, September 2012Powder (IV INJECTION)
600 mg British National Formulary, BNF 64, September 2012Tablet
0.013 Yin GG, Kookana RS, Ru YJ., Environ Int. 2002 Dec;28(6):545-510.15 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (Co administered NORETHYNODREL)
7.2 SRC PHYSPROP 25 1500 mg British National Formulary, BNF 64, September 2012Tablet
2.8 AQUASOL dATAbASE 6th edition25 300 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
0.2 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS MALEATE)
750 mg British National Formulary, BNF 64, September 2012Capsule
20000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonP wder (IV AS SODIUM)
40 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.09 AQUASOL dATAbASE 6th editionambi nt temp 50 mg British National Formulary, BNF 64, September 2012Tablet (Buccal)
0.0004748 AQUASOL dATAbASE 6th edition22.5 600 mg British National Formulary, BNF 64, September 2012Tablet 
The 100% value is based on a low dose of 25mg, dose dependancy at higher doses saturation occurs > 50 mg absorption saturation occurs
Ref: Pharmacokinetics of miglitol : Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man, AHR H.-J., (1997), increasing the dose can reduce the FA down in the region of 50-70%100 g FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete dru  reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
>1000 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000435/WC500046721.pdf100 mg British National Formulary, BNF 64, September 2012Capsule
1 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV)
0.4 mg British National Formulary, BNF 64, September 2012Tablet
0.0001 SRC PHYSPROP 25 3000 mg British National Formulary, BNF 64, September 2012Tablet
2 mg/ml British National Formulary, BNF 64, September 2012Solution (AS INJECTION CHLORIDE)
200 mg British National Formulary, BNF 64, September 2012Tablet
15 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
4 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
10 mg British National Formulary, BNF 64, September 2012Tablet  (AS SODIUM SALT)
0.02 Alelyunas YW, Liu R, Pelosi-Kilby L, et al., Eur J Pharm Sci. 2009 May 12;37(2):172-8225 300 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
10000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IV INFUSION)
400 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
80 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.8003 AQUASOL dATAbASE 6th edition 0.6 mg British National Formulary, BNF 64, September 2012Tablet

















0.006 AQUASOL dATAbASE 6th edition22.5 1000 mg British National Formulary, BNF 64, September 2012Tablet
0.8 mg/actuation FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonT pical (Nasal)
200 mg British National Formulary, BNF 64, September 2012Tablet (AS OXALATE)
35 http://www.gsk.com.au/resources.ashx/prescriptionmedicinesproductschilddataproinfo/1592/FileName/6202B57DE3B8BD676581EE8A076127FE/PI_Naramig.pdfHydrochlo ide 2.5 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
180 mg British National Formulary, BNF 64, September 2012Tablet
2 % FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonOPHTHALMIC
0.0326 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 300 mg FDA Ora ge Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
90 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
1000 mg British National Formulary, BNF 64, September 2012Tablet (AS SULFATE)
100 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution (IV INFUSION AS SULFATE)
17.1 AQUASOL dATAbASE 6th edition20 1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (extended release)
30 mg British National Formulary, BNF 64, September 2012Tablet
150 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
60 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (Prolong rel ase)
40 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (extended release)
250 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, London
21.4 AQUASOL dATAbASE 6th edition25 300 mg British National Formulary, BNF 64, September 2012Tablet
50 mg Ringoir S, Lameire N, Munche M., et al., Br J Clin Pharmacol. 1977;4Suppl 2:129S-134STablet
0.25 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (Co-administered with ETHINYL ESTRADIOL)
120 mg British National Formulary, BNF 64, September 2012Capsule
1500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
30 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.084 Douroumis D, Fahr A. Eur J Pharm Biopharm. 2006 Jun;63(2):173-5600 mg British National Formulary, BNF 64, September 2012Tablet
800 mg Perucca E, Parini J, Albrici A., et al., Eur J Drug Metab Pharmacokinet. 1987 Apr-Jun;12(2):145-8Tablet
2 mg Ensing K, de Zeeuw RA, in 't Hout WG., et al., Eur J Clin Pharmacol. 1989;37(5):507-12Tablet ( S BROMIDE)
96 mg Wetzelsberger N, Birkel M, Fuder H., et al., Methods Find Exp Clin Pharmacol. 1995 Apr;17(3):185-91Tablet
0.02 AQUASOL dATAbASE 6th editionIntrinsic (RT) 100 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
7.548 AQUASOL dATAbASE 6th edition21 500 mg British National Formulary, BNF 64, September 2012Tablet (AS DIHYDRATE)
100 mg Sigurdsson JA, Bengtsson C, Bjurö T., et al., Eur J Clin Pharmacol. 1984;26(5):549-53Tablet
500 The Merck Index: 12th edition 199625 2 mg/ml British National Formulary, BNF 64, September 2012Solution (BROMIDE IV)
80 mg British National Formulary, BNF 64, September 2012Tablet (AS SODIUM)
100 mg Scatina JA, Hicks DR, Kraml M., Eur J Drug Metab Pharmacokinet. 1990 Jan-Mar;15(1):37-48Tablet/Capsule
7 AQUASOL dATAbASE 6th editionRT 80 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS SULFATE)
3 Harnden MR, Jarvest RL, Boyd MR., et al., J Med Chem. 1989 Aug;32(8):1738-431 % British National Formulary, BNF 64, September 2012Cream
100 mg British National Formulary, BNF 64, September 2012Capsule
0.77 AQUASOL dATAbASE 6th edition25 200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS SODIUM)
77 SRC PHYSPROP 25 400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (extended release)
300 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS maleate)
8 mg British National Formulary, BNF 64, September 2012Tablet (AS ERBUMINE)
0.182 AQUASOL dATAbASE 6th edition 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
200 mg British National Formulary, BNF 64, September 2012Tablet
6 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
4.2 AQUASOL dATAbASE 6th edition25 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Capsule
50 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
0.59 SRC PHYSPROP 37
5 Chaw CS, Tan CW, Yang YY., et al., Biomaterials. 2003 Mar;24(7):1271-7pH 7.4
0.4 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Per inhalation
6 mg Meyer BH, Müller FO, Werkman IM., et al., S Afr Med J. 1985 Feb 9;67(6):206-8Tablet
150 mg Lee TG, Goldberg AD, Chang T., et al., J Cardiovasc Pharmacol. 1983 Jul-Aug;5(4):632-7.Capsule
50 mg Fauvel JP, Bernard N, Laville M, et al., Br J Clin Pharmacol. 1995 Feb;39(2):187-9.T blet
1.5 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS MALEATE)
4 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf4 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdfCap ule
1000 mg British National Formulary, BNF 64, September 2012Powder (IV INFUSION AS CHLORIDE)
225 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
0.47 AQUASOL dATAbASE 6th edition25 750 mg British National Formulary, BNF 64, September 2012Tablet

















0.000005 US Patent 2005/0171,203 Serial number A1 11/016,511500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
500 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV INFUSION AS HYDROCHLORIDE)
50 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
30 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
500 mg Jenner PJ, Ellard GA, Gruer PJ., J Antimicrob Chemother. 1984 Mar;13(3):267-77Tablet
500 Hazardous Substances Data Bank (HSDB) 10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
1000 SRC PHYSPROP 25 900 mg Rasmussen FV, Waldorff S, Madsen L., Eur J Respir Dis. 1984 Jan;65(1):20-7Tablet
17.4 AQUASOL dATAbASE 6th editionEFG (25) 2000 mg British National Formulary, BNF 64, September 2012Tablet
0.01 AQUASOL dATAbASE 6th edition 75 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.15 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
100 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (AS SODIUM)
40 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
Active metabolite
0.395 Mallikarjuna Gouda M, Somashekar S, Putta RK., et al, J. Chem. Pharm. Res., 2010, 2(3):187-192pH 7.5 60 mg British National Formulary, BNF 64, September 2012Tablet (AS SODIUM)
10 mg British National Formulary, BNF 64, September 2012Tablet
600 mg Davies RF, Lineberry MD, Funck-Brentano C., et al., Clin Pharmacol Ther. 1989 Sep;46(3):324-34Tablet
200 mg Widerlöv E, Franzén G, Jansson P., et al., Int Clin Psychopharmacol. 1990 Apr;5(2):125-34Tablet
20 mg Lode H, Huettemann U, Huckauf H., et al., Respiration. 1979;38(5):280-8.Tablet
10 mg Evans, ME., Shenfield, GM., Thomas, N., et al., Xenobiotica, 1974, 4(11) , 681-692 Tabl t
10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (AS HYDROCHLORIDE)
10 mg British National Formulary, BNF 64, September 2012Tablet (AS BENZOATE)
5 mg Strandgârden K, Höglund P, Nordle O., et al., Biopharm Drug Dispos. 1999 Oct;20(7):347-54Tablet
0.031 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021911s000_EA.pdf1600 mg British National Formulary, BNF 64, September 2012Tablet
4.3 AQUASOL dATAbASE 6th edition25 2000 mg Sweatman TW, Renwick AG, Burgess CD., et al., Xenobiotica. 1981 Aug;11(8):531-40Tablet
17.95 AQUASOL dATAbASE 6th editionEFG (25) 8 mg British National Formulary, BNF 64, September 2012Tablet (AS SULFATE)
750 mg The AARP Guide to Pills, 2006, Ed Hochadel MA., pg818, AARPTablet
5 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
100 mg Shi J, Ripley E, Gehr TW., et al., J Clin Pharmacol. 1996 Feb;36(2):131-43Tablet
2.9 Li DX, Jang KY, Kang W., et al, Biol Pharm Bull. 2010;33(2):279-84hydrochloride monohydrate15 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
250 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
100 mg British National Formulary, BNF 64, September 2012Tablet (AS PHOSPHATE MONOHYDRATE)
10 mg British National Formulary, BNF 64, September 2012Tablet (AS SUCCINATE)
24 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IM INJECTION SULFATE)
5.066 AQUASOL dATAbASE 6th edition25 1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IV INJECTION/INFUSION)
0.49 AQUASOL dATAbASE 6th edition38
0.076 AQUASOL dATAbASE 6th edition25 0.05 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IV INFUSION)
5000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IV co-administered with AMPICILLIN SODIUM INFUSION)
0.4453 AQUASOL dATAbASE 6th edition25 2000 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (Co-administered as SULFADIAZINE;SULFAMERAZINE)
2.601 AQUASOL dATAbASE 6th edition22 200 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
1.382 AQUASOL dATAbASE 6th edition25
400 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
1 % FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonOPHTHALMIC
1000 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonPowder (IV INJECTION)
1 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
150 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
400 mg British National Formulary, BNF 64, September 2012Powder (IV INJECTION)
0.0929252 Du-Cunya,L.,  Huwylerb, J.,  Wiese, M., et al., European J Med Chem, 2008 Mar, 43(3), 501–512Intrinsic, pH 6.5 30 mg British National Formulary, BNF 64, September 2012Tablet
400 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
25 mg Johansson HE, Jönsson M, Olovson SG., et al., Pharmacol Toxicol. 1987 Aug;61(2):148-52Tablet (AS HYDROCHLORIDE)
1 mg Ericsson, H., Hamrén, B., Bergstrand, S., et al., Drug Metab Dispos, 2006 Sept;32(9) 923-929 Tablet
0.05 AQUASOL dATAbASE 6th editionIntrinsic (25) 3000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet 
0.001113 AQUASOL dATAbASE 6th edition22.5 200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
2.5 mg British National Formulary, BNF 64, September 2012Tablet
3000 mg British National Formulary, BNF 64, September 2012Powder (IV INFUSION co ad inistered with Clavulanic acid AS SODIUM)
0.001 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4  (22.5-24.5) 250 mg FDA Ora ge Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
50 mg Martindale, Tablet (AS HYDROCHLORIDE)

















112 mg British National Formulary, BNF 64, September 2012Powder (INHALATION)
600 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet (AS HYDROCHLORIDE)
25 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution (IV AS INJECTION HYDROCHLORIDE)
400 mg Lloyd-Jones JG, Henson R, Nichols JD., et al., Eur J Clin Pharmacol. 1981 Jan;19(2):119-25Capsule
200 mg Passariello N, Sepe J, Marrazzo G, et al., Diabetes Care. 1993 May;16(5):789-95Tabl t
12 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020771s028lbl.pdfTartrate 2 mg British National Formulary, BNF 64, September 2012Tablet (AS TARTRATE)
60 mg British National Formulary, BNF 64, September 2012Tablet (AS CITRATE)
20 mg British National Formulary, BNF 64, September 2012Tablet
4 mg British National Formulary, BNF 64, September 2012Capsule  
200 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.07999 AQUASOL dATAbASE 6th edition25 4 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Tablet
0.041 AQUASOL dATAbASE 6th edition25 40 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution (IV INJECTION)
0.01223 AQUASOL dATAbASE 6th edition24 5 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
0.0006709 AQUASOL dATAbASE 6th edition22.5 5 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
10 mg British National Formulary, BNF 64, September 2012Tablet (AS TARTRATE)
150 mg Greiner,J., Küfer, R., Reske, SN., et al., Case Reports in Medicine, 2010, Mar; 2010, 1-4Tablet
5 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
50 Dutcher, JD., . Am. Chem. Soc., 1946, 68 (3), pp 419–424Chloride (22) 3 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV INJECTION AS CHLORIDE)
90 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
500 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
1 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS TARTRATE)
16 http://www.aspenpharma.com.au/product_info/pi/PI_Vecure.pdfpH 3, Br ide (25) 10 mg British National Formulary, BNF 64, September 2012Powder (IV INJECTION AS BROMIDE)
1000 mg British National Formulary, BNF 64, September 2012Tablet
0.32 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000ClinPharmR.pdfHydrochl ri e 40 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
0.017 Szuts EZ, Harosi FI., Arch Biochem Biophys. 1991 Jun;287(2):297-304110 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47Tablet
0.0209 AQUASOL dATAbASE 6th edition33 50 mg/ml British National Formulary, BNF 64, September 2012Solution (ORAL)
30 mg Taylor, IW., Chasseaud, LF., Taylor, T., et al., Br J Clin Pharmacol. 1991 August; 32(2): 242–245C psule
0.058 AQUASOL dATAbASE 6th edition25 80 mg British National Formulary, BNF 64, September 2012Tablet
70.98 AQUASOL dATAbASE 6th edition 0.75 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
18 http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21036lbl.pdf10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonP wder (Inhalation)
600 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
7.5 mg http://products.sanofi.ca/en/imovane.pdfTablet
100 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
6 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule  
2.794 AQUASOL dATAbASE 6th edition20 50 mg Popa C, Beck O, Brodin K., et al, J Anal Toxicol, 1998, 22, 142-7.Syrup
0.8 AQUASOL dATAbASE 6th edition25 30 mg British National Formulary, BNF 64, September 2012Tablet
0.0095 Robarge KD, Brunton SA, Castanedo GM., et al., Bioorg Med Chem Lett. 2009 Oct 1;19(19):5576-81pH 6.5 150 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Capsule
800 mg Shiveley L, Struthers-Semple C, Cox S., et al., J Clin Pharm Ther. 2008 Feb;33(1):45-54Capsule
32.26 AQUASOL dATAbASE 6th edition 750 mg Lücker PW, Wetzelsberger K, Erking W., et al., Arzneimittelforschung. 1980;30(11b):2045-53 (German);
Ziegler WJ, Metz G, Specker M., Arzneimittelforschung. 1980;30(11b):2053-8 (German)Capsule
0.006 Boxenbaum HG, Posmanter HN, Macasieb T., et al., J Pharmacokinet Biopharm. 1978 Aug;6(4):283-93pH 7.4 (37) 2 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
100 mg British National Formulary, BNF 64, September 2012Tablet
300 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule (AS HYDROCHLORIDE)
13.6 http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500066946.pdf100 mg FDA Orange Book: Approv d D ug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)T blet (Extended release)
0.2118 AQUASOL dATAbASE 6th edition25 50 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)P wder (IV co-administered SULFADIAZINE)
0.12 AQUASOL dATAbASE 6th edition25 100 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
20 mg Krause W, Schwartzkopff W., Arzneimittelforschung. 1983;33(9):1306-7;
Krause W, Kampf D, Fischer HC., Eur J Clin Pharmacol. 1984;27(4):429-33Tablet
0.013 AQUASOL dATAbASE 6th edition25 720 mg British National Formulary, BNF 64, September 2012Tablet (AS MYCOPHENOLATE SODIUM)
500 mg Atkinson AJ Jr, Ruo TI, Piergies AA., Clin Pharmacol Ther. 1989 Aug;46(2):182-9Tablet (AS HYDROCHLORIDE)
45 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
0.01 http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf
25 20 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
200 mg Van Durme, JP., Bogaert, MG., Rosseel, MT., Br J Clin Pharmacol. 1974 December; 1(6): 461–466Capsule
30 AQUASOL dATAbASE 6th editionIntrinsic 400 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS MESYLATE)
20 mg Caccia S, Conforti I, Duchier J., et al., Eur J Clin Pharmacol. 1985;29(2):221-4Tablet
<0.0003 Pubchem (AID 1996): Burnham Center for Chemical Genomics (BCCG-A233-Analiza-Solubility-Assay)pH 7.4 (22.5-24.5) 30 mg British National Formulary, BNF 64, September 2012Tablet  
450 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
2 % FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Shampoo


















50 mg British National Formulary, BNF 64, September 2012Tablet (AS CITRATE)
300 mg Holmes C, Whittaker N, Heredia-Moya J., et al., Clin Chem. 2010 May;56(5):832-8Capsule
1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonP wder (IV INFUSION AS SODIUM)
35 mg British National Formulary, BNF 64, September 2012Capsule
0.295 SRC PHYSPROP 37 20 mg Tüber U, Posern U, Bickel U., et al., Eur J Clin Pharmacol. 1988;35(2):177-81;
Täuber U, Haack D, Nieuweboer B., et al., Int J Clin Pharmacol Ther Toxicol. 1984 Jan;22(1):48-55Tablet
2.5 mg British National Formulary, BNF 64, September 2012Tablet
0.8 mg British National Formulary, BNF 64, September 2012Tablet (AS HYDROCHLORIDE)
60 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS DIPOTASSIUM)
400 mg Cottrell PR, Streete JM, Berry DJ, et al., Epilepsia. 1982 Jun;23(3):307-13
112 Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47200 mg British National Formulary, BNF 64, September 2012Capsule
2 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
2 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS HYDROCHLORIDE)
0.3215 AQUASOL dATAbASE 6th edition0.05N NaCl (25) 400 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
600 mg Täuber U, Beiersdorff RO, Matthes H., et al., Eur J Drug Metab Pharmacokinet. 1988 Jul-Sep;13(3):215-20Tablet
500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
10 mg El-Brashy, A., Aly, FA., Belal, F., Microchimica Acta 1993, 110(1-3), 55-60Tablet
0.002343 AQUASOL dATAbASE 6th edition
40 mg British National Formulary, BNF 64, September 2012Tablet (AS DIHYDROCHLORIDE)
10 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
0.5 mg British National Formulary, BNF 64, September 2012Capsule (AS HYDROCHLORIDE)
250 mg British National Formulary, BNF 64, September 2012; Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
300 mg Berry H, Coquelin JP, Gordon A., et al., Br J Rheumatol. 1983 May;22(2):89-94;
de Gara,C., Taylor,M., Hedges, A., Postgrad Med J. 1982 August; 58(682): 489–492Tablet
2.5 SRC PHYSPROP 25 200 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
50 mg Fillastre, JP., Aparicio, M., Porquet, C., Br J Clin Pharmacol. 1991 August; 32(2): 261–262;
Weber S, Kahan A, Pinquier JL., et al., Br J Clin Pharmacol. 1990 Sep;30(3):411-6Tablet (AS HYDROCHLORIDE)
500 mg British National Formulary, BNF 64, September 2012Solution (IV INFUSION)
0.02 AQUASOL dATAbASE 6th edition21
0.5 mg British National Formulary, BNF 64, September 2012Capsule
0.0106 AQUASOL dATAbASE 6th editionpH 3 (25) 250 mg Marks JW, Bonorris GG, Chung A., et al., Am J Dig Dis. 1977 Oct;22(10):856-60Tablet (Uneq al dosing)
600 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (extended release)
0.003533 AQUASOL dATAbASE 6th editionpH 3 (25) 850 mg British National Formulary, BNF 64, September 2012Tablet
10 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet
3000 mg British National Formulary, BNF 64, September 2012Dispersable Tablet 100-250 g/kg daily in 2-4 divdied doses
~0.04 www.novartis.com.au/DownloadFile.aspx?t=p&f=exj.pdf&dateid37 2000 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet mad into suspension
0.01 http://www1.astrazeneca-us.com/pi/brilinta.pdfRT 180 mg http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022433s006lbl.pdfTablet
50 mg British National Formulary, BNF 64, September 2012Tablet
0.091 AQUASOL dATAbASE 6th edition 50 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonCapsule
1000 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV INJECTION)
77.8 AQUASOL dATAbASE 6th edition10 500 mg Moertel CG, Ames MM, Kovach JS., et al., JAMA. 1981 Feb 13;245(6):591-4;
Ames MM, Moyer TP, Kovach JS., et al., Cancer Chemother Pharmacol. 1981;6(1):51-7Tablet
5000 mg Lim JK., Kisaengchunghak Chapchi. 1975 Jun;13(1):19-30Powder (Oral)
25 mg British National Formulary, BNF 64, September 2012Tablet (AS CHLORIDE)
0.0420 AQUASOL dATAbASE 6th edition22.5 2.5 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonTablet (AS GLUCONATE)
500 Hazardous Substances Data Bank (HSDB)25 66 % FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (Oral)
1 SRC PHYSPROP 500 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Tablet
755 mg Benet LZ, Broccatelli F, Oprea TI., AAPS J. 2011 Dec;13(4):519-47;
FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online)Solution ( RAL, IV) Solution (equivalent to 350 mg I per mL)
10000 mg Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonPowder (IV INFUSION AS MEGLUMINE)
10.5 % Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonPowder (IV INFUSION AS MEGLUMINE)
0.042 mg FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonInhalation (AS BROMIDE)
250 mg Bentur Y, Raikhlin-Eisenkraft B, Singer P., Vet Hum Toxicol. 2003 Feb;45(1):33-5Powder (IV INFUSION)
15 mg/ml British National Formulary, BNF 64, September 2012Solution (SODIUM IV)
10 mg/ml FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, 2012-2013 (online); Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, LondonSolution (IV)
30 mg British National Formulary, BNF 64, September 2012Tablet (AS BROMIDE)

























MP (°C) MP Reference
Tablet (AS SODIUM)
Capsule (AS HYDROCHLORIDE) 157 Hazardous Substances Data Bank (HSDB)
Paracellular Saitoh R, Sugano K, Takata N, Pharm Res. 2004 May;21(5):749-55* 221.5 MSDS Sigma aldrich http://www.sigmaaldrich.com
Tablet as potassium salt 120 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E
Carrier mediated, p-gp, BCRP/MXREstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1. E 204 Hazardous Substances Data Bank (HSDB)
Carrier Mediated, EffluxWang Q, Rager JD, Weinstein K, et al., Int J Pharm. 2005 Jan 20;288(2):349-59E
Carrier mediated, PEPT1Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I 194 Hazardous Substances Data Bank (HSDB), (Beta-Naphthalensulfonate Trihydrate) 
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E
Carrier mediated, OCT1/OCT2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1;
Sai, Y., Tsuji. A., Drug Discov Today. 2004 Aug 15;9(16):712-20I 255 SRC PHYSPROP
Paracellular, Carrier mediated, OATP1A2Pha macokine ics and Metabolism in Drug Design, 3rd Edition 2012, Wiley, Chapter 3, pg 46;
Alt A, Potthast H, Moessinger J., et al., Eur J Pharm Biopharm. 2004 Jul;58(1):145-50;
Liu W, Okochi H, Benet LZ., et al., Pharm Res. 2012 Jul;29(7):1768-74I* 206.75 SRC PHYSPROP
Carrier mediated, BCRP/MXR, OCT3Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.;
Minuesa G, Volk C, Molina-Arcas M., et al., J Pharmacol Exp Ther. 2009 Apr;329(1):252-61;
Morrissey KM, Wen CC, Johns SJ, et al., Clin Pharmacol Ther. 2012 Nov;92(5):545-6.B
Carrier mediated, Pgp, PEPT1, OCTN1 and OCTN2S nberg P, Norinder U, Luthman K,et al., J Med Chem. 2001 Jun 7;44(12):1927-37
Watanabe K, Sawano T, Terada K, et alB 178 SRC PHYSPROP
Tablet (AS DIHYDRATE)
Carrier Mediated, PEPT1 & p-gpOgihara T, Kano T, Wagatsuma T, Wada S., Drug Metab Dispos. 2009 Aug;37(8):1676-81B 194 http://www.roche.com/pages/csds/english/out/0471755.20070104.7029.pdf
Carrier mediated, LAT1,S wart BH, Kugler AR, Thompson PR, et al,  Pharm Res, 1993, 10, 276-81;
Uchino H, Kanai Y, Kim DK., et al., Mol Pharmacol. 2002 Apr;61(4):729-37
I 164 Hazardous Substances Data B nk (HSDB)
Carrier mediated, p-gpEstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E
Seral, C.,Michot, J-M.,Chanteux, H., et al., Antimicrob Agents Chemother. 2003 March; 47(3): 1047–1051E 187.5 Hazard us Substances Data Bank (HSDB)
Carrier mediated, OCT1Sai, Y., Tsuji. A., Drug Discov Today. 2004 Aug 15;9(16):712-20I 250 SRC PHYSPROP
Carrier mediated efflux, BCRP, MRP2

Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.;
Kusuhara H, Furuie H, Inano A., et al., Br J Pharmacol. 2012 Jul;166(6):1793-803;
Dahan A, Amidon GL., et al., Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7E 220 SRC PHYSPROP
116.50 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gp, paracellularVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21, 128E* 14 SRC PHYSPROP
Tablet (AS SUCCINATE) 170 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E
Carrier mediated, OCT1/OCT2, p-gp & paracellular Collett A, Sims E, Walker D., et al., Pharm Res. 1996 Feb;13(2):216-21;
Collett A, Higgs NB, Sims E., et al., J Pharmacol Exp Ther. 1999 Jan;288(1):171-8;
Lennernäs, H., Palm, K., Fagerholm, U., et al., Int J Pharm, 1999 Jan;127(1) 103-107A 69.5 SRC PHYSPROP
Tablet (AS MONOHYDRATE HEMI-ETHANOLATE) 114 SRC PHYSPROP
Carrier mediated, p-gp, paracellularLe  K, Ng C, B ouwer KL., et al., J Pharmacol Exp Ther. 2002 Nov;303(2):574-80;
Pharmacokinetics and Metabolism in Drug Design, 3rd Edition 2012, Wiley, Chapter 3, pg 46E* 163.5 SRC PHYSPROP
Carrier mediated, influxGao S, Singh J., J. Control Release, 1998, 51 (2–3), 193–199I 155.5 SRC PHYSPROP
Tablet (Coated AS HYDROCHLORIDE) 172.5 SRC PHYSPROP
350 SRC PHYSPROP
Paracellular Lacombe O, Woodley J, Solleux C., et al., Eur J Pharm Sci. 2004 Dec;23(4-5):385-91*
Carrier Mediated, p-gp, BCRP, MRP2, OATP2B1
Li J, Volpe DA, Wang Y., et al., Drug Metab Dispos. 2011 Jul;39(7):1196-202B
Carrier mediated, p-gp, OATP1A2Varma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21;
Franke RM, Baker SD, Mathijssen RH., Clin Pharmacol Ther. 2008 Dec;84(6):704-9B 191 SRC PHYSPROP
Carrier mediated, Amino acid transporterThwaites DT, Basterfield L, McCleave PM., et al., Br J Pharmacol. 2000 Feb;129(3):457-64I 207 SRC PHYSPROP
Paracellular Hilgendorf C, Spahn-Langguth H, Regårdh CG., J Pharm Sci, 2000, 89, 63-75* 295 SRC PHYSPROP
Carrier mediated, p-gp, OATP1A2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.B
Carrier mediated, PEPT1Hu, M.; Chen, J.; Zhu, Y.; et al., Pharm.Res. 1994, 11, 1405-1413.I
Paracellular Collett A, Sims E, Walker D., et al., Pharm Res. 1996 Feb;13(2):216-21* 274 SRC PHYSPROP
Paracellular Karlsson J, Ungell A, Gråsjö J., et al., Eur J Pharm Sci. 1999 Oct;9(1):47-56* 168 SRC PHYSPROP
Carrier mediated, p-gp, MRP2Estudante , Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E 213.5 Hazardous Substances Data Bank (HSDB)
Paracellular Hilgendorf C, Spahn-Langguth H, Regårdh CG., J Pharm Sci, 2000, 89, 63-75;
Matsson P, Bergström CA, Nagahara N., et al., J Med Chem. 2005 Jan 27;48(2):604-13*
Carrier mediated, p-gpSchmitt U, Abou El-Ela A, Guo LJ, et al., J Neural Transm. 2006 Jul;113(7):787-801126.5 SRC PHYSPROP
Paracellular and Carrier mediated, OATP1A2Hilgendorf C, Spahn-Langguth H, Regårdh CG., J Pharm Sci, 2000, 89, 63-75;
Collett A, Sims E, Walker D., et al., Pharm Res. 1996 Feb;13(2):216-21I* 147 SRC PHYSPROP
Carrier mediated, PEPT1Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I 300 SRC PHYSPROP
114.5 SRC PHYSPROP
135 SRC PHYSPROP
Carrier mediated, p-gp, MRP4Estudante , Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1;
Knox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 194.5 Hazardous Substances Data Bank (HSDB),  (Monohydr te)
Carrier Mediated, BCRP/MXR, OATP1A2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.B 256 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gp, BCRP/MXREstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1;

















Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41;
Matsson P, Bergström CA, Nagahara N., et al., J Med Chem. 2005 Jan 27;48(2):604-13E 130 SRC PHYSPROP
Carrier mediated p-gp, influxPauli-Magnus C, Mürdter T, Godel A., et al., Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43;
Taub ME, Mease K, Sane RS., et al., Drug Metab Dispos. 2011 Nov;39(11):2093-102B 249 SRC PHYSPRO
Carrier mediated, p-gp, OATP1A2Troutman MD, Thakker DR., Pharm Res. 2003 Aug;20(8):1210-24;
Kato Y, Miyazaki T, Kano T., et al., J Pharm Sci. 2009 Jul;98(7):2529-39B 1 1 SRC PHYSPROP
Carrier mediated, p-gpSol ner A, Benet LZ, Mutschler E., et al., Br J Pharmacol. 2000 Mar;129(6):1235-43E 184 SRC PHYSPROP
Capsule (AS HYCLATE) 201 AQUASOL dATAbASE 6th edition
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 242.5 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 244 SRC PHYSPROP
Carrier mediated p-gp, PEPT1Susanto M, Benet LZ., Pharm Res. 2002 Apr;19(4):457-62.
Luckner P, Brandsch M., Eur J Pharm Biopharm. 2005 Jan;59(1):17-24.B Medium to low affinity for PEPT1
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 243.5 SRC PHYSPROP
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 22 SRC PHYSPROP
94.75 SRC PHYSPROP
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E
Carrier Mediated, PEPT1, OATPEstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1., Knox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41I Poor subsrate for PEPT1143.75 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gpCrivori , P., Reinach, B. , Pezzetta, D., et al., Mol. Pharm. , 2006, 3, 33–44E 226 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 112.5 SRC PHYSPROP
248 SRC PHYSPROP
Carrier mediated, BCRP/MXR, p-gpEstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1;
Varma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 163 SRC PHYSPROP
Capsule (25mg/kg at 70 kg adult) 150.5 SRC PHYSPROP
Tablet (AS ACETATE) 146 SRC PHYSPROP
Carrier mediated, p-gpFaassen F, Vogel G, Spanings H., et al., Int J Pharm. 2003 Sep 16;263(1-2):113-22E 196.5 SRC PHYSPROP
Tablet (AS MONOHYDRATE)
Carrier mediated, p-gpEstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E
Tablet (AS HYDROCHLORIDE) 293.5 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Carrier mediated, PEPT1Buyse,M., Berlioz, F., Guilmeau, S. et al, J Clin Invest. 2001 November 15; 108(10): 1483–1494I
Efflux, pgp http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdfE
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 146 SRC PHYSPROP
254 SRC PHYSPROP
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 289 SRC PHYSPROP
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 12 Morissette SL, Soukasene S, Levinson D., et al., Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2180-4
Capsule (AS HYDROCHLORIDE) 180.5 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gpCrivori , P., Reinach, B. , Pezzetta, D., et al., Mol. Pharm. , 2006, 3, 33–44E 235 SRC PHYSPROP
Tablet (AS ACETATE) 203.5 SRC PHYSPROP
Carrier mediated, BCRP, CNT1Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.
Shugarts, S. Benet, LZ., Pharm Res. 2009 September; 26(9): 2039–2054B 114 SRC PHYSPROP
Carrier mediated, p-gpEstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E
Solution (IV INJECTION AS SULFATE) 118.5 SRC PHYSPROP
Carrier mediated, p-gpKim WY, Benet LZ., Pharm Res. 2004 Jul;21(7):1284-93E 183 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 183.5 SRC PHYSPROP
Carrier Mediated, SVCT1 MacDonald L, Thumser AE, Sharp P., et al., Br J Nutr. 2002 Feb;87(2):97-100I 191 SRC PHYSPROP
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 201 SRC PHYSPROP
>300 Hazardous Substances Data Bank (HSDB), (Hydrochloride monohydrate)
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 147 SRC PHYSPROP
174.5 Hazardous Substances Data Bank (HSDB), (under nitrogen)
Carrier mediated, p-gp, BCRP/MXREstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E 279 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E Substrate/inhib tor -weak affinity151.5 SRC PHYSPROP
Carrier mediated, p-gp, OCTN1Varma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21;
Shugarts, S. Benet, LZ., Pharm Res. 2009 September; 26(9): 2039–2054B 174 SRC PHYSPROP
Carrier mediated, p-gpDilger K, Schwab M, Fromm MF., et al., Inflamm Bowel Dis. 2004 Sep;10(5):578-83E 234 SRC PHYSPROP
Capsule (AS SODIUM SALT)
Tablet (AS HYDROBROMIDE) 182.5 Hazardous Substances Data Bank (HSDB), (Hydrobromide)
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 232.5 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
Tablet (AS HYDROCHLORIDE) 193 Hazardous Substances Data Bank (HSDB)
Tablet (Chewable) 59 SRC PHYSPROP


















Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E Conflicting result  however paper: Inhibition of P-glycoprotein enhances transport of imipramine across the blood–brain barrier: microdialysis studies in conscious freely moving rats, FE O’Brien, 2012 states pgp efflux limits transport of drug through blood brain barrier in rats174.5 SRC PHYSPROP
Carrier Mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 149.1 SRC PHYSPROP
Carrier mediated, p-gp,Mashayekhi SO, Sattari MR, Routledge PA., Res Pharm Sci. 2010 Jul;5(2):99-106E 255 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 188 SRC PHYSPROP
Carrier mediated, p-gpVautier S, Lacomblez L, Chacun H., et al., Eur J Pharm Sci. 2006 Feb;27(2-3):167-74E
Tablet (AS HYDROCHLORIDE) 87 SRC PHYSPROP
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21;
Morrissey KM, Wen CC, Johns SJ, et al., Clin Pharmacol Ther. 2012 Nov;92(5):545-6.E 26 SRC PHYSPROP
Tablet (co-administered with PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM)139 SRC PHYSPR P
34 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 170 SRC PHYSPROP
Tablet (AS TARTRATE) 196 SRC PHYSPROP
Tablet (AS SODIUM OR POTASSIUM) 157 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 180 Hazardous Sub tances Data Bank (HSDB)
Tablet (AS TARTRATE)
167 SRC PHYSPROP
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 288.5 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 99.5 Hazardous Substances Data Bank (HSDB)
Carrier mediated, MCTChoi JS, Jin MJ, Han HK., J Pharm Pharmacol. 2005 Sep;57(9):1185-9I 94 SRC PHYSPROP
Carrier mediated, p-gp, BCRP Choi MK, Song IS., J Pharm Pharmacol. 2012 Aug;64(8):1074-83E 188 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 135 SRC PHYSPROP




Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E <25 SRC PHYSPROP
Capsule (AS HYDROCHLORIDE) 219 SRC PHYSPROP
Capsule (AS SODIUM) 286 SRC PHYSPROP
Carrier mediated, MRP2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E
< 25 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
Carrier mediated, p-gpEstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E 220 SRC PHYSPROP
238 SRC PHYSPROP
215.5 SRC PHYSPROP
Carrier mediated, OATP-BKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41I 128.5 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
234 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gpFaassen F, Vogel G, Spanings H., et al., Int J Pharm. 2003 Sep 16;263(1-2):113-22E Subsrate and inhibitor170 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 76 SRC PHYSPROP
132 SRC PHYSPROP
161 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 21 Hazardous Substances Data Bank (HSDB)
228.25 Hazardous Substances Data Bank (HSDB)
Solution (IV AS HYDROCHLORIDE INJECTION) 140.8 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 169 SRC PHYSPROP
180 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 60 SRC PHYSPROP
Tablet (AS MALEATE) <25 AQUASOL dATAbASE 6th edition
183.5 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 96 SRC PHYSPROP




178 Hazardous Substances Data Bank (HSDB)
Carrier mediated, OCTN1/2, PMAT, p-gpEstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.B <25 SRC PHYSPROP
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 159 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 130 SRC PHYSPROP





















Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 137 SRC PHYSPROP
Solution (IV INJECTION) 68.5 SRC PHYSPROP
199 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 97 SRC PHYSPROP
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 173 SRC PHYSPROP
Carrier mediated, p-gpLuna-Tortós C, Fedrowitz M, Löscher W., Neuropharmacology. 2008 Dec;55(8):1364-75.E 177 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Tablet (AS HYDROCHLORIDE)
Capsule (AS UNDECANOATE OILY SOLUTION) 155 SRC PHYSPROP
233.5 Hazardous Substances Data Bank (HSDB), (Hydrochloride)
Carrier mediated, p-gpWolf DC, Horwitz SB, Int J Cancer. 1992 Aug 19;52(1):141-6E 181 SRC PHYSPROP
Capsule (Micronized) 121 SRC PHYSPROP
Carrier mediated, LAT1, LAT2Lennernäs H, Nilsson D, Aquilonius SM., et al., Br J Clin Pharmacol. 1993 Mar;35(3):243-50
Soares-da-Silva, P., Serrão, MP., Am J Physiol Renal Physiol. 2004 Aug;287(2):F252-61.I 285 SRC PHYSPROP
Tablet (AS SODIUM FORM) 234 SRC PHYSPROP
Powder (IV INFUSION) AS MESILATE 140 SRC PHYSPROP
Capsule (AS SODIUM SALT) 250 SRC PHYSPROP
Carrier mediated, RFCTherapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.;
Matherly LH, Goldman DI., et al., Vitam Horm. 2003;66:403-56;
Balamurugan K, Said HM., et al., Am J Physiol Cell Physiol. 2006 Jul;291(1):C189-93I 245 Hazard us Substances Data Bank (HSDB)
Powder (IV INJECTION/INFUSION) 184 http://www.pfizer.ca/en/our_products/products/monograph/273
Carrier mediated, MCT1, NAP1 & ParacellularEstudante M, Morais JG, Sover l G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.;
Pang KS., Drug Metab Dispos. 2003 Dec;31(12):1507-19;
Lennernäs H., Pharm Res. 1995 Nov;12(11):1573-82I*
Paracellular Matsson P, Bergström CA, Nagahara N., et al., J Med Chem. 2005 Jan 27;48(2):604-13;
Dawson DJ, Lobley RW, Burrows PC., et al., Clin Sci (Lond). 1988 Apr;74(4):427-31.* 80 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
Solution (IV AS SODIUM INFUSION)
Carrier mediated, OATP1A2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I 200 SRC PHYSPROP
Powder (IV INJECTION/ORAL SUSPENSION) 170 Hazardous Substances Data Bank (HSDB)
Tablet (AS HYDROCHLORIDE) 148.5 SRC PHYSPROP
241 SRC PHYSPROP
Carrier mediated, MRP2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E
Tablet (AS SULFATE) 100 SRC PHYSPROP
Carrier mediated, p-gpCallegari E, Malhotra B, Bungay PJ., et al., Br J Clin Pharmacol. 2011 Aug;72(2):235-46E
257.25 Hazardous Substances Data Bank (HSDB),(0.4 H2O)
Carrier Mediated, CNT2Shugarts, S. Benet, LZ., Pharm Res. 2009 September; 26(9): 2039–2054I 167 Hazardous Substances Data Bank (HSDB)
Tablet (AS HYDROCHLORIDE WITH ATROPINE SULFATE) 221.25 Hazardous Substances Data Bank (HSDB)
Tablet/Capsule - extended release 260.5 SRC PHYSPROP
Capsule (granules) 161.5 SRC PHYSPROP
Paracellular Matsson P, Bergström CA, Nagahara N., et al., J Med Chem. 2005 Jan 27;48(2):604-13;
Carlson SJ, Webster C, Craig RM., Dig Dis Sci. 1997 Dec;42(12):2599-602;
O'Rourke M, Shi X, Gisolfi C., et al., Am J Med Sci. 1995 Mar;309(3):146-51* 169 SRC PHYSPROP
283 SRC PHYSPROP
Carrier Mediated, PEPT1 & p-gpOgihara T, Kano T, Wagatsuma T, Wada S., Drug Metab Dispos. 2009 Aug;37(8):1676-81B
216 SRC PHYSPROP
Solution (IV INJECTION)
Powder (IV INJECTION) 150.5 SRC PHYSPROP
Carrier mediated, PEPT1Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I
Paracellular Pharmacokinetics and Metabolism in Drug Design, 3rd Edition 2012, Wiley, Chapter 3, pg 46* N  experimental results but 2 s urces states this rou
Carrier Mediated, PEPT1 , MRP2 Br tschneider, B., Brandsch, M., Neubert, R., Pharm Res, 1999, 16: 55-61B 208 SRC PHYSPROP
Carrier mediated, p-gpEstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E
Carrier mediated, PEPT1, MCT, possibility of mulitple othersM non RM, Barr WH., Biopharm Drug Dispos. 2002 Nov;23(8):317-26I
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 149.5 SRC PHYSPROP
>300 SRC PHYSPROP
Tablet (AS BROMIDE)
Powder (IV AS ISETIONATE)

















Carrier mediated, p-gpWalker DK, Abel S, Comby P, et al, Drug Metab Dispos, 2005, 33, 587-95E 197.5 Hazardous Substances Data Bank (HSDB)
Tablet (AS CALCIUM)
296.5 van Beek TA., Bioorg Med Chem. 2005 Sep 1;13(17):5001-12
Paracellular Matsson P, Bergström CA, Nagahara N., et al., J Med Chem. 2005 Jan 27;48(2):604-13; 
Turner JR, Cohen DE, Mrsny RJ., et al., Dig Dis Sci. 2000 Nov;45(11):2122-6* 300 SRC PHYSPROP
187 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gp, OATPKis O, Zastre JA, Hoque MT., et al, Pharm Res. 2013 Apr;30(4):1050-64B Possible inhibitory effects
Carrier mediated, PEPT1W nzel U, Kuntz S, Diestel S., et al., Antimicrob Agents Chemother. 2002 May;46(5):1375-80I
Carrier mediated, PMAT & paracellularEstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.;
Zhou M, Xia L, Wang J., Drug Metab Dispos. 2007 Oct;35(10):1956-62I* 219 Hazardous Substances Data Bank (HSDB)
Tablet (Co-administered NADOLOL) 222 SRC PHYSPROP
Tablet (active metabolite) 149.5 SRC PHYSPROP
208 SRC PHYSPROP
Carrier mediated, PEPT1Luckner , Brandsch M., Eur J Pharm Biopharm. 2005 Jan;59(1):17-24I Mode ate affinity for PEPT1
Powder (IV INJECTION/INFUSION AS SODIUM SALT)
Powder (IV INJECTION AS SODIUM SALT)
Carrier mediated, MRP2, OATP2B1Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.B
Carrier mediated, BCRPMorrissey KM, Wen CC, Johns SJ, et al., Clin Pharmacol Ther. 2012 Nov;92(5):545-6;
Mason JB, Shoda R, Haskell M., et al., Biochim Biophys Acta. 1990 May 24;1024(2):331-5E 250 SRC PHYSPROP
Solution (IV AS ACETATE)
Tablet (AS MALEATE OR MESILATE)
Tablet (AS HYDROCHLORIDE)
Carrier mediated, p-gp, BCRP and MRP2Choi MK, Song IS., J Pharm Pharmacol. 2012 Aug;64(8):1074-83E
148 SRC PHYSPROP
Carrier mediated, PEPT1Behrens I, Kamm W, Dantzig AH., et al., J Pharm Sci. 2004 Jul;93(7):1743-54;
Inui K, Yamamoto M, Saito H., J Pharmacol Exp Ther. 1992 Apr;261(1):195-201I 140 SRC PHYSPROP
Powder for IV recon as sodium salt
Solution (IV INJECTION)
Tablet (AS HYDROCHLORIDE) 145 Hazardous Substances Data Bank (HSDB)
Carrier mediated, PEPT1Knox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41I
Powder for inhalation 139 Hazardous Substances Data Bank (HSDB)
Carrier mediated , BCRPM rino G, Alvarez AI, Pulido MM., et al., Drug Metab Dispos. 2006 Apr;34(4):690-5E 227.5 SRC PHYSPROP
Carrier mediated, p-gpCrivori , P., Reinach, B. , Pezzetta, D., et al., Mol. Pharm. , 2006, 3, 33–44E
Tablet (AS dihydrate of the sodium salt) 178.5 SRC PHYSPROP
135 SRC PHYSPROP
235.5 SRC PHYSPROP
Solution (IV INJECTION) 199 Hazardous Substances Data Bank (HSDB), (Sodium)
Carrier mediated, p-gpGarver E, Hugger ED, Shearn SP., et al., Drug Metab Dispos. 2008 Dec;36(12):2492-8E 220 SRC PHYSPROP
239.75 SRC PHYSPROP
128.5 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000ClinPharmR.pdf
185.5 Hazardous Substances Data Bank (HSDB)
206 SRC PHYSPROP
160.5 SRC PHYSPROP
Carrier mediated, p-gpWhomsley R, Gerin B, Brochot A., et al, Allergy 2003; 58: 274E Weak subsrate
Solution (IV INFUSION/INJECTION) 160.25 SRC PHYSPROP
159.5 AQUASOL dATAbASE 6th edition
Tablet (AS HYDROCHLORIDE)
256 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 183 http://www.amgen.ca/Sensipar.pdf
222 SRC PHYSPROP
183 SRC PHYSPROP
Carrier mediated, p-gp, BCRPOzawa N, Shimizu T, Morita R., Pharm Res. 2004 Nov;21(11):2133-4E
209 SRC PHYSPROP
Carrier mediated, pgpHarrison A, Betts A, Fenner K, et al, Drug Metab Dispos, 2004, 32,Faassen F, Vogel G, Spanings H., et al., Int J Pharm. 2003 Sep 16;263(1-2):113-22-204.E
182 Hazardous Substances Data Bank (HSDB)


















Carrier mediated, p-gpGnoth MJ, Buetehorn U, Muenster U., et al., J Pharmacol Exp Ther. 2011 Jul;338(1):372-80E
Tablet (AS HYDROCHLORIDE) 273 SRC PHYSPROP
280 SRC PHYSPROP
156 SRC PHYSPROP
Carrier mediated, PEPT1Sai, Y., Tsuji. A., Drug Discov Today. 2004 Aug 15;9(16):712-20I
Tablet (AS HYDROCHLORIDE) 179 Bernstein CD, Albrecht KL, Marcus DA., Expert Opin Pharmacother. 2013 May;14(7):905-16
226 SRC PHYSPROP
OPHTHALMIC (AS HYDROCHLORIDE)
Tablet/Capsule 105 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) < 25 SRC PHYSPROP
175.5 SRC PHYSPROP
Tablet (AS CALCIUM SALT) < 25 SRC PHYSPROP
Carrier mediated, pgp,MRP2Jin HE, Song B, Kim SB., et al., Xenobiotica. 2013 Apr;43(4):355-67E 236 Hazardous Substances Data Bank (HSDB)
191 SRC PHYSPROP
Carrier mediated, OCTN2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I 134.5 SRC PHYSPROP
Carrier mediated, p-gpTaubert D, von Beckerath N, Grimberg G, et al., Clin Pharmacol Ther. 2006 Nov;80(5):486-501E
Tablet (AS MESILATE) 278 Hazardous Substances Data Bank (HSDB), Methanesulfonate
Tablet (AS DIHYDROCHLORIDE) 238 http://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Fluanxo_MKT_PM_ctrl148918_18OCT2011_eng.pdf
Tablet (AS CITRATE) 48 SRC PHYSPROP
167 SRC PHYSPROP
Carrier mediated, MCT1Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I 158 SRC PHYSPROP
158 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 172.5 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41;




164 MSDS Sigma aldrich http://www.sigmaaldrich.com
100 SRC PHYSPROP
Carrier mediated, InfluxGoto Y, Itagaki S, Umeda S., et al., Biol Pharm Bull. 2005 Dec;28(12):2235-9I No exact details specifying typ  and gene of tranpsporter, similar to MCT262 Hazardous Substances Data Bank (HSDB), Methanesulfonate
Emulson (IV INJECTION) 18 SRC PHYSPROP
Capsule no longer presecribed as oral now only IV 295 SRC PHYSPROP
254 SRC PHYSPROP
230.5 SRC PHYSPROP
Tablet (AS MALEATE) < 25 SRC PHYSPROP
Carrier Mediated, pgpSk rjanec, A., Clin Pharmacokinet, 2006, 45, 325-50E
Carrier Mediated, SGLT1Fine KD, Santa Ana CA, Porter JL., et al., Gastroenterology. 1993 Oct;105(4):1117-25;
Carruthers A, DeZutter J, Ganguly A., et al., Am J Physiol Endocrinol Metab. 2009 Oct;297(4):E836-48;
Takata K., J Electron Microsc (Tokyo). 1996 Aug;45(4):275-84
I 83 SRC PHYSPROP
Carrier mediated, p-gph tp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001114/WC500053735.pdfE Weak subsrate 198.5 www.novartis. a/a knovartispharma
Carrier mediated, pgp, uptakeToyobuku H, Tamai I, Ueno K., et al., J Pharm Sci. 2003 Nov;92(11):2249-59B 16 SRC PHYSPROP
Carrier mediated, PEPT1Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I 283 SRC PHYSPROP
Tablet (co-administered with ethinylestradiol) 197.9 SRC PHYSPROP
192 SRC PHYSPROP
192 Hazardous Substances Data Bank (HSDB)
146.5 SRC PHYSPROP
209 Ramana, MV., Himaja, M., Dua, K., et al., Asian J. Pharm, 2008, 2(2) 96-101
INHALANT CARTRIDGE -79 SRC PHYSPROP
Carrier mediated, p-gpCrivori , P., Reinach, B. , Pezzetta, D., et al., Mol. Pharm. , 2006, 3, 33–44E 211 SRC PHYSPROP
181 SRC PHYSPROP
271 SRC PHYSPROP
Capsule (AS HYDROCHLORIDE) 180.5 Hazardous Substances Data Bank (HSDB)

















Carrier mediated, influx, similar to MCT1Kuwayama K, Miyauchi S, ateoka R., et al., Biochem Pharmacol. 2002 Jan 1;63(1):81-8I 315 SRC PHYSPROP
125.5 Hazardous Substances Data Bank (HSDB)
127.5 SRC PHYSPROP
248 Hazardous Substances Data Bank (HSDB)
207 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Tablet (AS SULFATE) 57 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 119 SRC PHYSPROP
173.5 SRC PHYSPROP





171 Hazardous Substances Data Bank (HSDB)
Tablet (AS SULFATE) >300 Hazardous Substances Data Bank (HSDB)
183 SRC PHYSPROP
176 SRC PHYSPROP
Carrier mediated, OCT1/2Sai, Y., Tsuji. A., Drug Discov Today. 2004 Aug 15;9(16):712-20; 
Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I 258 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 71 SRC PHYSPROP
136 SRC PHYSPROP
146 SRC PHYSPROP
Carrier mediated, OCTN2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I 125 SRC PHYSPROP
Capsule (AS SODIUM)
134.5 MSDS Sigma aldrich http://www.sigmaaldrich.com
Carrier Mediated, GLUT1Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.;
Christie GR, Ford D, Howard A., et al., Gastroenterology. 2001 Feb;120(2):439-48;




Tablet (AS PHOSPHATE) 154 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Tablet (AS HYDROCHLORIDE) 114 SRC PHYSPROP
219 SRC PHYSPROP
216.5 SRC PHYSPROP
Tablet (AS HYDROGEN FUMARATE) 151 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
205.5 SRC PHYSPROP
Capsule (AS HYDROCHLORIDE) 204 SRC PHYSPROP
Carrier mediated, OCTNSai, Y., Tsuji. A., Drug Discov Today. 2004 Aug 15;9(16):712-20;
Evans AM, Fornasini G., Clin Pharmacokinet. 2003;42(11):941-67I absorption both by transporter and passive absorption210 Chemfi d r DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Tablet (AS HYDROCHLORIDE) 88 SRC PHYSPROP
Carrier mediated, p-gpCummins CL, Jacobsen W, Christians U., et al., J Pharmacol Exp Ther. 2004 Jan;308(1):143-55E 184 Hazardous Substances Data Bank (HSDB)
Tablet (AS HYDROCHLORIDE) 126.5 Hazardous Substances Data Bank (HSDB)
Tablet (AS BROMIDE) 153 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gp, BCRP/MXR, OCTN2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.B 226 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gpShaik N, Giri N, Pan G., Drug Metab Dispos. 2007 Nov;35(11):2076-85E
Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E
Carrier mediated, BCRP/MXREstudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E 263 SRC PHYSPROP
Carrier mediated p-gph tp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/076175s030lbl.pdfE 259.5 Hazardou  Substances Data Bank (HSDB)
Tablet (AS MESILATE)
Tablet (AS MESILATE) 170.5 Hazardous Substances Data Bank (HSDB)
226 SRC PHYSPROP




















Carrier mediated, p-gpVarma MV, Sateesh K, Panchagnula R., Mol Pharm. 2005 Jan-Feb;2(1):12-21E 195 SRC PHYSPROP
160.5 SRC PHYSPROP
Carrier mediated p-gpMoons T, de Roo M, Claes S., et al., Pharmacogenomics. 2011 Aug;12(8):1193-211E Intermediate affinity
Tablet (AS HYDROCHLORIDE) 192 Hazardous Substances Data Bank (HSDB)
Tablet (AS HYDROCHLORIDE) 103 Hazardous Substances Data Bank (HSDB)
171.4 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 172.5 Hazardous Sub tances Data Bank (HSDB)




Tablet (AS HYDROGEN TATRATE)
Tablet (AS HYDROCHLORIDE) 74.5 Hazardous Substances Data Bank (HSDB)
161.5 Hazardous Substances Data Bank (HSDB)
Tablet (AS BITARTRATE co-administered with ACETAMINOPHEN) 198 SRC PHYSPROP




114 Hazardous Substances Data Bank (HSDB)
Tablet (AS HYDROCHLORIDE) 214 Hazardous Substances Data Bank (HSDB)
154 Hazardous Substances Data Bank (HSDB)
Tablet (AS HYDROCHLORIDE) 129.5 Hazardous Substances Data Bank (HSDB)
138 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Capsule (AS HYDROCHLORIDE) 189.5 SRC PHYSPROP
225 SRC PHYSPROP
62 SRC PHYSPROP
Capsule (AS MALEATE) 45 SRC PHYSPROP
263 SRC PHYSPROP
Solution (IV INJECTION AS HYDROCHLORIDE) 218 Hazardous Substances Data Bank (HSDB)
Tablet (AS HYDROCHLORIDE) 93 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 174 SRC PHYSPROP
Capsule (AS HYDROCHLORIDE) < 25 SRC PHYSPROP
Solution (IV INJECTION) 202 SRC PHYSPROP
144.5 MSDS Sigma aldrich http://www.sigmaaldrich.com, (hydrochloride)
Tablet (AS HYDROCHLORIDE) 86 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 141.5 Hazardous Substances Data Bank (HSDB)
Capsule (AS HYDROCHLORIDE) 79.5 SRC PHYSPROP
229.5 SRC PHYSPROP
197 SRC PHYSPROP
Capsule, Based on 50/mg/kg being dosed and the average man being 70kg of metabolic active mass114.3 SRC PHYSPROP
189 AQUASOL dATAbASE 6th edition
178.5 SRC PHYSPROP
229 SRC PHYSPROP
Tablet (AS DIPIVOXIL FORM) >250 Hazardous Substances Data Bank (HSDB)
Tablet (AS mesylate), never made to market
Solution (IV 0.25 mg/kg INFUSION) based on average human being 70kg
136 SRC PHYSPROP
139 SRC PHYSPROP
Carrier mediated, CNT, SLCPang KS., Drug Metab Dispos. 2003 Dec;31(12):1507-19I 350 SRC PHYSPROP
Capsule (AS BISMESYLATE)


















Solution (IV/IM AS SULFATE INJECTION/INFUSION) based on average human being 70kg203.5 SRC PHYSPROP
149.5 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 156 Hazardous Substances Data Bank (HSDB)
Capsule (AS SODIUM) 157 SRC PHYSPROP
175.5 SRC PHYSPROP
Capsule (AS HYDROCHLORIDE) >280 Hazardous Substances Data Bank (HSDB)
81.5 Hazardous Substances Data Bank (HSDB)
Powder (IV/IM INJECTION)
Tablet (with Proguanil hydrochloride) if taken as oral suspension 150mg/mL217.5 MSDS Sigma aldrich http://www.sigmaaldrich.com
Solution (IV INJECTION AS BESILATE)
Tablet (AS MALEATE)
243.5 SRC PHYSPROP






Tablet (AS DIHYDROCHLORIDE) 152 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013, (hydrochloride)
< 25 SRC PHYSPROP
Tablet (modified release value increases to 400mg) 186 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
Carrier Mediated, SMVTTherapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.;
Luo S, Kansara VS, Zhu X., et al., Mol Pharm. 2006 May-Jun;3(3):329-39I 232 SRC PHYSPROP
Ophthalmic (AS SODIUM)
Capsule (AS HYDROCHLORIDE) 238 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
230.5 SRC PHYSPROP
Solution (IV AS ANHYDROUS HYDROCHLORIDE) 107.5 SRC PHYSPROP
287 SRC PHYSPROP
143 Hazardous Substances Data Bank (HSDB), (Bromide)
Carrier mediated, p-gp, MRP2h tp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdfE Weak pgp subsrate
Tablet based on surface area 115.5 Hazardous Substances Data Bank (HSDB)









Carrier mediated, PEPT1Shugarts, S. Benet, LZ., Pharm Res. 2009 September; 26(9): 2039–2054;
Knox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41
I
134.2 Arora SC, Sharma PK, Irchhaiya R., et al., J Adv Pharm Technol Res. 2010 Jul;1(3):326-9
Carrier mediated, p-gp, OATP1A2Kato Y, Miyazaki T, Kano T., et al., J Pharm Sci. 2009 Jul;98(7):2529-39;





















Tablet (AS CARBAMATE) 78 SRC PHYSPROP
128 SRC PHYSPROP
103.5 SRC PHYSPROP
Solution (IV INFUSION) 260 MSDS Sigma aldrich http://www.sigmaaldrich.com, (hydrate)




Powder (IV) co administered with with ticarcillin
253 MSDS Sigma aldrich http://www.sigmaaldrich.com
< 25 SRC PHYSPROP
Capsule (AS OILY BASE)
Tablet (AS SULFATE) 184 Hazardous Substances Data Bank (HSDB), (Hydrogen sulfate)
Granules (AS HYDROCHLORIDE)
Powder (IV INFUSION AS HYDROCHLORIDE)
Curvall M, Elwin CE, Kazemi-Vala E, et al., Eur J Clin Pharmacol. 1990;38(3):281-7. 41 SRC PHYSPROP
238 SRC PHYSPROP
Tablet (AS ANHYDROUS) 51.5 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 112.8 SRC PHYSPROP
200.5 Hazardous Substances Data Bank (HSDB)
Capsules (AS BITARTRATE) 98 SRC PHYSPROP
Tablet (Extended release) 158.5 SRC PHYSPROP
Capsule (AS SODIUM) 279.5 SRC PHYSPROP
Solutionn (Mouthwash)
Tablet (Co administered with ethinyl estradiol) 109.5 SRC PHYSPROP
182 SRC PHYSPROP
330.5 SRC PHYSPROP
Capsule (AS HYDROCHLORIDE) 165 Hazardous Substances Data Bank (HSDB), (Hydrochloride)
Tablet (Co administered with estradiol valerate) 214 http://www.bayerresources.com.au/resources/uploads/PI/file9439.pdf
Tablet (AS HYDROCHLORIDE)
170.5 SRC PHYSPROP
Carrier mediated, p-gpMorrissey KM, Wen CC, Johns SJ, et al., Clin Pharmacol Ther. 2012 Nov;92(5):545-6;
Pauli-Magnus C, Mürdter T, Godel A., et al., Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43E 255.5 SRC PHYSPROP
Tablets (AS DIHYDROCODEINE TARTRATE) 112.5 SRC PHYSPROP
Solution (IM, SC AS MESYLATE)
Tablet (AS FUROATE)
Tablet 15mg/kg based on body weight 161.5 SRC PHYSPROP
Tablet (AS BROMIDE)
71.5 SRC PHYSPROP
Capsule (AS HYDROCHLORIDE) 56 SRC PHYSPROP
Tablets (AS MESILATE)
190 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE Co-adminsitered with paracetemol)
Powder (IV INFUSION)  
Carrier mediated, BCRPAllred AJ, Bowen CJ, Park JW, et al., Br J Clin Pharmacol. 2011 Aug;72(2):321-9;
Takeuchi K, Sugiura T, Umeda S., et al., Drug Metab Dispos. 2011 Jun;39(6):1088-96E
Antonaccio MJ, Verjee S., Am J Cardiol. 1986 Aug 29;58(5):114C-116C.
Solution (IV INJECTION) 256 SRC PHYSPROP
Tablet (AS MESILATE) 249 Hazardous Substances Data Bank (HSDB)
192 MSDS http://www.sciencelab.com/msds.php?msdsId=9923917
Tablet (sublingual AS TARTRATE) 213.5 SRC PHYSPROP


























Tablet (AS HYDROCHLORIDE) 167.5 Hazardous Substances Data Bank (HSDB), hydrochloride
Capsule (micronised) 80.5 SRC PHYSPROP
156.5 SRC PHYSPROP
Carrier mediated, pgph tp://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM249353.pdfE
253 SRC PHYSPROP
Capsule (AS SODIUM SALT)
Solution (IV INFUSION) 296 SRC PHYSPROP
Tablet (AS ACETATE) 233.5 Hazardous Substances Data Bank (HSDB)
AEROSOL, METERED; INHALATION 
270 SRC PHYSPROP
Capsule (AS MALEATE) 115.5 SRC PHYSPROP
Solution (IV INFUSION)
Granules (ORAL SUSPENSION) 94 SRC PHYSPROP
Carrier mediated, MRP2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.E
Tablet (AS SUCCINATE)
Carrier mediated, GLUT5Therapeutic drugs, 2ed (1999), Edinburgh : Churchill Livingstone, Dollery, C.;
Barone S, Fussell SL, Singh AK., et al., J Biol Chem. 2009 Feb 20;284(8):5056-66I 119 Ch mfind r DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
192.5 SRC PHYSPROP
136 MSDS Sigma aldrich http://www.sigmaaldrich.com, hydrochloride
162 MSDS Sigma aldrich http://www.sigmaaldrich.com
105 SRC PHYSPROP
215 SRC PHYSPROP
333.5 van Beek TA., Bioorg Med Chem. 2005 Sep 1;13(17):5001-12
181 SRC PHYSPROP
Tablet (AS BROMIDE) 192.5 SRC PHYSPROP
153 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
214.25 Hazardous Substances Data Bank (HSDB), (Sulfate)
146.5 SRC PHYSPROP
270.5 SRC PHYSPROP
266.5 Hazardous Substances Data Bank (HSDB)
Tablet (AS SULFATE) 90 SRC PHYSPROP
119 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
141 SRC PHYSPROP
Solution (IV INFUSION AS FUMARATE) 118 Hazardous Substances Data Bank (HSDB)
Powder (IV INFUSION) 40 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
Powder (IV AS co-adminsitered CILASTATIN SODIUM)
Tablet (AS HYDROCHLORIDE EXTENDED RELEASE) 94-95 SRC PHYSPROP
213.5 SRC PHYSPROP
70 SRC PHYSPROP

















174.5 Hazardous Substances Data Bank (HSDB)
Capsule (AS SULFATE) 182 Hazardous Substances Data Bank (HSDB)
143 http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500064326.pdf
Carrier mediated, p-gph tp://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021880s028lbl.pdfE
230 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013, Hydrochloride
117 Hazardous Substances Data Bank (HSDB)
Carrier mediated, pgpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E Weak affin ty
Tablet (AS MALEATE) 117 AQUASOL dATAbASE 6th edition
240 SRC PHYSPROP
Tablet/Capsule




113 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Capsule (Co administered with an oestrogen) 159 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 35.5 SRC PHYSPROP
257 SRC PHYSPROP
215 Hazardous Substances Data Bank (HSDB)




Tablet (Co administered NORETHYNODREL) 150.5 SRC PHYSPROP
93 SRC PHYSPROP
52.5 SRC PHYSPROP
Tablet (AS MALEATE) 172 SRC PHYSPROP
50.5 SRC PHYSPROP
Powder (IV AS SODIUM)
Tablet (AS HYDROCHLORIDE) 283 Hazardous Substances Data Bank (HSDB)
Tablet (Buccal)
150 Hazardous Substances Data Bank (HSDB)
114 Hazardous Substances Data Bank (HSDB)
>300 SRC PHYSPROP
77 SRC PHYSPROP
Solution (AS INJECTION CHLORIDE)
165 Hazardous Substances Data Bank (HSDB)
Carrier mediated, PEPT1  Knox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41I Medium to weak affinity
140.5 SRC PHYSPROP
Carrier Mediated, OATP2B1 and OATP1A2Mougey EB, Feng H, Castro M., et al., Pharmacogenet Genomics. 2009 Feb;19(2):129-38I
156.5 SRC PHYSPROP
Powder (IV INFUSION)
Tablet (AS HYDROCHLORIDE) 208.5 Hazardous Substances Data Bank (HSDB)
Tablet (AS HYDROCHLORIDE) 144.5 SRC PHYSPROP



















172 Li G, Su GQ, Xu QW., et al., Yao Xue Xue Bao. 2001 Jul;36(7):532-4
299 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 83.5 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
Tablet (AS SULFATE)
Solution (IV INFUSION AS SULFATE)




Martindale, The complete drug reference, Ed 36th, Sweetman, SC., Pharmaceutical Press, London180 SRC PHYSPROP
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 131 SRC PHYSPROP
180 SRC PHYSPROP
Carrier mediated, MRP2Knox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 216 SRC PHYSPROP






Tablet (AS DIHYDRATE) 184.5 SRC PHYSPROP
Solution (BROMIDE IV) 215 Hazardous Substances Data Bank (HSDB)
Tablet (AS SODIUM) 139.5 Hazardous Substances Data Bank (HSDB)
Tablet/Capsule
Tablet (AS SULFATE) 130.5 MSDS Sigma aldrich http://www.sigmaaldrich.com
146.3 SRC PHYSPROP
Capsule (AS SODIUM) 129.5 SRC PHYSPROP
Tablet (extended release) 105 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Tablet (AS maleate)































Solution (IV INFUSION AS HYDROCHLORIDE) 167 Hazardous Substances Data Bank (HSDB)
Tablet (AS HYDROCHLORIDE) 224.5 Hazardous Substances Data Bank (HSDB)
Carrier mediated, p-gp, MRP2May K, Giessmann T, Wegner D, et al., Eur J Clin Pharmacol. 2008 Nov;64(11):1085-92. E
136.7 SRC PHYSPROP





Tablet (AS SODIUM) 100 SRC PHYSPROP
Carrier mediated, PEPT1Knütter I, Wollesky C, Kottra G., et al., J Pharmacol Exp Ther. 2008 Nov;327(2):432-41I Low affinity for this transporter, suggested not transported via this route but acts as a uncompetitive inhibitior120 Hazardous Subst ces Data B nk (HSDB)
Tablet (AS SODIUM) 99.5 Hazardous Substances Data Bank (HSDB)





Tablet (AS SULFATE) 151 SRC PHYSPROP
147 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
194.25 Hazardous Substances Data Bank (HSDB), hydrochloride monohydrate
Carrier mediated, p-gpYamaguchi H, Yano I, Saito H., et al., J Pharmacol Exp Ther. 2002 Mar;300(3):1063-9;
Ito T, Yano I, Tanaka K., et al., J Pharmacol Exp Ther. 1997 Aug;282(2):955-60
E
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E
Tablet (AS SUCCINATE)
Carrier mediated, PEPT1Knox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41I Medium to low affinity
Powder (IM INJECTION SULFATE)
Powder (IV INJECTION/INFUSION) 115 SRC PHYSPROP
193.5 SRC PHYSPROP
Powder (IV INFUSION) 97 SRC PHYSPROP
Powder (IV co-administered with AMPICILLIN SODIUM INFUSION)





Carrier mediated, p-gpBuxbaum E., Eur J Biochem. 1999 Oct 1;265(1):64-70E





























Tablet (AS HYDROCHLORIDE) 256 SRC PHYSPROP
Solution (IV AS INJECTION HYDROCHLORIDE) 174 SRC PHYSPROP
Tablet (AS TARTRATE)
Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E
Carrier mediated, PEPT1Knox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41I Medium to low affinity
100 SRC PHYSPROP
270 SRC PHYSPROP
Solution (IV INJECTION) 293 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 232 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 114 Hazardous Substances Data Bank (HSDB)
Tablet (AS TARTRATE) 68 SRC PHYSPROP
50.5 SRC PHYSPROP




Carrier mediated, p-gpBalayssac D, Authier N, Cayre A., et al., Toxicol Lett. 2005 Apr 28;156(3):319-29E 228 SRC PHYSPROP
Carrier Mediated, PAT1Abbot EL, Grenade DS, Kennedy DJ., et al., Br J Pharmacol. 2006 Feb;147(3):298-306I
63.5 SRC PHYSPROP
Solution (ORAL) 3 SRC PHYSPROP
178 SRC PHYSPROP
256 SRC PHYSPROP
Carrier mediated, OCT1/OCT2Estudante M, Morais JG, Soveral G., et al., Adv Drug Deliv Rev. 2012 Oct 4. pii: S0169-409X(12)00303-1.I 217.5 SRC PHYSPROP
Powder (Inhalation) 256 Hazardous Substances Data Bank (HSDB)
178 SRC PHYSPROP






166.5 Hazardous Substances Data Bank (HSDB)
Capsule (AS HYDROCHLORIDE) 188.7 SRC PHYSPROP
Tablet (Extended release)
Powder (IV co-administered SULFADIAZINE) 236 SRC PHYSPROP
239 SRC PHYSPROP
96 SRC PHYSPROP
Tablet (AS MYCOPHENOLATE SODIUM) 141 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE)
Tablet (AS HYDROCHLORIDE) 183.5 Hazardous Substances Data Bank (HSDB)
120.5 SRC PHYSPROP
Tablet (AS MESYLATE) 227 Hazardous Substances Data Bank (HSDB)



















Carrier mediated, p-gpKnox C, Law V, Jewison T., et al., Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41E 117.25 Hazardous Sub tances Data Bank (HSDB)
Carrier mediated, LAT1Uchino H, Kanai Y, Kim DK., et al., Mol Pharmacol. 2002 Apr;61(4):729-37I
Powder (IV INFUSION AS SODIUM) 192 MSDS http://www.sciencelab.com/msds.php?msdsId=9923917
188 SRC PHYSPROP
161 SRC PHYSPROP
Tablet (AS HYDROCHLORIDE) 127 SRC PHYSPROP
76 SRC PHYSPROP
Tablet (AS DIPOTASSIUM)
Cottrell PR, Streete JM, Berry DJ, et al., Epilepsia. 1982 Jun;23(3):307-13 120 Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
138 Hazardous Substances Data Bank (HSDB)
228.5 SRC PHYSPROP
198.5 Hazardous Substances Data Bank (HSDB)
Carrier mediated, PEPT1Tsu a M, Terada T, Irie M., et al., J Pharmacol Exp Ther. 2006 Jul;318(1):455-60150 Hazardous Substances Data Bank (HSDB)
254 SRC PHYSPROP







Solution (IV INFUSION) 160.5 Hazardous Substances Data Bank (HSDB), (Monohydrate)
175 SRC PHYSPROP
113 SRC PHYSPROP
Tablet (Unequal dosing) 119 SRC PHYSPROP
Tablet (extended release)
203 SRC PHYSPROP
Dispersable Tablet 100-250mg/kg daily in 2-4 divdied doses
Carrier mediated, MRP2, BCRPh tp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000670/WC500033929.pdfE
128 SRC PHYSPROP
173 Hazardous Substances Data Bank (HSDB)
Solution (IV INJECTION) 156 SRC PHYSPROP
224.5 SRC PHYSPROP
Tablet (AS CHLORIDE)
Tablet (AS GLUCONATE) 134 SRC PHYSPROP
>300 Hazardous Substances Data Bank (HSDB)
245 SRC PHYSPROP
Solution (ORAL, IV), Solution (equivalent to 350 mg I per mL) 177 SRC PHYSPROP
Powder (IV INFUSION AS MEGLUMINE)
Powder (IV INFUSION AS MEGLUMINE)
Inhalation (AS BROMIDE)
Powder (IV INFUSION) 220 SRC PHYSPROP
Solution (SODIUM IV) 227 Hazardous Substances Data Bank (HSDB)
Tablet (AS BROMIDE) 160 Hazardous Substances Data Bank (HSDB)

















MSDS Sigma aldrich http://www.sigmaaldrich.com
Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Hazardous Substances Data Bank (HSDB), (Beta-Naphthalensulfonate Trihydrate) 
http://www.roche.com/pages/csds/english/out/0471755.20070104.7029.pdf

















Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Morissette SL, Soukasene S, Levinson D., et al., Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2180-4
Hazardous Substances Data Bank (HSDB), (Hydrochloride monohydrate)
Hazardous Substances Data Bank (HSDB), (under nitrogen)


































MSDS Sigma aldrich http://www.sigmaaldrich.com
Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Hazardous Substances Data Bank (HSDB), (Hydrochloride)
http://www.pfizer.ca/en/our_products/products/monograph/273

















van Beek TA., Bioorg Med Chem. 2005 Sep 1;13(17):5001-12


















Bernstein CD, Albrecht KL, Marcus DA., Expert Opin Pharmacother. 2013 May;14(7):905-16
Hazardous Substances Data Bank (HSDB), Methanesulfonate
http://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Fluanxo_MKT_PM_ctrl148918_18OCT2011_eng.pdf
MSDS Sigma aldrich http://www.sigmaaldrich.com
Hazardous Substances Data Bank (HSDB), Methanesulfonate

















Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
MSDS Sigma aldrich http://www.sigmaaldrich.com
Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013

















Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013

















MSDS Sigma aldrich http://www.sigmaaldrich.com
Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013, (hydrochloride)
Hazardous Substances Data Bank (HSDB), (Bromide)

















MSDS Sigma aldrich http://www.sigmaaldrich.com, (hydrate)
MSDS Sigma aldrich http://www.sigmaaldrich.com
Hazardous Substances Data Bank (HSDB), (Hydrogen sulfate)



















MSDS Sigma aldrich http://www.sigmaaldrich.com
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021856s003lbl.pdf
Hazardous Substances Data Bank (HSDB), hydrochloride
Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
MSDS Sigma aldrich http://www.sigmaaldrich.com, hydrochloride
MSDS Sigma aldrich http://www.sigmaaldrich.com
van Beek TA., Bioorg Med Chem. 2005 Sep 1;13(17):5001-12
Hazardous Substances Data Bank (HSDB), (Sulfate)
Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013


















Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013, Hydrochloride


















Li G, Su GQ, Xu QW., et al., Yao Xue Xue Bao. 2001 Jul;36(7):532-4
MSDS Sigma aldrich http://www.sigmaaldrich.com


































MSDS Sigma aldrich http://www.sigmaaldrich.com
MSDS http://www.sciencelab.com/msds.php?msdsId=9923917


















Chemfinder DEMO PerkinElmer Imformatics database; Accessed 22Apr2013-6May2013
MSDS Sigma aldrich http://www.sigmaaldrich.com





















Transport Route Comments References
Oseltamivir Antiviral
Influx, PEPT1 & Efflux, P-
gp
PEPT1 is not detected in MDCK cells;therefore higher 
permeability for the caco-2 cell lines
Ogihara, T.; Kano, T.; Wagatsuma, T.; Wada, S.; Yabuuchi, H.; Enomoto, S.; Morimoto, K.; Shirasaka, Y.; Kobayashi, S.; Tamai, I., Oseltamivir (Tamiflu) Is a Substrate of Peptide Transporter 1
Loperamide Opioid/gastrointestinal Efflux, P-gp
In this case the MDCK permeability is lower compared to caco-2 
permeability due to the strain of MDCK used which over 
expresses the p-gp transporter therefore would expect lower 
permeability in MDCK-MDR1 cells compared to caco-2
Varma, M. V. S.; Sateesh, K.; Panchagnula, R., Functional role of P-glycoprotein in limiting intestinal absorption of drugs: Contribution of passive permeability to P-glycoprotein mediated efflux transport. Molecular 
Pharmaceutics 2005, 2, 12-21.
Troutman, M. D.; Thakker, D. R., Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. 
Pharmaceutical Research 2003, 20, 1210-1224.
Amitriptyline Antidepressant Efflux, P-gp
In this case the MDCK permeability is lower compared to caco-2 
permeability due to the strain of MDCK used which over 
expresses the p-gp transporter therefore would expect lower 
permeability in MDCK-MDR1 cells compared to caco-2
Faassen, F.; Vogel, G.; Spanings, H.; Vromans, H., Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. International Journal of Pharmaceutics 2003, 263, 113-122.
Troutman, M. D.; Thakker, D. R., Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. 
Pharmaceutical Research 2003, 20, 1210-1224.
Phenazopyridine Analgesic Passive Transcellular Poor solubility (dissolution limiting) - BCS class 2 compound
Gao, Z., Development of a Continuous Dissolution/Absorption System—a Technical Note. AAPS PharmSciTech 2012, 13, 1287-1292.
Sotalol  Antiarrhythmic
Paracellular & influx 
transporter OATP-A
OATP-A is expressed in caco-2 but not determined in MDCK II. In 
addition MDCK II cells are leakier compared with caco-2 hence 
both reasons could contribute to higher absorption through the 
MDCK cell line
Liu, W. et al, Sotalol Permeability in Cultured-Cell, Rat Intestine, and PAMPA System. Pharmaceutical Research 2012, 29, 1768-1774.
Dicloxacillin Antibiotic
Influx, PEPT1 & Efflux, P-
gp
Higher expression of p-gp in caco-2 and higher efflux of 
dicloxacillin by this transporter than uptake by PEPT1 could 
explain higher permeability in MDCK cell line. 
Luckner, P.; Brandsch, M., Interaction of 31 β-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. European Journal of Pharmaceutics and Biopharmaceutics 
2005, 59, 17-24.
Susanto M, Benet LZ. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res. 2002 Apr;19(4):457-62.
Levodopa  Psychoactive Influx, LNAA
Higher abundance of LNAA in MDCK cells compared with caco-
2, in addition the possibility of paracellular absorption has been 
proposed and based on the MDCK cell line which is leakier both 
could explain the higher permeability in MDCK compared to caco-
2
Putnam, W. S.; Ramanathan, S.; Pan, L.; Takahashi, L. H.; Benet, L. Z., Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and 
Caco-2 cells. Journal of Pharmaceutical Sciences 2002, 91, 2622-2635.
Lennernas, H.; Nilsson, D.; Aquilonius, S. M.; Ahrenstedt, O.; Knutson, L.; Paalzow, L. K., The effect of L-leucine on the absorption of levodopa, studies by regional jejunal perfusion in man. British Journal of Clinical 
Pharmacology 1993, 35, 243-250.
Sildenafil
Erectile dysfunction and 
pulmonary arterial 
hypertension
Efflux, P-gp & BCRP
BCRP transporter was not determined in MDCK II cells indicating 
that the combined efflux effect of p-gp and BCRP transporters in 
caco-2 reduce the permeability more compared to the single efflux 
transporter in the MDCK cell line hence the higher permeability in 
the MDCK cell line
Choi, M. K.; Song, I. S., Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. Journal of Pharmacy and Pharmacology 2012, 64, 1074-1083.
Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard, D. F.; Lai, Y. R.; Federico, J. J.; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C.; Feng, B.; Rotter, C.; Varma, M. V.; Kempshall, S.; Fenner, K.; 
El-Kattan, A. F.; Liston, T. E.; Troutman, M. D., Development of a New Permeability Assay Using Low-Efflux MDCKII Cells. Journal of Pharmaceutical Sciences 2011, 100, 4974-4985.
Glipizide  Anti-diabetic Passive Transcellular Poor solubility (dissolution limiting) - BCS class 2 compound
Mehramizi, A.; Alijani, B.; Pourfarzib, M.; Dorkoosh, F. A.; Rafiee – Tehrani, M., Solid Carriers for Improved Solubility of Glipizide in Osmotically Controlled Oral Drug Delivery System. Drug Development and Industrial 
Pharmacy 2007, 33, 812-823.
Higher permeability in caco-2 
compared to MDCK














Supporting Information III 
Table S1. Comparison of small intestine and in vitro cell lines; ‘y’ indicates transporter and 
enzyme expression; Bold text indicates high expression; italic indicates moderate, normal text 
indicates low expression according to the literature 
Cell line Small intestine Caco-2 MDCK Refs 
Species Human Human Canine 1, 2 




 3-5 1, 2 
TEER (Ω.cm2) 25-40 300-500 
Parental MDCK <200 
MDCK I >1000 










<100 1000-2500 NF 10-13 
Transporter 
expression 
Transporter expression is highest in small intestine (area dependent) compared to cell lines in 
most cases. Transport expression is lower in MDCK cells compared to Caco-2 cells4 
MDR1(P-gp) y y 
y 




MDR3 y y y MDCK II 6, 18, 20 
HPT1  y y NF 18, 20-22 
PEPT1 y  y ND MDCK II 6, 15-18, 20, 22, 23 
PEPT2 ND ND y MDCK II 6, 15, 18, 20, 24 
OCTN1 y y NF 17, 18, 20, 22 
OCTN2 y y NF 1, 16-18, 20 
MCT1 y y y MDCK II 16, 17, 20, 25 
MCT2 ND y NF 26-28 
MCT3 y y ND MDCK II 18, 22, 25 
MCT4 y y y MDCK II 18, 25-27, 29 
MCT5 y y NF 18, 20 
IBAT y y NF 5, 18, 20 
OAT1 ND ND ND MDCK II 6, 16, 18, 20, 30 
OAT2 y y NF 16, 20 
OAT3 ND ND NF 18, 20 
OAT4 ND y NF 18, 20, 31 
OATP-A y y ND MDCK II 6, 17, 20, 32, 33 
OATP-B y y NF 16-18, 23, 32 
OATP-C ND ND ND MDCK II ND* 
18, 20, 33
 
OATP-D y y NF 18, 20, 34 
OATP-E y y NF 18, 20, 34 













OATP-H y y ND* ND MDCK II 
18, 20, 35, 36
 
OATP8 y ND ND MDCK II 6, 18, 20, 32 
BCRP  y y ND* ND MDCK II 
6, 14, 16-19, 23, 37
 
MRP1 y y 
y* 




MRP2 y y 
ND* 
y MDCK II 
y MDCK-MDR1 
6, 14, 16-18, 20, 23, 
33
 
MRP3 y y y MDCK II 6, 16, 17, 20 
MRP5 y y y MDCK II y MDCK-MDR1 
6, 14, 19, 20, 22
 
MRP6 y y NF 17 
OCT1 y y NF 16-18, 20 
OCT2 ND ND y MDCK II 6, 18, 20, 38 
OCT3 y y ND MDCK II 6, 16-18 
ENT1 y y y MDCK II 6, 18, 22, 39 
LNAA 
(LAT1/LAT2) y y y* 
5, 40
 
PHT1 y y y MDCK II 6, 41 
LRP y NF NF 20, 42 
Cycloph A y NF NF 20 
CNT3 ND y ND* 18, 20, 43 
Enzyme 
expression Enzymes expressed in the small intestine have higher abundance compared to the cell lines.  
CYP3A4 y y (very low) ND* 4, 22, 44-46 
CYP2D6 y y (very low) NF 18, 44, 45 
CYP2C9 y y NF 18, 22, 44, 45 
CYP2C19 y y NF 18, 22, 44, 45 
CYP1A1 y y NF 44, 45 
CYP2J2 y y ND MDCK II 6, 22, 44, 45 
CYP3A5 y y NF 18, 44, 45 
UGT y y NF 22 
GST y y y* 1, 22, 47 
ST y y y MDCK II 1, 22, 48 
AT y y NF 
22
 
AcyT y y NF 22 
awhen P-gp expression is at its maximum4; NF- not found in the literature; ND - not detected in experimental assay; MDR - multi drug 
resistant protein; HPT1 - human oligopeptide transporter;  PEPT- peptide transporter; OCTN - organic cation transporter; MCT- 
monocarboxylate transporters; IBAT - ileal sodium-dependent bile acid transporter/ intestinal bile acid transporter; OAT - organic anion 
transporter; OATP - Organic anion-transporting polypeptide; BCRP - Breast cancer resistance protein; MRP - multidrug resistance 
associated protein; OCT - organic cation transporter; ENT - equilibrative nucleoside transporter; LNAA/ LAT - Large neutral amino acids; 
LRP - lipoprotein transporter; Cycloph A - cyclophilin A/ Peptidyl-prolyl Isomerase A, CNT - Concentrative nucleoside transporter; CYP - 
Cytochrome P450 enzyme; UGT- Uridine 5'-diphospho-glucuronosyltransferase; GST - glutathione S-transferase;  ST- sulfotransferase; AT 
- N-acetyltransferase; AcyT – acyltrtransferase 
*Note: A generic term MDCK is used unless specific information regarding the transporter in a specific strain is known. Therefore MDCK 














Comparison of absorption through MDCK and Caco-2 cell lines using different 
mechanisms/ routes 
The statistical significance of the regression lines (slope and intercept) of the absorption 
mechanisms highlighted in Table 3 (in manuscript) was tested and the results are shown in 
Table S2. As some of the compounds undergo more than one absorption mechanism (Groups 
D, F, G and H in Table 3), the significance was also tested in either mechanism. For 
example, for group D (efflux and paracellular) this was tested with all these compounds 
classed as efflux or classed as paracellular. P values < 0.05 indicate that there is a significant 














Table S2. Linear regression results and significance of the different absorption 
transport routes (First absorption mechanism is dominant for that set) 
Model Description N Slope  Slope p value Intercept Intercept p 
value 









2 Carrier mediated (C-H) Vs 








3 Efflux (C, D, G, H) Vs  








4 Influx (E, F, G, H) Vs  








5 Efflux (C, D, G, H) Vs  








6 Influx (E, F, G, H) Vs  








7 Influx (E, F) Vs  








* Paired t tests were carried out on the smaller group of permeability values to test the significance between the two cell lines of the group of 
compounds. In addition paired t tests were also carried out for all the groups in models 1-7 to test for significance between the cell lines. All 
tests revealed not significant differences between the two cell lines. 














Table S3. Molecular descriptors utilised in 12 models from Table 6 in manuscript 
Descriptor Description 
Model used (1-
12) from Table 6 
ABSQ 
Sum of absolute values of atomic partial charges of the 
molecule 2,8,9,10 
ACD_PSA Polar Surface Area 2,3,4,5,6,7,9 
Balaban 
Topological Index 
Highly discriminant topological descriptor, gives an indication 
of shape including branching and cyclicity of a molecule 1,3,4,7,8,10,11,12 
Dipole 
Measure of polarity plus other internal electronic effects of the 
molecules 2,5,9 
GSE solubility 
Aqueous solubility calculated using the general solubility 
equation 3,5,7,10,11 
Hmin Minimum hydrogen EState value in molecule 2,5,9 
Inertia Moment 2 
Length 
Indicates the strength and orientation behaviors of molecule in 
an electrostatic field. 6 
logDN logarithm of dose number 6 
LogP Octanol/water partition coefficient  1,11,12 
logPapp logarithm of cell apparent permeability (cm/s-1) 1-12 
logS (M) 
logarithm of experimental aqueous solubility in Molar units 
(M) 8,9,10 
LogS (mg/mL) logarithm of experimental aqueous solubility in mg/mL 2,5,9 
Max Neg Largest negative charge over the atoms in the compound 1 
MPbAP Melting Point based Absorption Potential 4,6,7,8,12 
Phia Kappa flexibility index 1 
Qv Molecular and group polarity index 1 
SHHBd 
Sum of the hydrogen atom level E-state values for all 
hydrogen atoms bonded to donating atoms. 1,11,12 
SsCH3 Sum of all (-CH3 -) E-state values in molecule 1,11,12 
VAMP HOMO 
Energy of the highest occupied molecular orbital calculated by 
AM1 semi empirical method 1,11,12 
VAMP LUMO 
Energy of the lowest unoccupied molecular orbital calculated 





















Figures showing the relationship between the different transport mechanisms between the 185 
compounds for caco-2 and MDCK permeability 
 




































































Figure S2. Comparison of regression between carrier mediated transport and passive 








































Figure S3. Comparison of regression between compounds identified as carrier mediated 









































Figure S4. Comparison of regression between compounds identified as carrier mediated 


















































































Figure S6.  Comparison of regression between carrier mediated efflux and influx transport 








































Figure S7.  Comparison of regression between carrier mediated influx (groups E, F Table 3) 













12 C&RT models from Table 7 from manuscript 
Model 1 
Tree graph for 80.000000









































<= -5.150000 > -5.150000
SHHBd
<= 6.612200 > 6.612200
VAMP HOMO
<= -8.757106 > -8.757106
SsCH3
<= 3.509010 > 3.509010
LogP
<= 1.239340 > 1.239340
Balaban Topological index
<= 1.537850 > 1.537850
phia
<= 3.809000 > 3.809000
Qv
<= 0.985034 > 0.985034
MaxNeg
<= -0.392230 > -0.392230
LOW     
HIGH
 
Model 2  
Tree graph for 80.000000









































<= -5.150000 > -5.150000
LogS (mg/ml)
<= 1.870000 > 1.870000
ABSQ
<= 3.689000 > 3.689000
LogS (mg/ml)
<= -1.390000 > -1.390000
ACD_PSA
<= 68.535000 > 68.535000
Dipole
<= 6.863740 > 6.863740
ACD_PSA
<= 58.720000 > 58.720000
VAMP LUMO
<= -0.624116 > -0.624116
Hmin
<= 0.654000 > 0.654000




























Tree graph for 80.000000





















<= -5.150000 > -5.150000
GSE solubility
<= -1.120000 > -1.120000
ACD_PSA
<= 89.240000 > 89.240000
GSE solubility
<= -4.740000 > -4.740000
Balaban Topological index
<= 1.569850 > 1.569850




Tree graph for 80.000000

















<= -5.150000 > -5.150000
MPbAP
<= 0.940000 > 0.940000
ACD_PSA
<= 81.800000 > 81.800000
MPbAP
<= 2.160000 > 2.160000
Balaban Topological index
<= 1.539019 > 1.539019
















Tree graph for 80.000000









































<= -5.150000 > -5.150000
GSE solubility
<= -1.120000 > -1.120000
ACD_PSA
<= 89.240000 > 89.240000
LogS (mg/ml)
<= -1.390000 > -1.390000
ACD_PSA
<= 68.535000 > 68.535000
Dipole
<= 6.863740 > 6.863740
ACD_PSA
<= 58.720000 > 58.720000
VAMP LUMO
<= -0.624116 > -0.624116
Hmin
<= 0.654000 > 0.654000




Tree graph f or 80.000000

































<= -5.150000 > -5.150000
MPbAP
<= 0.940000 > 0.940000
ACD_PSA
<= 81.800000 > 81.800000
logDN
<= -3.400000 > -3.400000
ACD_PSA
<= 58.780000 > 58.780000
VAMP LUMO
<= -0.666425 > -0.666425
Inertia Moment 2 Length
<= 3.243200 > 3.243200




















Tree graph for 80.000000





















<= -5.150000 > -5.150000
GSE solubility
<= -1.120000 > -1.120000
ACD_PSA
<= 89.240000 > 89.240000
MPbAP
<= 2.160000 > 2.160000
Balaban Topological index
<= 1.539019 > 1.539019




Tree graph for 80.000000

























<= -5.150000 > -5.150000
LogS (M)
<= -0.680000 > -0.680000
ABSQ
<= 3.678900 > 3.678900
MPbAP
<= 2.160000 > 2.160000
Balaban Topological index
<= 1.539019 > 1.539019

















Tree graph for 80.000000









































<= -5.150000 > -5.150000
LogS (M)
<= -0.490000 > -0.490000
ABSQ
<= 3.678900 > 3.678900
LogS (mg/ml)
<= -1.390000 > -1.390000
ACD_PSA
<= 68.530000 > 68.530000
Dipole
<= 6.863740 > 6.863740
ACD_PSA
<= 58.720000 > 58.720000
VAMP LUMO
<= -0.624116 > -0.624116
Hmin
<= 0.654000 > 0.654000




Tree graph for 80.000000





















<= -5.150000 > -5.150000
LogS (M)
<= -0.490000 > -0.490000
ABSQ
<= 3.678900 > 3.678900
GSE solubility
<= -4.740000 > -4.740000
Balaban Topological index
<= 1.569850 > 1.569850




















Tree graph for 80.000000

































<= -5.150000 > -5.150000
SHHBd
<= 6.612200 > 6.612200
VAMP HOMO
<= -8.757106 > -8.757106
SsCH3
<= 3.509010 > 3.509010
LogP
<= 1.239340 > 1.239340
GSE solubility
<= -4.740000 > -4.740000
Balaban Topological index
<= 1.569850 > 1.569850




Tree graph for 80.000000

































<= -5.150000 > -5.150000
SHHBd
<= 6.612200 > 6.612200
VAMP HOMO
<= -8.757106 > -8.757106
SsCH3
<= 3.509010 > 3.509010
LogP
<= 1.239340 > 1.239340
MPbAP
<= 2.160000 > 2.160000
Balaban Topological index
<= 1.539019 > 1.539019
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